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Abstract
Bioactive peptides can be released, during gastrointestinal digestion or food processing,
from many plant and animal proteins and represent an important source of potential
health-enhancing components. Therefore, the aim of this study is to investigate
antioxidant, antieancer and antihypertensive activities of proteins and peptides extracted
from egg yolk. Defatted egg yolk (EY) was hydrolysed using pepsin and pancreatin and
sequentially fractionated by ultrafiltration, followed by gel filtration (EYGF), resulting
in three different fractions of which two (EYGF-23 and EYGF-33) effectively inhibited
the oxidation of linoleic acid in a dose-dependent manner. Both fractions (80 mg/ml)
exhibited antioxidant activity comparable to trolox and butylated hydroxytoluene
(0.2 mg/ml). The antioxidant mechanism involved superoxide anion and hydroxyl
radicals scavenging, ferrous chelating and reducing ability. The protective effect of one
of the fractions (EYGF-23) was also tested in Caco-2 colon cancer epithelial cells,
exposed to 3 mM of tert-huty\ hydroperoxide (/-BHP) to induce oxidative stress.
Induced cell toxicity by r-BHP was significantly inhibited when Caco-2 cells were
treated with 1.0 mg/ml of the fraction for 24 hours. This fraction protected the cells by
inhibiting intracellular ROS as well as lipid peroxidation products by 60.0% (p <0.001)
and 24.15%, (p <0.05). In addition, total glutathione level and superoxide dismutase
activity were significantly elevated to 0.29 pM {p <0.001) and 55.10% {p <0.01),
respectively, in comparison to cells treated with /-BHP alone. Amino acids lysine,
pro line, tyrosine and tryptophan in this fraction may be responsible for antioxidant
activity. The main highlight of this study was that cytotoxic effects of the second
fraction (EYGF-33) was observed in vitro in cancer colon cells but not in normal colon
cells. Apoptosis was mediated by mitochondrial ROS, evidenced by PARP-1 cleavage.
Reduced cell viability could be explained by cell cycle arrest in the S-phase which
III
stopped DNA synthesis. Arginine, lysine, leucine, alanine, valine and tryptophan 
residues, which are mainly presented in the second fraction, may be responsible for the 
anti-proliferative activity. A third fraction (EYLCF-16) was successfully purified from 
egg yolk protein by both gel filtration and HPLC. This fraction exhibited high 
angiotensin converting enzyme (ACE) inhibitory activity (91.8%) at 10 mg/ml and IC50 
value (1.53). ACE inhibition exhibited by the fraction was probably due to the 
positively charged amino acid residues, lysine and arginine, and hydrophobic amino 
acid residues, leucine and tryptophan. These project findings indicate a substantial 
potential for producing peptides with antioxidant, antieancer and ACE inhibitory 
activity from egg yolk.
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Chapter 1: Introduction
1 Introduction
1.1 Proteins
Proteins are polymers that have a highly complex structure. Together with lipids and 
carbohydrates, proteins are important macro components in living systems, and are 
equally important in food, due to their high nutritional value and their functional 
properties. Nutritionally, proteins are considered as a source of energy and amino acids 
that are essential for well-being and growth. Additionally, the nutritional quality of 
proteins depends entirely on their amino acid composition and how they are used in the 
body following digestion and absorption. On the functional side, proteins have a strong 
impact on physio chemical properties such as foaming, émulsification and gelation. 
Scientific evidence has shown that many dietary proteins include specific biological 
properties that may be used as ingredients of nutraceutical or health promoting foods 
(Mine and Shahidi, 2005). Hence, numerous food proteins have been isolated and 
purified (Udenigwe and Aluko, 2012).
1.1.1 Protein biochemistry
All proteins are composed of one or more polypeptide; they are linear polymers of 
peptides built from a certain sequence of monomeric units called amino acids joined up 
by a peptide (covalent) bond (Chakrabarti and Pal, 2001).
1.1.1.1 Structure of amino acids
The total number of common amino acids is 20 and their active form is L-a. These 
amino acids are similar in the main structure but differ in the side-group. The central
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carbon atom, which is known as a-carbon, holds carboxyl group (C-terminus), amino 
group (N-terminus) and variable side chain (R) (figure 1.1).
Amino
Group
OH
N —  C Carboxyl
Group
Variable 
Group 
(Side Chain)
Figure 1.1. Structure of an amino acid.
Amino acids are amphoteric compounds because they carry both a negatively charged 
carboxylate group and positively charged protonated amino group in the same molecule. 
This character enables them to react either as an acid (proton donor) or as a base (proton 
acceptor), depending on the pH of the medium. Although the number o f amino acids is 
limited, the properties and functions of a particular protein depend mainly on the type 
and the precise sequence of its amino acid which is unique to that protein. Moreover, 
the variability of the structure and the size of R- group play a fundamental role in the 
physical properties of the protein (Fennema et a l, 2008).
1.1.1.2 Classification of amino acids
Various approaches have been employed in the classification of amino acids, but the 
most suitable one is to apply the classification in terms of the properties of their side- 
chain (R) rather than their chemical structure as indicated in figure 1.2 (Fennema et a l, 
2008).
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Figure 1.2. Classification of amino acids. Source: Fennema etaL, 2008.
1.1.1.3 Protein synthesis
The component amino acids are linked together by substituted covalent bonds named 
peptide or amide bond, formed by the loss of a water molecule as a by-product. This 
condensation reaction occurs between amino group of one amino acid and carboxyl 
group of adjacent amino acid residues as depicted in figure 1.3.
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Figure 1.3. Binding of amino acids via peptide bond. Source: Fennema et al, 2008.
Although the number of amino acids is limited, the nutritional and physicochemical 
properties of proteins are diverse. This is due to the fact that the unique properties of 
any protein depend entirely on the nature of its amino acid content and their sequence in 
the polypeptide chain (Friedman, 1996). Scientific evidence has shown that the actual 
reaction involved in protein synthesis in living systems is much more complicated than 
that illustrated in the above figure; this is because not only must the peptide bond be 
forged, but the amino acids must be combined in the correct sequence.
1.1.1.4 Protein structure
It has become clear that there are four distinct levels of protein structure, and each 
protein has a unique three-dimensional structure as illustrated in figure 1. 4 (Fennema et 
a/., 2008).
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Figure 1.4. Four levels of protein structure. Source: Fennema et al, 2008.
1.1.1.4.1 Primary structure
The sequence of amino acids in the polypeptide chain is illustrated as a linear 
arrangement with C-terminus at one side and N-terminus on the other side. In this 
structure, the peptide bond places some restrictions on the shape of the molecule, as free 
rotation does not occur around the covalent bond.
1.1.1.4.2 Secondary structure
This structure is represented by the coiling of the long chain, which is held in a more
rigid position by weak bonds (chiefly hydrogen bonds). The side chains (R groups) are
extended out of the backbone structure. It has become clear that the secondary structure
includes two configurations. The most common one is a-helix that occurs when intra-
5
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chain hydrogen bonds connect different parts of the same chain, leading to a very stable 
rod like cylinder. The second type of conformation, which is known as p-sheet or 
pleated sheet, occurs when the hydrogen bonds are inter-chain. This means that the 
bond in this conformation is formed between atoms of two separate chains, leading to 
strands lining up in a parallel or anti parallel fashion, and results in a zigzag shape. This 
zigzag shape helps strengthen the polypeptide chain to a great extent as compared to a- 
helix form (Fennema et a l, 2008).
1.1.1.4.3 Tertiary structure
The tertiary structure represents the overall shape of a single protein molecule, which 
results from folding the secondary structure of the polypeptide chain. This structure is 
stabilized by non-covalent hydrogen bonds (that link various amino acid residues), 
hydrophobic forces (that link non-polar side groups), electrostatic interactions and 
covalent disulfide bridges, which link cysteine amino acids at various places in the poly 
peptide chain.
As the chain folds, non-polar hydrocarbon side groups tend to turn towards the interior 
of the molecule where they can form hydrophobic bonds with one another. In contrast, 
the polar side chains tend to move towards the exterior of the molecule, and give water- 
dispersible properties to proteins either by forming hydrogen bonds with water 
molecules or with other parts of the chain. Therefore, the tertiary structure determines 
the basic function of protein (Fennema et a l, 2008).
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1.1.1.4.4 Quaternary structure
The quartemary structure represents the non-covalent associations that occur when two 
or more proteins in the form of tertiary structure are merged to form a multi-subunit 
protein. This structure exists in proteins with complex functions. The most common 
example is the haemoglobin molecule which comprises four polypeptide chains 
(Fennema et a l, 2008).
1.2 Egg yolk protein
It has been proven scientifically that the whole egg protein is nutritionally better than 
milk and meat protein (Yamaguchi and Matsuno, 1974; Shibata et a l,  1987), and is 
used as a benchmark for measuring the quality of other food proteins. Although several 
studies have focused on albumen protein (Navarrete et al., 1977; Komatsu et al., 1983), 
few have examined the nutritional value of egg yolk proteins, mainly due to their lipid 
content that negatively affects human health.
The main components of egg yolk are phospholipids, triacylglycerols and proteins 
(table 1.1). The first two components are used as lecithin in food or cosmetics. It is 
noteworthy that egg yolk lecithin has oxidative stability that is higher than that of 
soybean lecithin. Scientific evidence has shown that egg yolk lecithin can be totally 
metabolized by humans and is non-toxic when ingested. Accordingly, lecithin is used in 
pharmaceutical application as a surfactant, lubricant and emulsifying agent; as a 
wetting, stabilizing agent; for émulsification and encapsulation, and as a good 
dispersing agent. Lecithin is also used as a form of choline supplement. The third 
component of egg yolk is protein that represents approximately 30% of dried egg yolk.
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Many studies have shown that egg yolk proteins have antioxidant activities (Sakanaka 
et al., 2004).
Fresh yolk (%) Dry yolk (%)
Water 51.1 -
Lipids
Triglycerides 62% 
Phospholipids 33% 
Cholesterol <5% 
Carotenoids <1%
3.6 625
Proteins 16.0 320
Carbohydrates 0.6 1.2
Minerals 1.7 3.5
Table 1.1. Composition of chicken egg yolk. Source: Anton , 2007.
1.3 B ioactive  peptides
Bioactive peptides are food-derived peptides that usually contain 2-20 amino acid 
residues per molecule resulting from specific hydrolysis of plant or animal proteins. 
They are released upon enzymatic hydrolysis, during food processing or during 
gastrointestinal digestion and, consequently, become bioactive despite the fact that they 
are inactive within the sequence of their parent protein (Meisel, 1997; Korhonen, 2003).
Once bioactive peptides have been liberated, they exhibit physicochemical and 
functional activities beyond their nutritional properties (Korhonen and Pihlanto, 2006). 
For nutritional aspects, small peptides such as di- or tri-peptides are considered as a 
suitable nitrogen source because of their absorption wliich is higher than that of their 
free amino acids (Epstein et al., 1998). From a physiological point of view, bio active
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peptides resist hydrolysis and, therefore, they are able to exert local effects in the 
gastrointestinal tract or directly on entering the blood circulation, after their absorption 
through the intestine, to exert systemic effects (Vermeirssen et ah, 2002a; Vermeirssen 
et aL, 2002b).
It is now well established that these peptides exhibit multiple beneficial health effects 
on the biological system, and the magnitude of these benefits is entirely dependent on 
the size and the sequence of amino acids inherent in the specific peptides 
(Samaranayaka and Li-Chan, 2011). Most recent studies have examined the impact of 
bio active peptides on numerous physiologically-related activities including 
antithrombotic (Erdmann et a i,  2008), antimicrobial (Haque and Chand, 2008), 
antioxidant action against unsaturated fatty acids (Je et al., 2005) and antihypertensive 
activities (Matsui et al., 2002). Additionally, these bioactive peptides play a 
fundamental role in functional and nutraceutical applications in order to supply the 
standard nutrients and reduce the risk of human chronic diseases (Mine and Shahidi, 
2005).
Many types of plant and animal protein have been used to isolate and identify bioactive 
peptides. For example, sunflower (Megias et al., 2004), casein (Suetsuna et al., 2000), 
soybean (Gibbs et al., 2004), egg (Miguel and Aleixandre, 2006b), Pacific hake (Cinq- 
Mars et a l, 2007), mackerel (Sampath Kumar et a l, 2012), skin of sole and squid 
(Giménez et al., 2009) and chicken breast muscle (Saiga et al., 2006). However, there is 
a wide consensus among the scientists that there are other applications o f bio active 
peptides yet to be identified and more studies are needed in order to examine the 
efficacy of bio active peptides on human health prior to their application as ingredients 
of the nutraceutical foods.
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1.3.1 Production o f bioactive peptides
Peptides are released from their parent proteins by hydrolysis using chemicals (acid or 
alkali) and enzymes. During hydrolysis, the peptide bond between two adjacent amino 
acids is cleaved to produce peptides. In vivo, protein digestion starts in the stomach at 
acidic pH by the action of a specific enzyme called pepsin, to produce polypeptides. 
The resultant polypeptides are cleaved further in the small intestine by the action of 
pancreatic proteases such as trypsin, a-chymotrypsin, elastase and carboxypeptidase at 
alkaline pH. As a result of the action of these enzymes, a wide variety o f free amino 
acids and ohgopeptides are produced (Korhonen and Pihlanto, 2006). While free amino 
acids are directly absorbed through specific amino acid transport systems, the 
oligopeptides undergo further hydrolysis by peptidases located in the brush border 
membrane. Studies have been conducted to isolate peptides from different protein 
sources by using different enzymes with different selectivity and specificity such as 
microbial enzymes, synthetic enzymes and gastrointestinal enzymes (Vioque et aL, 
2000; Korhonen and Pihlanto, 2006). The resultant hydrolysates contain mixtures of 
low and high molecular weight peptides.
1.3.2 Protein and peptide separation
The characterization of proteins and peptides is determined by their molecular weight 
(size), electric charge, hydrophobicity, amino acid composition and their sequence. The 
properties of the side chain (R-group) in the amino acid structure are responsible for its 
chemical reactivity, polarity and its ionic charge. Therefore differences in these 
properties can be utilized in separation methods and purification strategy.
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1.3.2.1 Molecular weight
The molecular weight (size) of a protein is the mass of one mole and is usually 
measured in units called daltons. The molecular weight can be measured by mass 
spectrometry. Separation methods, which depend on the size of molecules, include 
centrifugation using ultrafiltration membranes with different molecular weight cut-off, 
polyacrylamide gel electrophoresis and gel filtration chromatography (size exclusion 
chromatography) (Greaser and Warren, 2012).
1.3.2.2 Electric charge
According to the structure of proteins and peptides which consists of different amino 
acids with different functional groups in their side chains, each protein and peptide 
carries a different net charge. The net charge on the molecule is highly influenced by 
the pH of the surrounding medium as it can become more positively or negatively 
charged due to the gain or loss of protons. A separation method which depends on the 
charge of the molecules includes ion exchange chromatography (Hennrich et aL, 2011).
1.3.2.3 Hydrophobicity
The degree of polarity of each protein and peptide is determined according to the 
number, type and distribution of polar and non-polar amino acids incorporated in their 
structure. A separation method which depends on the hydrophobic character of proteins 
and peptides is hydrophobic interaction in solid-liquid chromatography (Armarego and 
Chai, 2012).
11
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1.3.3 Peptide sequencing
1.3.3.1 Edman degradation
Edman degradation can be used to sequence up to 30 amino acids by labelling and 
cleaving the N-terminal residue from the peptide without affecting peptide bonds 
existing between other amino acid residues. The N-terminal amino residue is labelled 
with phenylisothiocyanate which reacts with uncharged terminal amino groups, under 
alkaline conditions, to form a cyclical phenylthiocarbamoyl derivative. Acidic 
conditions cleave this derivative to a thiazolinone derivative that is subsequently 
extracted into an organic solvent and treated with acid to form the phenylthiohydantoin 
(PTH) - amino acid derivative, a stable compound that can be identified by using 
electrophoresis or chromatography technique (HPLC). By repeating this process all the 
amino acids can be identified. The advantage of this method is its ability to identify low 
levels of peptides up to 10-100 picomoles (Kinter and Sherman, 2005).
1.3.3.2 Liquid chromatography and mass spectroscopy (LC-MS)
Liquid chromatography-mass spectroscopy (LC-MS) is a powerful technique that can 
be used to separate and identify complex compounds and macromolecules such as 
peptides and proteins. The principle of LC-MS is based on the separation of compounds 
using liquid chromatography (LC) followed by mass analysis using mass spectroscopy 
(MS). Electro spray ionization (ESI) is used in mass spectroscopy in order to facilitate 
the direct analysis of peptides when eluted from HPLC in the LC/MS experiment by 
producing ions (Peng et ah, 2003). The ions produced are subsequently filtered 
according to their mass-to-charge ratio (m/z) and then detected by MS (Allen, 2011).
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1.4 Role of food-derived bioactive peptides
Peptides that are derived from food proteins may help to reduce the worldwide epidemic 
of chronic diseases as they have the potential to exert a high and sustainable effect on 
the major systems in the human body, including the cardiovascular system, nervous 
system, immune system and gastrointestinal system. As far as the cardiovascular system 
is concerned, bioactive peptides play a crucial role in reducing the risk of heart diseases 
through a variety of mechanisms namely antioxidant, antithrombotic, 
hypocholestérolémie and antihypertensive (Mine and Shahidi, 2005). Hence, the aim of 
this study is to investigate the antioxidant, anticancer and angiotensin-I-converting 
enzyme inhibitory activities of enzymatically prepared peptides derived from animal 
protein after ultrafiltration and purification using a combination of chromatographic 
techniques. The following section will elaborate ftirther on three different mechanisms: 
antihypertensive effect via ACE inhibition, antioxidant and anticancer properties.
1.4.1 Angiotensin-I- converting enzym e (ACE) inhibition activity
The regulation of arterial blood pressure in human body is mainly achieved through 
diverse physiological systems including the kinin-nitric oxide system (KNOS), the 
neutral endopeptidase system (NEPS), the renin-chymase system (RCS) and the rennin- 
angiotensin system (RAS). Any disturbance in the blood pressure by increasing 
(hypertension) or decreasing (hypotension) will trigger a number of chronic diseases, 
such as, cardiovascular diseases, peripheral vascular disease and renal dysfunction 
(Mine and Shahidi, 2005).
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1.4.1.1 The role of rennin-angiotensin system in cardiovascular disease
It has been recognized that the rennin-angiotensin system (RAS) regulates blood 
volume and systemic vascular resistance, which control cardiac ou^ut and arterial 
pressure. RAS exists in various human body organs, such as the brain, kidney and lung, 
as well as in the circulatory blood system. In the RAS system, the angiotensinogen is 
cleaved from the liver by the action of the renal rennin enzyme to angiotensin-I (Asp- 
Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu). One of the key elements constituting the 
rennin-angiotensin system is the angiotensin converting enzyme (ACE; EC3.4.15.1, 
dicarboxy peptidase). ACE hydrolyzes the inactive decapeptide (angiotensin-I), through 
the removal of the dipeptide His-Leu from the C-terminus, to produce a potent 
vasoconstrictor octapeptide (Angiotensin-II) (Johnston, 1990; Crowley e/ aL, 2006). As 
a result of Angiotensin-II production, many physiological processes such as systematic 
vasoconstriction, water and sodium retention and cardiac hypertrophy, are initiated 
(figure 1.5).
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Figure 1.5. The rennin angiotensin system.
Angiotensin-II acts through two types of receptors termed AT-1 and AT-2. When 
angiotensin-II acts through the AT-1 receptor, the aldosterone hormone will be released 
leading to hypertensive events such as vasoconstriction. On the other hand, if 
angiotensin-II acts through the AT-2 receptor, it initiates antihypertensive events (de 
Gasparo et ah, 2000) (figure 1.6).
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Figure 1.6. Formation and effect of angiotensin-II.
Angiotensin converting enzyme (ACE) exists in two isoforms termed somatic and 
germinal forms. The somatic form exists in the endothelium of multiple tissues such as 
lungs, kidneys and the vascular endothelium while the germinal exist in sperm (Turner 
and Hooper, 2002). ACE is a metalloprotease that mediates its action by the presence of 
zinc (Natesh et aL, 2004). In addition to the ability of ACE to convert angiotensin-I to 
vasoconstrictor angiotensin-II, it also enhances the reabsorption of renal tubular sodium 
by increasing the release of adrenal aldosterone. Moreover ACE plays an important 
role in the depressor hormonal (Kinin-Kallikrein) system. In this system ACE 
hydrolyzes vasodilatory bradykinin to inactive metabolites (Tschope et aL, 2002; Zhao 
and Xu, 2008), as depicted previously in figure 1.5. Therefore, the utilization of ACE
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inhibitors will block the generation of vasoconstrictor angiotensin II and will enhance 
the action of vasodilator bradykinin, thus reducing blood pressure.
1.4.1.2 The ACE inhibitors
It has been recognised that the inhibition of ACE, by ACE inhibitory drugs like 
captopril and natural ACE inhibitory peptides, leads to an antihypertensive effect in 
hypertensive human subjects and animals. The IC50 value is used to specify the 
effectiveness of different ACE inhibitory peptides. This value represents the 
concentration of inhibitory compound that inhibits 50% of ACE activity. Although the 
potent synthetic ACE inhibitors Captopril, Fosinopril, Lisinopril and Perindopril are 
used extensively in the clinical treatment of hypertension, they have significant side 
effects such as dry cough, dizziness, skin rashes and headache (Morimoto et aL, 2004). 
On the other hand, the most recent studies on natural ACE inhibitors such as ACE 
inhibitor peptides, which are derived from food proteins, have so far indicated that these 
inhibitors do not have known side effects on the human body (Hong et aL, 2008; Kim 
and Wijesekara, 2010; Norris and FitzGerald, 2013). Accordingly, more studies are now 
directed towards understanding how to produce food derived peptides that can act as 
ACE inhibitors for the clinical treatment of hypertension.
1.4.1.3 Methods used to determine ACE inhibitory activity
There are a number of methods that have been developed for the measurement of ACE 
inhibitory activity. These methods include spectrophotometry (Cushman and Chung., 
1971), bioassay (Anderson., 1967), fluorimetry (Friedland and Siverstein., 1976), high 
performance liquid chromatography (Neels et aL, 1983), the use of radioisotopes 
(Chung and Ryan, 1978), capillary electrophoresis (Vandyck et aL, 2003) and internally 
quenched fluorogenic methods (Araujo etaL, 1999).
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The most common method used is the spectrophotometric method described by 
Cushman and Cheung (1971). This method is based on the hydrolysis of the synthetic 
tripeptide substrate, hippuryl-histidyl-leucine (HHL) by ACE. ACE will release 
histidyl-leucine (HL) and hippuric acid (HA) which are detected by UV at 228 nm. The 
production of HA is directly related to ACE activity.
However, a major drawback of the Cushman and Cheung (1971) method is that the 
measurement of hippuric acid concentration can only be achieved after several steps 
including HA extraction with ethyl acetate, evaporation, redissolution in water, 
followed by measuring the absorbance of HA in a spectrophotometer at 228nm (Wu et 
al, 2002). Furthermore, ethyl acetate is also able to extract unhydrolyzed HHL, thus 
resulting in the overestimation of ACE activity.
Since bioactive peptides may have the potential to affect major systems in the human 
body as described above, the next section will discuss further their effect as an 
antioxidant to protect biological and food systems against harmful reactive oxygen 
species.
1.4.2 Antioxidant activity
1.4.2.1 Free radicals and lipid oxidation
Free radicals are described as atoms, molecules or ions with unpaired electrons, in an 
open shell configuration which arises as a consequence of oxidative metabolism. The 
unpaired electron causes free radicals to be unstable and highly reactive, until the 
unpaired electron is paired up to finally reach a stable configuration. Free radicals are
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classified into two major classes: reactive nitrogen species (RNS) and reactive oxygen 
species (ROS). Examples for the former class include the nitroxyl anion (NO*) and 
peroxynitrite (ONOO ). Examples o f the latter class include the hydroxyl radical (HO*) 
and the peroxyl radical (ROO ) (Michal and Schomburg, 2013).
Lipids represent a diverse group that possesses similar properties including glyceride 
lipids as fats, oils and phospholipids, and non-glyceride lipids such as waxes and 
steroids. Lipids are hydrophobic molecules associated with all living systems playing a 
vital role in physiological functions. They act as structural elements of cell membranes, 
energy reservoir, and as an important precursor for the synthesis of vitamins and 
hormone-like substances (Michal and Schomburg, 2013).
The main building blocks of lipids are fatty acids that are classified into saturated, with 
no double bonds, and unsaturated with one double bond (monounsaturated) or more 
than one double bond (polyunsaturated). Polyunsaturated fatty acids are more 
susceptible and readily oxidised by oxygen or any free radicals, than saturated fatty 
acids, due to the presence of multiple double bonds along the chain. The double bonds 
next to methylene-CHi- groups possess a reactive centre that can be attacked easily by 
reactive species and cause lipid oxidation.
Free radicals can abstract electrons from lipids and produce lipid peroxide products via 
the free radical chain reaction mechanism (Dalrymple et aL, 2010). This mechanism of 
lipid oxidation occurs in the following three stages, as illustrated in figure 1.7.
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Figure 1.7. Free radical chain reaction mechanism. Source: Dalrymple et al., 2010.
The initiation stage: Reactive oxygen species (ROS) initiate this step by abstracting 
hydrogen from the active methylene site, available in unsaturated fatty acids (RH), to 
produce lipid free radical (R*).
The propagation stage: The conjugated diene (R*) is highly unstable. Hence, it reacts 
with an oxygen molecule to achieve the stability and form a peroxyl radical (ROO ). 
Peroxyl radicals abstract hydrogen from another unsaturated lipid molecule to form 
another lipid radical (R*) and lipid peroxides (ROOH).
The termination stage: This stage occurs when two radicals react and produce a non­
radical species. This chain, as demonstrated in figure 1.7 above, will be terminated only 
when the concentration of radical species is high enough so there will be a high 
probability that two radicals will collide and form stable molecules.
Lipids in all foods are esters of long chain fatty acids with different degrees of
saturation. The unsaturated fatty acids are more easily oxidised by free radicals. There
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are many factors affecting lipid oxidation in food products, namely, moisture content, 
temperature of storage and light exposure. These factors enhance the production of free 
radicals and hence the process of lipid oxidation. Free radical attack on lipids in food 
not only causes alteration in the organoleptic properties, giving unacceptable taste, odd 
flavour and rancidity but also produces toxic compounds that reduce the quality and the 
shelf life o f the products (Christen, 2000; Valko et aL, 2004; Alghazeer et aL, 2008). In 
food systems, lipid oxidation occurs when the free radicals attack the unsaturated lipids 
through the following different pathways:
Autoxîdatîon: The process of autoxidation is triggered when free radicals present in the 
living cells interact with polyunsaturated fatty acids and monounsaturated fatty acids, 
and results in the production of intermediate substances such as alkyl and peroxyl 
radicals (Sikorski and Kolakowska, 2002).
Photoxidation: In this process, light, including ultraviolet light, works as a source of 
energy which raises the oxygen from the ground state (two electrons with same spin in 
two orbitals) to the excited energy state (two electrons with different spin in one orbital) 
that is referred to as singlet oxygen (^0%). The latter reacts with the unsaturated fatty 
acids to form free radicals. Photo sensitizers like chlorophyll, riboflavin and myoglobin 
mediate the production of singlet oxygen, as explained above (Sikorski and 
Kolakowska, 2002).
Enzymatic oxidation: The enzymatic oxidation reaction is determined by the presence 
of a lipoxygenase enzyme system that catalyses the reaction between the oxygen and 
unsaturated fatty acids in order to produce hydroperoxides (Sikorski and Kolakowska, 
2002).
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In biological systems, the existence of oxidative metabolism is crucial for the survival 
of cells. Consequently, a number of highly reactive free radicals arise as a by-product of 
enzyme and other reactions involving oxygen. Living cells have special enzymes that 
include superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). These 
enzymes help to maintain the redox state through a constant input of metabolic energy 
(Halliwell and Gutteridge, 1990).
Any disturbance to this normal redox state, between ROS production in the 
physiological system and its detoxifying ability, is referred to as oxidative stress. These 
imbalances lead to toxicity due to the excessive production of free radicals that destroy 
all cell components and their functions, including DNA, protein and lipids, causing 
severe human diseases (Cimen, 2008). Therefore, it is important to inhibit the 
occurrence of excess lipid oxidation in living organisms and food by using antioxidants.
1.4.2.2 Antioxidants
Lipid peroxidation plays a key role in the pathogenesis of many diseases such as cancer 
(Valko et ah, 2004), cardiovascular disease (Cai and Harrison, 2000) and Alzheimer’s 
disease (Christen, 2000). Additionally, it plays a vital role in the loss of food quality by 
producing undesirable flavours and toxic compounds, which subsequently shorten the 
product shelf-life (Lin and Liang, 2002; Alghazeer et aL, 2008). Therefore, it is 
important to inhibit the occurrence of lipid oxidation in food and the living body by 
using antioxidants.
Antioxidants are defined as substances that prevent or slow down the oxidation process 
(Huang et aL, 2005). Antioxidants are classified as antioxidant defence systems which 
occur naturally in biological system, synthetic antoxidants such as butylated
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hydroxyanisol and butylated hydroxyltoluene, and natural antioxidants such as vitamin 
C and plant phenols.
1.4.2.2.1 Antioxidants in biological systems
Aerobic cells utilize a wide array of enzymatic and non-enzymatic mechanisms that 
tightly control unwanted ROS accumulation. Cellular antioxidative enzymes such as 
superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) as well 
as non-enzymatic antioxidants such as glutathione (GSH) can protect cell membranes 
and cellular content by scavenging ROS. Some of the defence system enzymes are 
described below:
Superoxide dismutase (SOD) is responsible for the dismutation of the superoxide 
anion to hydrogen peroxide and a molecule of oxygen according to the following 
reaction (Scandalios, 1993; Inoue et aL, 2003).
2 02-+2H^^H202 + 02
Superoxide anion is responsible for generating further highly reactive oxygen species 
which damage biological macromolecules such as DNA, lipids and protein. There are 
four different SOD forms according to the type of metal which acts as a cofactor to 
catalyse the dismutation reaction. These forms are copper/zinc-SOD (Cu/Zn-SOD), 
iron-SOD (Fe-SOD), manganese-SOD (Mn-SOD) and nickel-SOD (Ni-SOD) (Halliwell 
and Gutteridge, 1990).
Catalase is another enzyme in the biological defence system. This enzyme protects 
cells by catalysing the conversion of hydrogen peroxide, which is considered a highly
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reactive free radical, to water and molecules of oxygen (Halliwell and Gutteridge, 1990) 
as depicted in the following reaction:
2 H2O2 —> 2 H2O + O2
Glutathione peroxidase (GPx) is a selenium-containing tetrameric glycoprotein. This 
enzyme plays a major role in the elimination of hydroperoxides by catalysing their 
conversion to water, alcohols and oxidized glutathione (GSSG) (Halliwell and 
Gutteridge, 1990) according to the following reaction.
GPx
H2O2 + 2 GSH GSSG + 2 H2O
ROOH + 2 GSH -> GSSG + H2O + ROH 
GR
GSSG + NAD (P) H + H^ 2 GSH + NADP+
In a healthy system, the high level of total glutathione plays a substantial role in 
protecting cells from unexpected attack by hydroxyl radicals. Under oxidative stress, the 
increase in the concentration of peroxides leads to a shift in thiol redox status that is 
represented by a severe decrease in the reduced form o f glutathione (GSH) and an 
increase in the level of the oxidised form (GSSG) (Baud et aL, 2004).
1.4.2.2.2 Synthetic antioxidants
The most common synthetic antioxidants are butylated hydroxytoluene (BHT) and 
butylated hydroxyanisole (BHA). They possess phenolic groups that form resonance 
stabilized phenolic radicals that have high antioxidant activities. These phenolic radicals
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undergo a number of degradation reactions that result in products with active hydroxyl 
groups. These products also have high antioxidant activities. Although the activity 
shown by synthetic antioxidant in inhibiting the deterioration of lipids during storage is 
excellent, their usage in food is a concern to consumers due to their potential toxicity 
and carcinogenicity at high levels of intake (Saito et aL, 2003; Vandghanooni et aL, 
2013). Therefore, the demand for antioxidants from natural resources has increased in 
recent years.
1.4.2.2.3 Natural autioxidauts
Plants and food additives are rich sources of natural antioxidants as they include 
vitamins (vitamin E, C and B-carotene), plant phenols (flavonoids, and other phenolic 
compounds), and peptides derived from proteins. Many types of plant and animal 
protein have been isolated and found to have antioxidant peptides. For example, 
sunflower protein (Megias et aL, 2004), casein (Suetsuna et aL, 2000), soybean protein 
(Gibbs et aL, 2004), egg-white albumen (Miguel et a/., 2004), Pacific hake protein 
(Cinq-Mars et aL, 2007), mackerel protein (Sampath Kumar et aL, 2012), skin of sole 
and squid protein (Giménez et aL, 2009) and hold frame protein (Kim et aL, 2007) have 
all been identified as potential sources o f antioxidant peptides. The antioxidant activity 
shown by food-derived compounds makes them a good natural replacement for the 
synthetic ones (McCarthy et aL, 2001; Shahidi, 2009).
As discussed previously, food derived bioactive peptides exhibit ROS scavenging 
activity. ROS has been implicated in the etiology of chronic diseases such as cancer. 
Therefore, the ability of bioactive compounds to scavenge ROS and act as 
antiproliferative agents on cancer cells will be discussed further.
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1.4.3 Anticancer activity
Cancer is the unrestrained growth of cells forming malignant tumours. Cells undergoing 
unregulated growth can easily invade surrounding tissue and can metastasize to nearby 
sites in the body (Surh, 2003). Due to its uncontrolled and rapid spread, cancer is 
considered a major cause of mortality all over the world. In 2011, about 331,487 cases 
were diagnosed in the UK with cancer and mortality reached 159,178 (CRUK, 2011). 
The four types of cancer where incidence and mortality prevail are lung, breast, prostate 
and bowel. Lung cancer has the highest incidence (18%) and highest mortality (22%) of 
any cancer. The percentage of breast, prostate and bowel cancer incidence is 15%, 13% 
and 13%, respectively. In cancer mortality, bowel represents 10%, while both breast and 
prostate cancer represent 7%. According to the latest CRUK statistics (2011), colorectal 
cancers are the second most common cause of cancer mortality (10 %) and the third 
most common cancer in men and women (14 %) (CRUK, 2011).
1.4.3.1 Cell division cycle and cancer disease
Cancer is caused as a result of changes in cells. In eukaryotic healthy cells, a series of 
events occur leading to cell division and produce two healthy daughter cells. The cell 
division cycle is represented by four important phases (figure 1.8)
Growth 1 or Gap 1 phase (G1-phase) is where the cells grow and are checked by the G1 
check points control mechanism to be sure that the cell is ready for the next phase. The 
next phase is (S-phase) where the DNA is synthesised and duplicated. This step is 
followed by the growth 2/Gap 2 phase (G2-phase) where the cell continues growing 
and is checked by G2 check points to ensure that the cell is ready for mitosis and 
division. The last phase is the mitosis phase (M-phase), in which the cell stops growing
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and divides into two distinct daughter cells. Metaphase check points check the cell in 
the middle of mitosis to ensure that the cell is ready for division. However, there is a 
specialised form of G1 named GO- phase which is considered as a resting phase where 
the cell leaves the cycle and stops dividing (Secko, 2003).
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Figure 1.8. Illustration of cell division cycle process. Adapted from Secko (2003).
The cell cycle process is controlled by a group of specific proteins such as cyclins and 
cyclin-dependent kinases (CDKs) that work as a check point control mechanism 
(Murray, 2004). Any disturbance in these check points can interrupt the cell division 
cycle leading to cell death or abnormal growth. Cyclins (A, B, D and E) are important 
groups that affect cell cycle regulation and progression through complex fonnation with 
CDKs. Cyclin D and E are responsible for controlling the G1 phase. Cyclin D/CDK4,6 
is responsible for the regulation of gene transcription which is associated with DNA 
replication. Cyclin E activates CDK2 to ensure the transition from the G1 phase to the S
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phase. In the S phase, cyclin A activates CDK2 and controls cell progression by protein 
phosphorylation which leads to DNA synthesis and replication. The G2 phase is 
regulated by cyclin A/CDKl complex and cyclin B/CDKl, which occur at the end of 
this phase. In the M phase, the upregulation of cyclin A/CDKl complex ensures the 
completion of this phase before cell division (Murray, 2004). Any interruption in the 
cell cycle process causes abnormality growth or failure in cell progression and hence 
cell death.
1.4.3.2 Cell death pathways
There are different cell death pathways as illustrated in figure 1.9. Apoptosis is a 
pathway that is also called programmed cell death (PCD). Apoptosis occurs in 
multicellular organisms and is characterized by biochemical events that lead to 
characteristic changes in cell morphology such as blebbing, cell shrinkage, chromatin 
condensation as well as nuclear and chromosomal DNA fragmentation (Rowan and 
Fisher, 1997). At the end of these events, cells split to apoptotic bodies. Some 
anticancer agents affect cancer cells through apoptosis induction which is controlled by 
intrinsic or extrinsic pathways. The intrinsic pathway is achieved by activation of the 
caspase family (intracellular cysteine family) which are released from mitochondria into 
the cytosol (Persson et aL, 2009). The extrinsic pathway is induced apoptosis at the cell 
surface and organised by specific trans-membrane death receptors such as tumor 
necrosis factor receptor (TNF-R) (Seeram et aL, 2005).
Necrosis is a non-programmed cell death and considered as a form o f cell injury.
Necrosis is activated by external factors such as toxin and infection leading to
unregulated digestion of cell content. Necrotic cells are characterized by cell membrane
swelling until rupture, leading to the release of cellular content causing inflammation
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(Edinger and Thompson, 2004). When necrotic cells induce inflammation, an 
inflammatory response is initiated preventing the adjacent phagocytes from presenting 
and removing the dead cells by phagocytosis. Another mechanism of cell death 
pathways is autophagy; this catabolic mechanism involves the decomposition of 
dysfunctional cellular components via lysosome action. In this mechanism, 
dysfunctional cytoplasmic components are insulated from the rest of the cell inside the 
autophagosome; these components are subsequently united with lysosomes and 
decomposed or recycled (Edinger and Thompson, 2004).
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Figure 1.9. Ceil death pathways. Adapted from Edinger and Thompson (2004).
To this end, finding a suitable anticancer agent which targets the above cell death 
pathways is one of the aims of this project.
1.4.3.3 Anticancer agents
Although the causes of cancer are diverse and their mechanisms are still not fully 
defined, a wealth of evidence points to lifestyle and diet as risk factors contributing to 
the cause and progression o f some types of cancer (Anand et ah, 2008). Lifestyle
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interventions and the development of preventive approaches to control the development 
of this disease have gained interest in recent years. One approach is to use natural 
bioactive compounds such as chemopreventative occurring in dietary substances agents 
(Milner, 2004; Stan et a l, 2008).
Bioactive compounds have a wide range of fiinctional groups that allow them to exhibit 
many biological functions. In order to exhibit their biological activity, it is important 
that they are released or extracted from the parent food source and are resistant to 
degradation by gut enzymes (Kris-Etherton et al., 2002). Many studies have revealed 
that bioactive compounds exhibit anti-carcinogenic activity via different mechanisms. 
They may quench ROS and thereby protect cellular components from oxidative stress, 
inhibit cell growth, induce apoptosis, alter cell cycle kinetics and interfere with 
intracellular signal transduction events in cancer cells (Yun, 2003; Hou, 2003; Heber, 
2004).
Bioactive peptides released from plant and animal protein have been the focus of 
increasing interest as anticancer agents due to their properties of multi-functionality and 
high stability (Lee et al., 2005; Leng et al., 2005). Several protein-rich sources 
including soy bean, milk, and cereal grains that can bear potential anticancer peptides 
have been reported (Kim et al., 2000; Xiao et al., 2004; Ward et a l, 2005; Kannan et 
a l, 2008).
Anticancer properties have also been documented in several egg proteins (Kovacs- 
Nolan et a l, 2005). Ovomucin, an egg white protein, has the potential to inhibit 
tumour growth by limiting angiogenesis in cells (Mine and Kovacs-Nolan, 2006). The 
role of the egg white protein avidin as an anticancer agent may involve changes in the
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host-tumour relationship or the host-mediated antitumor response (Gasparri et al., 
1999). Egg cystatin was also reported as a potential novel anticancer agent through its 
suppression effect on cysteine proteases. These proteases, tested in cancer cells, are 
implicated in multiple steps of cancer progression, for example, in the early stages of 
immortalization and transformation, in the intermediate steps of tumour invasion and 
angiogenesis, and in the late steps of metastasis and drug resistance (Keppler, 2006).
1.5 Aim and objectives
Nowadays, people are increasingly aware of the benefits of healthy foods and, therefore, 
scientists have been working on the identification of food-derived bioactive compounds 
that maintain health and/or reduce the risk of chronic disease. From this point of view, 
the current research is built on the investigation of bioactive properties exhibited by 
peptides isolated from egg yolk protein. To achieve this aim the following objectives 
were considered:
1) To extract proteins from egg yolk.
2) To prepare protein hydrolysates from defatted egg yolk proteins through 
enzymatic digestion using pepsin and pancreatin.
3) To isolate and characterize peptides from egg yolk protein with antioxidant 
activity and to study the mechanisms of oxidation inhibition.
4) To study the antioxidant behaviour of isolated peptide in Caco-2 cells exposed 
to a proxidant.
5) To study the isolated peptide as an anticancer agent in Caco-2 cells and to 
identify the mechanism of action by the flow cytometry.
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6) To isolate and characterize peptides from egg yolk protein with angiotensin 
converting enzyme (ACE) inhibitory activity and to study the mechanism of 
ACE inhibition.
7) To analyse the amino acid composition and molecular weight of isolated 
peptides.
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2 Purification and isolation of antioxidant peptides from 
egg yolk protein
2.1 Introduction
Lipid peroxidation plays a key role in the pathogenesis of many diseases such as cancer 
(Valko et a l, 2004), cardiovascular disease (Cai and Harrison, 2000) and Alzheimer’s 
disease (Christen, 2000). Additionally, lipid oxidation plays a vital role in the loss of 
food quality by producing undesirable flavours and toxic compounds, which 
subsequently shorten the product shelf-life (Lin and Liang, 2002; Alghazeer et a l, 
2008). Therefore, it is important to inhibit the occurrence of excess lipid oxidation in 
living organisms and food by using antioxidants.
Antioxidants are defined as substances that prevent or slow down the oxidation process 
(Huang et al., 2005). Although synthetic antioxidants show strong activity in inhibiting 
the deterioration of lipids during storage, there is a concern about their toxicity and 
carcinogenicity at high levels of intake (Saito et al., 2003; Vandghanooni et al., 2013). 
Therefore, the demand for antioxidants fi*om natural resources has increased in recent 
years.
In this regard, many studies have been conducted and have revealed that plant phenols 
and protein hydrolysates may have the ability to inhibit the oxidation process 
(McCarthy et al., 2001; Shahidi, 2009). The antioxidant activity shown by food-derived 
compounds makes them a good natural replacement of the synthetic ones. Protein 
hydrolysates can be obtained by hydrolysis of animal or plant protein using the process 
of fermentation or by using proteolytic enzymes. As a result of protein hydrolysis.
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bio active peptides are released, which impact positively on various physiological 
functions (Korhonen and Pihlanto, 2006).
Bioactive peptides are small protein fragments, they can exert diverse physiological 
effects such as antihypertensive (Matsui et ah, 2002), antimicrobial (Haque and Chand, 
2008), antithrombotic (Erdmann et al., 2008), hypocholesterolaemic (Zhong et al., 
2007) and antioxidant actions (Je et al., 2005). The activity shown by these peptides is 
not only related to the stmcture of amino acids making up the peptide and their 
sequence but also to their molecular weight (Elias et al., 2008; Samaranayaka and Li- 
Chan, 2011).
Many types of plant and animal protein have been used to isolate and identify 
antioxidant peptides. For example, sunflower protein (Megias et ah, 2004), casein 
(Suetsuna et ah, 2000), soybean protein (Gibbs et ah, 2004), egg-white albumen 
(Miguel et al., 2004), Pacific hake protein (Cinq-Mars et al., 2007), mackerel protein 
(Sampath Kumar et a l,  2012), skin of sole and squid protein (Giménez et al., 2009) and 
hoki frame protein (Kim et al., 2007) have all been identified as potential sources of 
antioxidant peptides.
It has been suggested that the whole egg protein is nutritionally better than milk and 
meat protein (Miki et ah, 1984), and is used as a benchmark for measuring the quality 
of other food proteins. Although several studies have focused on the protein albumen, 
(Miguel et a l, 2004; Miguel and Aleixandre, 2006b), few have examined the nutritional 
value of egg yolk proteins, mainly due to the lipid content of yolk, which negatively 
affects human health.
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The main components of egg yolk are phospholipids, triacylglycerols, and proteins. The 
first two components are used as lecithin in food or cosmetics. Accordingly, lecithin is 
used in pharmaceutical applications as a surfactant, a lubricant and as an emulsifying 
agent (Van Nieuwenhuyzen, 1976). The third component of egg yolk is protein, which 
represents approximately 30% of dried egg yolk. During the production of egg yolk 
lecithin, egg yolk protein is produced. Many studies have shown that egg yolk protein 
and its hydrolysates have antioxidant activities (Lee et al., 2002; Sakanaka et al., 2004; 
Sakanaka and Tachibana, 2006).
Park et al. (2001) conducted a study on isolating antioxidant peptides from lecithin-fi*ee 
egg yolk using industrial proteases. Their study showed that the isolated peptides were 
composed of 10 to 15 amino acid residues. Subsequently, other research groups 
(Sakanaka et al., 2004; Sakanaka and Tachibana, 2006) measured the antioxidant 
activity of egg yolk protein hydrolysates, which were obtained using a food-grade 
proteinase fi*om Bacillus sp. Their research showed that egg yolk hydrolysates were 
powerful firee radical scavengers that could be applied as natural antioxidants to prevent 
the oxidation of fatty acids.
While the majority o f the studies related to purifying bioactive peptides have employed 
microbial proteases, such as those involved in milk processing, few studies have used 
enzymes involved in human physiological digestion. Enzymes, including pepsin and 
pancreatin, could be used to demonstrate the impact of physiological digestion on 
proteins that yield bioactive peptides. Therefore, the aim of this study has to produce an 
enriched antioxidant peptide hydrolysate of egg yolk protein (EYP) using enzymatic 
digestion by physiological proteases and to investigate its antioxidant activity.
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To achieve this aim, many isolation and purification methods were employed. Briefly, 
the hydrolysate obtained was fi*actionated using ultrafiltration membranes. The 
antioxidant activity of peptides obtained by ultrafiltration was measured in an oxidising 
linoleic acid system using the ferric thiocyanate method (FTC) and the thiobarbituric 
acid reactive species (TBARS) reaction to select the most effective antioxidant fi*action; 
this was subjected to gel filtration chromatography. The antioxidant activity of the 
resultant peptides was compared with that of commercial antioxidants such as trolox 
and butylated hydroxytoluene (BHT). The composition of amino acids and the 
molecular weight distribution of the isolated peptide were also investigated.
2.2 Materials and methods
2.2.1 M aterials
Materials Suppliers
Chicken eggs Tesco UK
Linoleic acid
Sodium phosphate
BHT
Trolox
Sigma-Aldrich, Dorset, UK.
Sodium dodecyl sulphate (SDS)
2-Thiobarbituric acid (TBA)
Ammonium thiocyanate
Triethylamine (TEA)
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Phenylisothiocyanate (PITC)
Ferrous chloride
Tetraethoxypropane (TEP)
Pepsin from porcine gastric mucosa
Pancreatin from porcine pancreas
Amino acid standards
Hexane
Absolute ethanol
Sodium hydroxide (NaOH)
Hydrochloric acid (HCl)
Acetic acid Fisher Scientific,
Sulphuric acid
Loughborough, UK
Sodium acetate
Boric acid
Kjeldhal catalyst (9.5% Na2S0 4 , 1.5%
C uS04,2.0% Se)
Ultrafiltration membranes (2, 5 and 10 
kDaMWCO)
Vivaspin, Epsom, UK
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2.2.2 Methods
2.2.2.1 Protein extraction and quantification
2.2.2.1.1 Protein extraction
The method used was in accordance with Sakanaka et ah (2004) with some 
modifications that are detailed below. Briefly, eggs were broken and the yolk separated 
from the albumen using filter paper and forceps. In order to remove lipids, egg yolk was 
defatted eight times using hexane and 69% ethanol alternatively with slow agitation 
using a magnetic stirrer (SM5, Stuart Scientific, UK). The ratio of yolk to solvent was 
1:3 (v/v) and 1:5 (v/v) for 69% ethanol and hexane, respectively. The isolated protein 
was filtered and then stored at -80 °C for further study.
2.2.2.1.2 Protein quantification
The Kjeldhal method (AOAC, 2007) was used to quantify the protein content of egg 
yolk before and after extraction. The amount of protein was calculated from the 
nitrogen content. In the first stage (digestion), 1 g of sample was digested in 20 ml 
concentrated sulphuric acid in the presence of a Kjeldhal catalyst. This step was 
conducted using a Tecator Kjeltec apparatus consisting of an autodistillation unit (FOSS 
Kjeltec^”^  2200, Sweden) for intense heating. The mixture was left to boil at 400 °C 
until it became clear. Then the tubes were allowed to cool for 30 minutes. Under these 
conditions, organic material was oxidized and any organic nitrogen was converted to 
ammonium sulphate ([NH4 ]2S0 4 ). In the second stage (distillation), 20 ml of 0.5 M 
NaOH was used to release the ammonia via steam distillation in a Tecator distillation 
unit. The distillate was collected in flasks containing 25 ml of 4% boric acid. In the 
third stage (titration), the quantity of ammonia was estimated by titration using 0.1 M
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HCl in the presence of methylene red as an indicator. The percentage of nitrogen and 
protein was calculated using the following equations:
,  ^ 100 X  [(ml o f  titra n t o f  sam ple — m l o f  titra n t o f  blank) x  0.0014]
N(%) = -------------- ---------- / y — ^ ------------ ------------------------
W eight o f  sam ple m  gram s  
Where, 1 ml of M HCl = 0.0014 g N
Protein content was calculated by multiplying the nitrogen percentage by a constant 
factor. This factor varies slightly between different foodstuffs depending on the precise 
amino acid composition.
Protein(% ) = N x  K 
Where, K  is the conversion factor for egg products = 6.25 (Mariotti et al., 2008).
2.2.2.2 Preparation of protein hydrolysates by enzymatic digestion
The method of Sakanaka et al. (2000) was used. Isolated yolk protein powder (prepared 
using methods detailed in section 2.2.2.1.1) was homogenized with milli-Q water (1:2.5 
w/v) for approximately 3-5 minutes using a magnetic stirrer. The pH of the mixture was 
adjusted to pH 2.0 with 1 M HCl. Pepsin was added to the substrate in the ratio 1:35 
(w/w) and the suspension was incubated at 37 °C with continuous stirring. After one 
hour, the pH was adjusted to pH 7.5 using 1 M NaOH before adding the pancreatin to 
the mixture in the ratio 1:25 (w/w). The mixture was incubated again at 37 °C for 2 
hours with continuous stirring. After the completion of the digestion, the mixture was 
submerged in boiling water for 20 minutes to inactivate the enzyme and terminate the 
digestion process. The hydrolyzed protein was then transferred to centriftige tubes and
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centrifuged at 12000 x g  (Beckman, California, UK) for 15 minutes. The supernatant 
egg yolk protein hydrolysate (EYPH) was then lyophilized and stored at -80 °C for 
further study.
2.2.2.3 Fractionation of egg yolk hydrolysate by ultrafiltration
The freeze-dried EYPH samples produced by the enzymatic digestion step were 
dissolved in a minimum amount of milli-Q water (1:10) and homogenized for 10 
minutes. The solution was sequentially filtered using ultrafiltration membrane cartridges 
with molecular weight cut-offs (MWCO) of 10 kDa, 5 kDa and 2 kDa, moving from the 
highest to the lowest. After passage through each membrane, resultant aliquots were 
centrifuged at 3500 x g  for 30 minutes. The fractions collected from 2 kDa, 5 kDa and 
10 kDa filtrations were lyophilized and stored at -80 °C for further studies.
2.2.2.4 Gel filtration chromatography
Samples were fractionated by gel filtration chromatography using an Ultimate 3000 
HPLC (Thermo Fisher Scientific Inc., Loughborough, UK). The system consists of a 
pump (Ultimate 3000), column (Sephadex G-25), detector (Ultimate 3000 RS variable 
wavelength detector), collector (Foxy R% Fraction Collector) and software 
(Chromeleon). A gel filtration column (2.5 x 90 cm) was filled with Sephadex G-25 
(Sigma-Aldrich, Dorset, UK) and then equilibrated with a 50 mM sodium phosphate 
buffer (pH 7.0). The column was loaded with 240 mg of 2 kDa hydrolysate after 
dissolving in 6 ml of a 50 mM sodium phosphate buffer (pH 7.0) and filtering through a 
0.22 pm Millipore filter. The injected column was eluted with the same buffer for 
10 hours at a constant flow rate of 1 ml/min. Resultant fractions were collected, pooled 
from 15 different chromatogaphy runs, and lyophilized to be ready for measurement of 
inhibition of lipid oxidation activity.
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1 2 2 3  Measurement of lipid oxidation in linoleic acid model system
The inhibition of lipid peroxidation by the EYPH peptides was measured in an 
oxidising linoleic acid model system (Osawa and Namiki, 1985). The FTC method was 
used to monitor the formation of peroxides as primary products from lipid oxidation 
while the TBARS method was used to measure the production of carbonyl compounds 
as secondary lipid oxidation products.
2.2.2.5.1 Preparation of reaction mixtures for the lipid oxidation assays
Antioxidant activity was measured in hydrolysate, ultrafiltration, and gel filtration 
fractions. In a glass tube, 50 mg of each sample was dissolved individually with 10 ml 
absolute ethanol, 0.13 ml linoleic acid, 4.87 ml distilled water and 10 ml 50 mM 
phosphate buffer ^ H  7). Samples were homogenised by a sonicator (Labsonic® M, B. 
Braun Biotech International, Germany). The tubes were then sealed tightly with silicone 
rubber caps and kept in the dark at 40 °C in an oven (Raven oven, LTE Scientific Ltd, 
Great Britain). Aliquots for FTC and TBARS were taken from these samples daily to 
measure the activity over 7 days. A negative control was prepared in the same manner 
using distilled water in place of egg yolk hydrolysates. The commercial antioxidants, 
0.2 mg/ml of BHT and trolox (highest permitted limit commercially) were also used as 
positive controls.
2.2.2.5.2 Ferric thiocyanate (FTC) for peroxide formation
The liberated peroxides oxidise ferrous chloride to the ferric form, resulting in the
formation of a red thiocyanate complex which can be measured by spectrophotometry
(Mitsuda et a l, 1996). At 24 hour intervals, 100 pi aliquots were drawn from each of
the reaction mixtures with a micro syringe and added to a test tube containing 4.7 ml
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75% ethanol (v/v) and 100 pi 30% ammonium thiocyanate (w/v). Then, 100 pi 20 mM 
ferrous chloride solution was added. After exactly 3 minutes, the absorbance of the 
resulting ferric thiocyanate solution was read at 500 nm using a spectrophotometer 
(UVIKON 860, Kontron instrument, UK). The percentage (%) o f lipid oxidation 
inhibition was calculated according to the following formula:
Lipid oxidation inhibition(%) =  “f c o n tro l-A b so r ta n c e  o f  sa m p le  ^
^  A bsorbance o f  con tro l
A  standard curve was prepared by using serial dilution of ferrous chloride fi*om a stock 
solution of 0.20 mg/ml (curve concentration range: 0.04, 0.08, 0.12, 0.16, 0.20 mg/ml) 
(appendix 1). The absorbance of these dilutions was used to calculate the amount of 
peroxide value in the samples.
2.2.2.S.3 Thiobarbituric acid reactive species (TBARS)
Malondialdehyde (MDA), which is produced as a secondary product of the lipid 
oxidation process, was measured according to Ohkawa et ah (1979). In acidic medium 
and at high temperature, thiobarbituric acid (TBA) can bind MDA to form a red- 
complex pigment. At 24 hour intervals, a 50 pi aliquot was drawn from each of the 
previous reaction mixtures with a microsyringe and added to test tubes containing 0.8 
ml of distilled water, 0.2 ml of 8.1% SDS (w/v), (1.5 ml) 20% (w/v) acetic acid (pH 
3.5) and 1.5 ml 0.8% 2- TBA solution in water (w/v). The mixture was heated at 100 °C 
for 60 minutes. After cooling, the mixture was centrifuged at 4300 x g  for 10 minutes 
(Beckman, UK). The absorbance of the upper layer was measured at 532 nm using a 
spectrophotometer (UVIKON 860, Kontron instrument, UK). The % of antioxidant 
activity was calculated according to the following formula:
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Lipid oxidation inhibition(%) =  co n tro l-A b so rb a n ce  o f  sa m p le  ^
^  A bsorbance o f  co n tro l
A standard curve was prepared by using serial dilution of tetraethoxypropane (TEP) 
from a stock solution o f200 pg/ml (curve concentration range: 10, 50,100,150 and 200 
pg/ml) (Appendix 2). The absorbance at these dilutions was used to calculate the 
amount of MDA in the samples, reported as pg/ml of lipid.
2.2.2.S.4 Effects of peptide concentration on lipid oxidation
In order to determine the relationship between the lipid oxidation inhibitory activity and 
peptide concentration, the FTC method was conducted. A wide range of isolated peptide 
concentrations (20, 40, 60, 80, 100 mg/ml) was prepared in a linoleic acid oxidising 
system and the results compared with (0. 2 mg/ml) BHT and (0.2 mg/ml) trolox.
2.2.2.Ô Amino acid composition of isolated egg yolk peptide
2.2.2.6.1 Sample and standard preparation
Amino acid content was determined for samples exhibiting high antioxidant activity 
after the gel filtration process, according to Bidlingmeyer et al. (1987). Each sample 
(5 mg) was dissolved in 5 ml 6 N HCl in dark screw-cap tubes. Oxygen was expelled 
from the samples using a nitrogen pump before incubation in oven at 110 °C for 24 
hours. The hydrolysed samples were then subjected to a derivatisation step followed by 
analysis using HPLC as described below.
2.2.2.6.2 Derivatisation of amino acids with phenylisothiocyanate (PITC)
The derivatization step used was according to Gonzalez-Castro et al. (1997). Aliquots
of 20 pi hydrolysed samples and amino acid standard solution were placed in micro-
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tubes to be dried under vacuum at room temperature for 10 minutes. A 20 pi aliquot of 
drying reagent (see components below) was then added to dissolve the residue followed 
by vortexing. The solution was dried again under vacuum for another 10 minutes. The 
resultant residue was dissolved in 10 pi freshly prepared derivatising reagent (see 
components below). The sample mixture was then vortexed and left for 10 minutes at 
room temperature followed by further vacuum drying for another 10 minutes. The 
residue was dissolved in 20 pi methanol and completely dried under vacuum. Residue 
obtained from each sample was reconstituted in eluent A  and subjected to HPLC 
analysis.
Drying reagent consists of 200 pi methanol, 200 pi IM sodium acetate, and 100 pi 
triethylamine.
Derivatising reagent consists of 140 pi methanol, 20 pi phenylisothiocyanate (PITC), 
20 pi TEA, and 20 pi water.
2.2.2.6.3 HPLC equipment and conditions
Samples were analysed using HPLC system (Ultimate 3000 HPLC, Thermo Fisher 
Scientific Inc., Loughborough, UK) that consists of a pump, autosampler, a detector and 
integration software (Chromeleon). Amino acids were separated on a C l8 reverse-phase 
column (3.9 x 150 mm, 5 pm particle size) using gradient mobile phase consisting of 
two eluents; A  and B  (see table 2.1). Eluent v4 was composed of 0.22 M sodium acetate 
buffer containing 0.05 % (v/v) TEA, pH6.2 (adjusted using glacial acetic acid). Eluent 
B  was composed of 60:40 acetonitrile: water. The gradient profile used is shown in 
table 2.1. Amino acids were then detected at 254 nm.
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Time
(min)
Flow rate 
(ml/min)
Eluent A 
(%)
Eluent B 
(%)
0 1.0 100 0
10.0 1.0 54.0 46.0
10.5 1.0 0.0 100.0
11.5 1.0 0.0 100.0
12.0 1.5 0.0 100.0
12.5 1.5 100.0 0.0
20.0 1.5 100.0 0.0
20.5 1.0 100.0 0.0
Table 2.1. Gradient profile for chromatographic run of amino acids.
22 .2.1 Molecular mass of egg yolk peptides
The molecular mass and amino acid sequence of the most potent antioxidant fi-actions
identified after gel filtration were detennined by quadrupole time-of-flight mass
spectrometry (Q-TOF MS) (Q-STAR-XL, AB Sciex UK Limited, Cheshire, UK)
equipped with a nano-electrospray ionization source (ESI). Samples of 5 mg/ml were
dissolved in 500 pi of 2% acetonitrile containing 0.1% formic acid for the positive
mode. Fraction solutions were filtered through 0.2 pm Millex-GV polyvinylidene
difluoride (PVDF) (4 mm) filter paper (Millipore) then separately infused into the
electro spray source. An aliquot of 0.75 pi from the selected fraction was then directly
injected into the ESI through a harvard syringe pump using a 4 pl/min flow rate for an
8 minute injection. The system was controlled by the Analyst™ software version 1.1 and
peptide sequence information was acquired over the range 250-800 mass/charge (m/z).
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2.2.3 Statistical analysis
All experimental procedures were conducted with at least three independent replications 
on three separate occasions. Results were analysed using GraphPad Prism software 
version 6.0. Statistical analysis comparisons were made by one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test. P < 0.05 was considered 
statistically significant. Data were presented as means ± SD.
2.3 Results
2.3.1 Protein extraction and quantification
Use of organic and inorganic solvents to remove lipids from egg yolk resulted in a white 
powder as shown in figure 2.1. The protein content of the defatted egg yolk powder was 
determined using the Kjeldahl method, which measures total nitrogen and provides an 
accurate estimate of the total protein. The percentage of protein was determined before 
and after the defatting process. The high percentage of protein in the defatted egg yolk 
sample (91.0% ± 0.23) compared with native egg yolk (30.2% ± 0.19) demonstrated 
that the process used to remove lipid was successful.
Figure 2.1. Protein extraction process. Egg yolk before the defatting process (left) and egg 
yolk isolated protein after the defatting process (right).
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2.3.2 Egg yolk protein hydrolysation and ultrafiltration
In this study, the enzymes pepsin and pancreatin were chosen for the hydrolysis step. 
The aim of using a combination of these two enzymes was not only to mimic the 
digestive processes in the human body, but also to achieve a degree of hydrolysis 
greater than that produced when using either pepsin or pancreatin alone.
To isolate an antioxidative peptide from egg yolk, EYPH were fractionated by passing 
egg yolk protein sequentially through three ultrafiltration (UF) membranes with 
MWCOs of 10, 5, and 2 kDa. The ultrafiltered EYPH fractions were called EYUF-10 
(<10 kDa), EYUF-5 (< 5 kDa) and EYUF-2 (< 2 kDa). Table 2.2 shows the total yield 
for each fraction obtained after the ultrafiltration process. Fractions with a molecular 
weight equal to or less than 2 M)a represent the highest yield recovery (70%) followed 
by 12% for < 5 kDa and 10% for < 10 kDa peptides.
Fractions Yield recovery (%)
1 EYUF-10 10 ±1.09
EYUF-5 12 ±1.2
Î
1 EYUF-2 70±2.1
Table 2.2. Fraction yield after ultrafiltration process. Egg yolk protein hydrolysate was 
fractionated using ultrafiltration membranes. EYUF-10 indicates fractions <10 kDa, EYUF-5 
indicates fractions < 5kDa and EYUF-2 indicates fractions < 2kDa. Data correspond to the 
means ± SD of three independent experiments.
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2.3.3 Lipid oxidation inhibition activity of ultrafiltration fractions
The linoleic acid oxidising system was used to verify the oxidation inhibition activity of 
fi-actionated EYPH using the FTC and TBARS methods to choose the most effective 
peptide fractions for further purification. In this study, the antioxidant effect of three 
firactions (table 2.2) from EYPH was investigated and compared with trolox as a natural 
antioxidant and BHT as a synthetic antioxidant.
When the FTC method was conducted, samples were incubated with linoleic acid in the 
model system at 40 °C and peroxide formation was monitored for 7 days as shown in 
(figure.2.2-A). Peak peroxide concentrations were detected on day 4 in all samples, thus 
the percentage of lipid oxidation was estimated at this time point (figure 2.2-B). All 
fi-actions significantly decreased the percentage of lipid oxidation when compared to the 
negative control (all at least p  <0.01). Lipid oxidation (%) in the presence of EYUF-2, 
EYUF-5 and EYUF-10 was 65.86%, 77.36% and 80.74% respectively. BHT and trolox 
also significantly decreased the percentage of lipid oxidation to 23.32% and 32.17% 
respectively, when compared to the negative control (p <0.001).
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Figure 2.2. Effect of fractionated egg yolk protein hydrolysates on lipid oxidation by ferric 
thiocyanate (FTC) method. Lipid oxidation was measured in a linoleic acid model system. (A) 
Peroxide concentration was monitored every 24 hours for 7 days at 500 nm. (B) The pereentage 
of lipid oxidation was measured after four days incubation at 40°C. BHT and trolox (0.2 mg/ml 
of each) were used as positive controls, while milli-Q water was used in the control instead of 
sample. EYUF-10, EYUF-5 and EYUF-2 are fi-actions collected after passing through 10, 5 and 
2 kDa ultrafiltration membranes (50 mg/ml o f each fraction). Data correspond to the means ± 
SD of three independent experiments. ANOVA was performed in Graphpad Prism version 6.0. 
followed by Dumiett’s multiple comparisons test. The result was considered statistically 
significant versus the water control (* - p  < 0.05, ** = p < 0.01, *** - p  < 0.001).
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Lipid oxidation inhibition activity shown by the three fractions was compared with 
trolox (figure 2.3-A) and BHT (figure 2.3-B). Among the fractions, the highest 
inhibition activity was observed in the EYUF-2 sample, followed by EYUF-5, then 
EYUF-10 (34,14 %, 22.63 %, and 19.32 %, respectively) {p <0.001). Inhibitory activity 
was higher in fractions of lower molecular weight, although none were as effective as 
trolox (67.67%) or BHT (76.67%) {p < 0.001 for all comparisons).
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Figure 2.3. Comparative antioxidant activity of fractionated egg yolk protein hydrolysates 
by ferric thiocyanate (FTC) method. Lipid oxidation inhibition activity o f all fractions (50 
mg/ml o f each fraction) was compared to (A) trolox (0.2 mg/ml) as a natural antioxidant 
positive control and (B) BHT (0.2 rng/ml) as a synthetic antioxidant positive control. The 
activity was measured in a linoleic acid oxidising system using the FTC method after four days 
incubation in 40°C. Data correspond to the means ± SD of three independent experiments. 
ANOVA was perforated in Graphpad Prism version 6.0. followed by Durmett’s multiple 
comparisons test. The result was considered statistically significant (* = p <  0.05, ** = p < 0.01,
*** ^ p  < 0.001).
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In the TBARS assay, samples were incubated with linoleic acid in the model system at 
40 °C and formation of MDA was monitored for 7 days as shown (figure 2.4-A), 
Maximal concentrations o f MDA were measured on day 4, which formed the basis of 
this time-point selection for investigation of percent lipid oxidation (figure 2.4-B). The 
percentage of lipid oxidation was significantly decreased in the presence of EYUF-2 
followed by EYUF-5 then EYUF-10 when compared to the negative control (all p  
<0.001; figure 2.4-B). Among the three fractions, the lowest lipid oxidation was 
observed for the 2 kDA fi*action (52.54 %) followed by 5 kDa (56.28%) then 10 kDa 
(61.25%). The presence of BHT and trolox in a linoleic acid model system significantly 
inhibit lipid oxidation to 26.10% and 28.73% respectively when compared to the 
negative control {p <0.001 for both; figure 2.4-B).
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Figure 2.4. Effect of fractionated egg yolk protein hydrolysates on lipid oxidation by 
thiobarbituric reactive substance (TEARS) method. (A) Malondialdehyde concentration was 
monitored every 24 hours for 7 days at 532 nm. (B) Percentage o f lipid oxidation was measured 
after four days incubation at 40°C. BHT and trolox (0.2 mg/ml of each) were used as positive 
controls, while milli-Q water was used in the negative control instead o f sample. EYUF-10, 
EYUF-5 and EYUF-2 are fi-actions collected after passing through 10, 5 and 2 kDa 
ultrafiltration membranes (50 mg/ml of each fi'action). Data correspond to the means ± SD of 
three independent experiments. ANOVA was performed in Graphpad Prism version 6.0. 
followed by Dunnett’s multiple comparisons test. The result was considered statistically 
significant versus the water control (* = p  < 0.05, ** = p <  0.01, *** = p  < 0.001).
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The percentage of lipid oxidation inhibition activity shown by all fractions was 
significantly different to trolox (71.27%) (figure 2.5-A; p  <0.001) as well as to BHT 
(73.89%) as depicted in figure (2.5-B; p  <0.001 ). Lipid oxidation inhibition activity 
exhibited by EYUF-2, EYUF-5 and EYUF-10 was 47.46%, 43.72% and 38.75%, 
respectively.
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Figure 2.5. Comparative antioxidant activity of fractionated egg yolk protein hydrolysates 
by thiobarbituric reactive substance (TBAI^) method. EYUF-10, EYUF-5 and EYUF-2 are 
fractions collected after passing through 10, 5 and 2 kDa ultrafiltration membranes. Lipid 
oxidation inhibition activity of all fi-actions (50 mg/ml of each fraction) was compared to (A) 
trolox (0.2 mg/ml) as a natural antioxidant positive control and (B) BHT (0.2 mg/ml) as a 
synthetic antioxidant positive control. The activity was measured in a linoleic acid model 
system using the TBARS method. Data correspond to the means ± SD of three independent 
experiments. ANOVA was performed in Graphpad Prism version 6.0. followed by Dunnett’s 
multiple comparisons test. The result was considered statistically significant (* = p < 0.05, ** ^
p  < 0.01, *** - p  < 0.001).
2 .3 .4  Lipid oxidation inhibition activity o f purified peptide after gel 
filtration
The EYUF-2 fraction with the highest antioxidant activity was collected from the 
ultrafiltration process and separated by gel filtration chromatography using a Sephadex 
G-25 column in order to obtain more purified peptides. The elution profile generated 
with a flow rate of 1 mFmin is shown in fïgure.2.6.
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Figure 2.6. Elution profile of EYUF-2 separated by GPC on a sephadex G-25 column.
Separation of peptides was detected at 215 nm with flow rate of Iml/min.
Fractions obtained from gel filtration chromatography were pooled then lyophilized and 
their oxidation inhibition activity was assayed using the FTC method. The method was 
conducted as a primary overview of all fi-actions to test their ability to inhibit lipid 
oxidation when used at a concentration of 50 mg/ml. Figure 2.7 shows that oxidation 
inhibition activity was widely observed for all gel filtration fi-actions (EYGF), but the 
most effective fi-actions depicted by shaded bars were EYGF-23 (60.48% inhibition) 
followed by EYGF-33 (59.82% inhibition). These two fi-actions were, therefore, 
collected for further study.
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Figure 2.7. Antioxidant inhibition activity (%) of gel filtration fractions using ferric 
thiocyanate (FTC) method. The activity was analysed for 50 mg/ml o f all fractions separated 
on a Sephadex G-25 column. The absorbance was measured after 4 days incubation at a 
wavelength o f 500 nm. Data correspond to the means ± SD of three independent experiments. 
The results were compared with (0.2 mg/ml) trolox and (0.2 mg/ml) BHT.
FTC and TBARS assays were conducted to compare the antioxidant activity o f  EYUF-2  
obtained from ultrafiltration, and the EYGF-23 and EYGF-33 sub-fractions obtained 
from gel filtration to examine i f  the purification process used w ould alter the inhibitory 
activity. The formation o f  peroxides was monitored over 7 days for selected fractions, 
using trolox and BHT as positive controls and a negative control containing only water 
(figure 2.8-A ). A ll fractions significantly decreased lipid oxidation compared with the 
negative control {p <0.001; figure 2.8-B). From the graph it was clearly observed that 
gel filtration fractions exhibited lower percentage o f  lipid oxidation than ultrafiltration 
ones. Oxidation in the presence o f  EYGF-23 and EYGF-33 was 39.52%  and 40.18% , 
respectively follow ed by ultrafiltration fraction EYUF-2 to reach 65.86% . The 
percentage o f  lipid oxidation was markedly reduced to 23.32%  and 32.17%  in the
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presence of BHT and trolox respectively when compared to the negative control 
ip <0.001 for both; figure 2.8-B).
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Figure 2.8. Effect of EYUF-2, EYGF-23, and EYGF-33 on lipid oxidation analysed by the 
ferric thiocyanate (FTC) method. EYUF-2 was obtained after ultrafiltration and EYGF-23 
and EYGF-33 were obtained from gel filtration (50 mg/ml of each fraction). Lipid oxidation 
was measured in a linoleic acid model system using the FTC method. (A) Peroxide 
concentration was monitored every 24 hours for 7 days at a wavelength o f 500 nm. (B) The 
percentage o f lipid oxidation was measured after four days incubation at 40 °C. BHT and trolox 
(0.2 mg/ml o f each) were used as positive controls, while milli-Q water was used in the negative 
control instead of sample. Data correspond to the means ± SD of three independent 
experiments. ANOVA was perfonned in Graphpad Prism version 6.0. followed by Dunnett’s 
multiple comparisons test. The result was considered statistically significant versus the water 
control (* = /? <  0.05, = p <  0.01, *** = p < 0.001).
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Lipid oxidation inhibition activity was also calculated and compared with the activity of 
trolox (figure 2.9-A) and BHT (figure 2.9-B), EYGF-23 and EYGF-33 achieved 
60.48% and 59.82% inhibition of lipid oxidation, respectively. The activity exhibited by 
the selected fractions from gel filtration was not significantly different to that of trolox 
(67.67%), which was used as a natural antioxidant positive control in the experiment 
(figure 2.9-A). On the other hand, inhibition activity exhibited by gel filtration fractions 
was significantly different compared with the synthetic antioxidant BHT (figure 2.9-B; 
p  <0.01 for both fractions). Moreover, the activity shown by both fractions was 
significantly more effective than EYUF-2, which inhibited lipid oxidation by only 
34.13%.
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Figure 2.9. Comparative antioxidant activity of EYUF-2, EYGF-23, and EYGF-33 
analysed by the ferric thiocyanate (FTC) method. EYUF-2 was after ultrafiltration and 
EYGF-23 and EYGF-33 were obtained from gel filtration (50 mg/ml o f each fraction). Lipid 
oxidation inhibition activity o f all fractions was compared to (A) trolox (0.2 mg/ml) as a natural 
anti oxidant positive control and (B) BHT (0.2 mg/ml) as a synthetic antioxidant positive control. 
The activity was measured in a linoleic acid model system using the FTC method after four 
days incubation at 40 °C. Data correspond to the means ± SD of three independent experiments. 
ANOVA was performed in Graphpad Prism version 6.0. followed by Dunnett’s multiple 
comparisons test. The result was considered statistically significant {* = p <  0.05, * * = p <  0.01, 
***=/? <0.001).
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The same potency of inhibitory activity was found when monitoring the formation of 
MDA for 7 days. Again, figure 2.10-A shows that maximum MDA concentrations were 
observed on day 4. The selected fractions significantly inhibited the formation of MDA, 
which represents one of the secondary products produced as a result of lipid oxidation 
(figure 2.10-B; p  <0.001 for all comparisons). Similar findings were observed as in FTC 
method that gel filtration fractions exhibited higher inhibition activity than 
ultrafiltration fractions. EYGF-23 and EYGF-33 inhibited MDA formation significantly 
to (33.59% and 44.74%, respectively) {p <0.001) followed by EYUF-2 which inhibit the 
formation of MDA to 52.54% (p <0.001).
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Figure 2.10. Effect of EYUF-2, EYGF-23, and EYGF-33 on lipid oxidation analysed by 
thiobarbituric reactive substance (TBARS) method. EYUF-2 was obtained after 
ultrafiltration and EYGF-23 and EYGF-33 were obtained fi*om gel filtration (50 mg/ml o f each 
fraction). Lipid oxidation was measured in a linoleic acid model system using the TBARS 
method. (A) Malondialdehyde (MDA) concentration was monitored every 24 hours for 7 days 
at a wavelength of 532 nm. (B) Percentage of lipid oxidation was measured after four days 
incubation at 40°C. BHT and trolox (0.2 mg/ml o f each) were used as positive controls, while 
milli-Q water was used in the negative control instead of egg yolk fraction sample. Data 
correspond to the means ± SD of three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test. The result was 
considered statistically significant versus the water control {* = p  < 0.05, ** = p  < 0.01, *** = p  
< 0.001).
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The percentage o f  lipid oxidation inhibition activity o f  selected fractions was also  
demonstrated in comparison with trolox and BHT. Am ong the fractions, EYGF-23 
exhibited the highest inhibitory activity (66.4% ) follow ed by EYGF-33 (55.26% ) 
follow ed by E YUF-2 (47.45% ). The activity o f  EYGF-23 was not significantly different 
when compared with trolox as shown in figure. 2. 11-A  or BHT as depicted in figure 
2.11-B .
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Figure 2.11. Comparative antioxidant activity of EYUF-2, EYGF-23 and EYGF-33 
analysed by thiobarbituric reactive substance (TBARS) method. EYUF-2 was obtained 
after ultrafiltration and EYGF-23 and EYGF-33 were obtained fi-om gel filtration (50 mg/ml o f  
each fi-action). Lipid oxidation inhibition activity of all fi-actions was compared to (A) Trolox 
(0.2 mg/ml) as a natural antioxidant positive control and (B) BHT (0.2 mg/ml) as a synthetic 
anti oxidant positive control. The activity was measured in a linoleic acid model system using 
the TBARS method. Data correspond to the means ± SD of three independent experiments. 
ANOVA was performed in Graphpad Prism version 6.0. followed by Dunnett’s multiple 
comparisons test. The result was considered statistically significant (* = /> <  0.05, ** = p  < 0.01, 
* * * = ^ < 0 .001).
2.3.5 Effect of peptide concentration on oxidation inhibition
Inhibition o f  linoleic acid oxidation using serial dilutions o f  EYGF-23 and EYGF-33
(from 20 m g/ml to 100 mg/m l) was observed by the FTC method. Inhibition o f  peroxide
formation increased with EYGF-23 peptide concentration (figure 2.12); the activity
shown by 20, 40, 60, 80 and 100 mg/ml was 53.13% , 59.82% , 67.02% , 72.58%  and
80.13%  respectively. At 80 mg/ml, EYGF-23 exhibited inhibition activity comparable
62
Chapter 2: Purification and isolation o f anti oxidant peptides fi-om egg yolk protein
to trolox and BHT. Moreover, inhibition activity exhibited by 100 m g/m l peptide was 
significantly greater than with trolox (67.67% , p  < 0 .01) (figure 2 .12-A ), but not 
significantly different to BHT (76.67% ) (figure 2.12-B ).
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Figure 2.12. Effect of EYGF-23 concentration on lipid oxidation inhibition. Concentration 
range of EYGF-23 (20, 40, 60, 80, 100 mg/ml) were incubated for 96 hours in a linoleic acid 
oxidising system at 40°C. The activity was measured using the ferric thiocyanate method. 
Trolox (A) and BHT (B) (both 0.2 mg/ml) were used as positive controls. Data correspond to 
the means ± SD o f three independent experiments. ANOVA was perfonned in Graphpad Prism 
version 6.0. followed by Dunnett’s multiple comparisons test. The result was considered 
statistically significant (* = p  < 0.05, ** = p  < 0.01, *** = p  < 0.001).
The same pattern o f  inhibition was observed when different doses o f  EYGF-33 were  
tested. A t concentrations o f  20 mg/ml, inhibition o f  linoleic acid oxidation was 
significantly less compared with trolox {p <0.01), however, inhibitory activity was 
similar to trolox (76.42% ) at higher concentrations o f  EYGF-33 (40 -100 m g/m l) 
(figure 2 .13-A ). Concentrations greater than 60 mg/m l were required to achieve a 
similar effect to BHT (figure 2.13-B ).
63
Chapter 2: Purification and isolation o f antioxidant peptides fi-om egg yolk protein
(A)
100
(B)
.2 ^
3  .2
100
EYGF-33 (mg/ml) EYGF-33 (mg/ml)
Figure 2.13. Effect of EYGF-33 concentration on lipid oxidation inhibition. Concentration 
range of EYGF-33 (20, 40, 60, 80, 100 mg/ml) were incubated for 96 hours in a linoleic acid 
oxidising system at 40°C. The activity was measured using the ferric thiocyanate method. 
Trolox (A) and BHT (B) (both 0.2 mg/ml) were used as positive controls. Data correspond to 
the means ± SD of three independent experiments. ANOVA was performed in Graphpad Prism 
version 6.0. followed by Dunnett’s multiple comparisons test. The result was considered 
statistically significant (* = p  < 0.05, ** = p  < 0.01, *** = p  < 0.001).
2.3.6 Amino acid analysis and determ ination o f molecular mass
Given the substantial inhibitory effects o f  EYGF-23 and EYGF-33 on peroxide and 
M D A  formation, both fi-actions were subjected to amino acid analysis and M S in order 
to elucidate the possible effect o f  amino acid com position and sequence on antioxidant 
activity. The chromatogram o f  amino acids and the calculated composition o f  the 
selected fi-actions after gel filtration are presented in figure 2.14 and table 2.3, 
respectively. W hile EYGF-23 contained large proportions o f  unique pro line (8.01% ), 
electrically charged lysine (11.03% ), and the hydrophobic amino acids tyrosine 
(12.40% ) and tryptophan (16.40% ), EYGF-33 contained hydrophobic amino acids such 
as alanine (7.80% ), leucine (13.82% ), and tryptophan (9.44% ), and positively charged 
lysine (8.27% ) and arginine (11.80% ).
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(A)
(B)
(C)
Figure 2.14. Amino acid chromatograms of (A) amino acid standards, (B) EYGF-23 
peptide after hydrolysis with 6 N HCl and (C) EYGF-33 peptide after hydrolysis with 6 N
HCl. Amino acids were separated on a C l8 reverse-phase column and detected at 254 nm. 
Gradient mobile phase was used consisting o f two eluents; A and B. Eluent A was composed of  
0.22 M sodium acetate buffer containing 0.05 % (v/v) TEA, pH 6.2 (adjusted using glacial 
acetic acid). Eluent B was composed of 60:40 acetonitrile: water.
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Amino acids
Amino acid residues in 
EYGF-23(%)
Amino acid residues 
in EYGF-33(%)
Aspartic acid 3.02 ±0.27
6.22 ± 0.02
Glutamic acid 3.41 ± 0.26 6.55 ±0.014
Serine 3.7 ±0.13 5.77 ±0.001
Glycine 2.60 ±0.11 5.70 ±0.015
Histidine 1.91 ±0.26 1.21 ±0.11
Arginine 3.82 ±0.12
11.80 ±0.001
Threonine 1.101 ±0.04 0.01 ±0.2
Alanine 2.4 ±0.14 7.80 ±0.05
Proline 8.01 ± 0.07 5.12 ±0.006
Tyrosine 12.40 ±0.16 5.01 ±0.011
Valine 5.30 ± 0.23 6.71 ±0.003
Methionine 2.72 ±0.17 0.03 ±0.021
Cysteine 0.90± 0.17 0.04 ±0.13
Isoleucine 3.12 ±0.05 0.10 ±0.09
Leucine 5.7 ±0.39 13.82 ±0.013
Phenylalanine 2.04 ±0.10 1.05 ±0.17
Tryptophane 16.40 ±0.07 9.44 ±0.016
Lysine 11.03 ±0.02 8.27 ±0.003
Table 2.3. Amino acid residues composition of EYGF-23 and EYGF-33. Data correspond to 
the means ± SD of three independent experiments.
EYGF-23 and EYGF-33 were subsequently subjected to MS for peptide sequence
identification. Figure 2.15-A shows the ion scan mass spectrum of EYGF-23; the
peptide sequence infomiation was acquired over the range 200-750 Da m/z. EYGF-33
was also subjected to MS to identify the amino acid sequence, over the range of 250-
66
Chapter 2: Purification and isolation o f antioxidant peptides from egg yolk protein
800 Da m/z as depicted in figure 2.15-B. However, the exact peptide sequences of the 
fractions were difficult to establish due to multiple possibilities and poor matching with 
the known peptide segments in egg yolk protein.
(A)
(B)
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Figure 2.15. Molecular weight distribution profiles of EYGF-23 and EYGF-33. Molecular 
weight distribution profiles o f (A) EYGF-23 and (B) EYGF-33 at small scale (250-750 Da m/z) 
performed by quadrupole time-of-flight mass spectrometry (Q-TOF MS) equipped with an 
electrospray ionisation (ESI) source.
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2.4 Discussion
The ability of bioactive peptides to exhibit antioxidant activity and to replace synthetic 
antioxidants are potentially usuful. Therefore, the aim of the current chapter is to 
investigate the antioxidant activity exhibited by peptides, which had been isolated from 
egg yolk protein. Egg yolk contains storage lipids as neutral lipids and conjugated lipids 
as phospholipids and glycolipids. Therefore, the defatting step was carried out by using 
a combination of hexane and ethanol. Hexane is a non-polar solvent that is considered 
to be a good extractor for neutral lipids, whereas ethanol is a good solvent for removing 
conjugated lipids. The protein content of egg yolk protein isolate was determined using 
the Kjeldahl method, the high percentage of protein content in defatted egg yolk sample 
demonstrated that the process used to remove lipid had been successful.
In this study, egg yolk protein was subjected to enzymatic hydrolysis in order to release 
bio active peptides. Pepsin and pancreatin have different selectivity, therefore they were 
chosen in this study to offer a wide range o f peptide. The high yield of the smaller 
molecular weight fraction, obtained from ultrafiltration process (EYUF-2), indicated 
that EYP was hydrolysed extensively (table 2.2). Chen et al. (1996) illustrated that the 
antioxidant potential o f protein hydrolysates can be enhanced by hydrolysis with 
specific enzymes and optimal conditions used during the proteolysis step. Accordingly, 
many studies have been conducted using enzymatic hydrolysis to improve the 
fimctional properties and activity exhibited by isolated proteins (Vioque et al., 2000; 
Pedroche et al., 2004).
The ultrafiltration process was used as a first step to purify peptides depending on their 
molecular weight. A linoliec acid oxidising system verified the oxidation inhibition
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activity of the peptides using FTC and TBARS methods; the highest activity was 
highlighted by the smallest molecular weight fraction EYUF-2. This finding may relate 
to the small molecular weight of the peptides in this fraction, as many studies have 
shown that peptides of smaller molecular weight exhibit greater antioxidative activity 
(Wu et al., 2003; Kim and Wijesekara, 2010). Therefore, only the EYUF-2 fraction with 
the highest antioxidative activity was chosen for further fractionation.
Further purification by gel filtration led to fractions EYGF-23 and EYGF-33 that scored 
the highest antioxidant activity (figure 2.7). For both FTC and TBARS methods, the 
inhibition activity exhibited by gel filtration fractions EYGF-23 and EYGF-33 was 
higher than the activity exhibited by EYUF-2 (figure 2.9 and figure 2.11). Therefore, 
EYGF-23 and EYGF-33 were chosen for structural characterization due to their highest 
antioxidant activity.
The result obtained from amino acid analysis of both EYGF-23 and EYGF-33 
demonstrated that both of them have different amino acids in their structure, probably 
due to the use of two enzymes with different selectivity. Many studies revealed that 
amino acid content, their sequence in the isolated peptide and peptide size, together play 
an important role in determining the activity of a peptide (Elias et al., 2008; 
Samaranayaka and Li-Chan, 2011).
It is well known that the presence of hydrophobic amino acids in protein hydro lysates or 
peptides elevates their antioxidant activity by increasing peptide solubility in a lipid 
system (Rajapakse et al., 2005; Wang et al., 2007). In this study, the presence of 
hydrophobic amino acids such alanine, tryptophan and tyrosine may play a role in 
increasing the interaction between peptides and fatty acids (table 2.3). Chen et al.
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(1995) isolated antioxidative peptides that contained the hydrophobic amino acid 
residues, valine and leucine at the N-terminus. Chen et al. (1996) illustrated that the 
presence of hydrophobic moieties in an antioxidant peptide was important to obtain 
access to hydrophobic targets. Tryptophan is also an important amino acid and removal 
of the labile hydrogen attached to the nitrogen of its indole ring produces a free radical 
that is easily stabilised due to electron delocalization, thereby allowing tryptophan to 
break the free radical chain reactions and stop the oxidation process (Tsopmo et al., 
2011). Tsopmo et al. (2011) also illustrated that the presence of tryptophan in human 
milk hydrolysates was essential to maintain scavenging activity; activity was markedly 
decreased upon tryptophan deletion.
Tyrosine-containing peptides can also scavenge radicals as shown by peptides derived 
from pepsin-digested cow casein (Suetsuna et al., 2000), and hydrolysed beta 
lactoglobulin produced both tyrosine and tryptophan peptides that could quench radicals 
(Hemandez-Ledesma et ah, 2008). Saeed et al. (2006) suggested that, due to the ability 
of tyrosine to donate hydrogen, it was preferentially oxidised by radicals to protect lipid 
systems from oxidation. As a result, the antioxidant activity of EYGF-23 and EYGF-33 
is thought to be related to their amino acid composition.
2.5 Conclusion
To conclude, the EYGF-23 and EYGF-33 fractions isolated from EYP using proteolytic 
enzymes inhibited oxidation induced in a linoleic acid oxidising system in a dose- 
dependent manner. The presence of hydrophobic amino acids, some of which can 
directly inhibit lipid oxidation due to their aromatic structure, may help to explain the 
mechanism of antioxidant activity of the peptides. The low molecular weight of
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peptides (200 -750 Da) was also an important determinant of antioxidant activity. Free 
radicals and oxidative stress have been implicated as main causative factors in food 
deterioration. Given their antioxidant properties, these results suggest that EYGF-23 
and EYGF-33 may serve as a good source of desirable antioxidant peptides.
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3 Antioxidant mechanisms of peptides derived from egg 
yolk protein
3.1 Introduction
Natural antioxidants included in the diet have drawn the attention of consumers and 
scientific researchers. Food-derived antioxidants play an important role in reducing the 
amount of free radicals and hence their adverse impact on biological systems (Yau, 
1979; Stadtman, 2006; Halliwell, 2009). In food systems, when free radicals attack 
lipids they not only cause alteration in the organoleptic properties, giving unacceptable 
taste, odd flavor and rancidity but also produce toxic compounds that reduce the quality 
and the shelf life of the products (Lin and Liang, 2002; Alghazeer et a l, 2008).
Free radicals such as the hydroxyl radical (OH*) are generated in biological systems via 
the Fenton reaction. The OH’ radical can easily ignite a free radical chain reaction by 
attacking all biological macromolecules (Valko et ah, 2007). The superoxide anion is 
another radical naturally generated in living cells after oxygen uptake (Stief, 2003). This 
radical enhances the formation of other reactive oxygen species (ROS) such as 
hydrogen peroxide, the hydroxyl radical and singlet oxygen. Superoxide anion can also 
react with nitric oxide and form reactive nitrogen species (RNS) such as peroxynitrite, 
which can generate toxic compounds such as nitrogen dioxide (Touyz and Briones, 
2011). Therefore, antioxidants have been used to retard the harmful effect that occurs as 
a result of oxidation.
It is well-known that protein hydrolysates and peptides prepared from food proteins
have emerged as a new source of natural antioxidants (Mine and Shahidi, 2005;
Hartmann and Meisel, 2007; Shahidi and Zhong, 2008). These protein-derived
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compounds have demonstrated strong antioxidant efficacy through different pathways, 
including radical scavenging and metal ion chelating activity (Qian et al., 2008). These 
pathways are discussed further below.
Radical quenching activity by antioxidant peptides is considered one of the most 
effective pathways in the prevention of lipid peroxidation propagation reactions. This 
activity is, therefore, very important as a means of protecting biological systems against 
various diseases and to protect food systems from deterioration. There is a structure- 
function relationship between the amino acid composition and the scavenging activity 
of the isolated peptide. Low molecular weight o f the isolated peptide, the presence of 
specific amino acid residues such as tryptophan and tyrosine, and their sequence within 
the peptide are noticeably correlated with radical scavenging activity of the peptides 
(Pena-Ramos et al., 2004; Elias et al., 2006; Hemandez-Ledesma et al., 2007).
Many studies have revealed that there is a direct correlation between the antioxidant 
activity of bioactive compounds and reducing power (Rice-Evans et al., 1996; Zhu et 
a l, 2006). Under oxidising conditions, where unsaturated fatty acids and active peptides 
are present in the same system, peptides are more susceptible to the donation of 
electrons than lipids. Peptides also form more stable compounds or non-reactive 
polymers through radical-radical interaction (Yildirim et al., 2000; Bougatef et al., 
2009). Therefore, the reducing power assay is often conducted to evaluate the ability o f 
an antioxidant to donate an electron to free radicals and inhibit their actions.
Chelation of transition metals, such as Fe^ "^  and Cu^^ is another cmcial mechanism by 
which antioxidant peptides function (Wang and Xiong, 2005; Megfas et a l, 2008). In 
food systems, the presence of transition metal ions enhances the autoxidation rate and
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formation of reactive oxygen species. Valko et al. (2006) illustrated the ability o f these 
metal ions to react very quickly with peroxides via an electron donation process to form 
alkoxyl radicals; these, in turn, enhance the initiation of the free radical chain reaction. 
Among these metals, ferrous ion (Fe^^ is considered to be one of the crucial pro­
oxidants that catalyses the generation of hydroxyl radicals (OH*) through the Fenton 
reaction. Therefore, chelation of transition metal ions by antioxidant peptides may 
retard the generation of reactive oxygen species and intercept the free radical chain 
process.
In the current study, our potential understanding of the antioxidant mechanisms of egg 
yolk peptides may well lead to the utilisation of egg yolk protein as a source of natural 
antioxidants. Therefore, the present study investigated the antioxidant mechanism of 
egg yolk protein fractions prepared with pepsin and pancreatine, followed by gel 
filtration. Different measurements, including the scavenging effect on free radicals, Fe^ "^  
chelating activity and reducing power are used to evaluate the antioxidant activities.
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3.2 Materials and methods
3.2.1 Materials
Materials Suppliers
Ferrous sulphate
1, 1-diphenyl-2-picrylhydrazyl (DPPH)
a-deoxyribose
Potassium ferricyanide
Ferric chloride
Sigma-Aldrich, Dorset, UK.
Ferrozine
Thiobarbituric acid (TEA)
Trichloroacetic acid (TCA)
Pyrogallol
Ethylenediaminetetraacetic acid (EDTA)
3.2.2 Experimental methods
3.2.2.1 Isolation and purification
EYGF-23 and EYGF-33 were isolated and purified as explained in chapter 2 sections
2.2.2.2 , 2.2.2.3 and 2.2.2.4
3.2.2.2 Reducing power assay
The principle of this assay is based on the reduction of ferricyanides to the ferrous form 
due to the presence of an antioxidant (reductant) in the reaction mixture. The resulting 
ferrocyanides form a complex with ferric chloride, which can be monitored by
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spectrophotometry at 700 nm. Elevations in absorption readings indicate increases in 
electron donating ability and hence the reducing power of the antioxidant.
The ability of the EYGF-23 and EYGF-33 to reduce iron (III) was determined 
according to the method of Yildinm et al. (2000). An aliquot of 1 ml EYGF-23 or 
EYGF-33 samples at different concentrations (0.5, 1, 5, 10 and 20 mg/ml) was mixed 
with 2.5 ml of 0.2 M phosphate buffer previously equilibrated to pH 6.6, and 2.5 ml of 
1% w/v potassium ferricyanide. The mixture was incubated at 50 °C for 30 minutes, and 
2.5 ml of 10 % w/v trichloroacetic acid was added, prior to centrifugation at 1650 x g  
for 10 minutes. Next, 2.5 ml of the supernatant solution was added to 2.5 ml distilled 
water and 0.5 ml of 0.1% w/v ferric chloride. After 10 minutes of reaction time, the 
absorbance of the solution was measured at 700 nm using a UV-visible 
spectrophotometer (Kontron Instrument UNIKON 860, UK). The yellow colour of the 
reaction mixture changed to different degrees of greenish blue depending on the extent 
of reduction. The values presented are the means of triplicate experiments.
3.2.2.3 DPPH (l,l-diphenyl-2-picryIhydrazyI) radical scavenging activity 
assay
DPPH is a stable nitrogen-centred free radical, characterized by its violet colour. The 
exposure of DPPH to hydrogen- or electron-donating substrates makes its purple colour 
fade from violet to yellow coloured diphenylpicrylhydrazine (DPPH-H), as shown 
below. The degree of colour fading reflects the ability of peptides to scavenge DPPH, 
showing maximum absorbance at 517 nm. Substances able to scavenge DPPH can be 
considered as radical scavengers (Ebrahimzadeh et al., 2009).
(DPPH*) + (H-A) ^  (DPPH-H) + (A*)
Purple Yellow
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Therefore, the DPPH method was conducted in this study to investigate the 
effectiveness of EYGF-23 and EYGF-33 as radical scavengers.
The method used was in accordance with Bersuder et al. (1998) using the synthetic free 
radical DPPH. Briefly, a volume of 500 pi EYGF-23 or EYGF-33 at different 
concentrations (0.5, 1, 5, 10 and 20 mg/ml) was mixed with 500 pi of 99.5% ethanol 
and 125 pi of 0.02% w/v DPPH prepared previously in 99.5% ethanol. The mixture was 
shaken vigorously then kept at room temperature in the dark. After 60 minutes, the 
colour reduction of the DPPH substrate was measured at an absorbance of 517 nm using 
a UV-visible spectrophotometer (Kontron Instrument UNIKON 860, UK). Trolox and 
BHT (both used at concentration 0.2 mg/ml) were also tested as positive controls for 
comparison, following the same method as above.
The DPPH radical scavenging activity was calculated as follows:
A —A
Radical scavenging activity(%) = —^ — - x 100
Ac
Where Ac  is the absorbance for negative control samples measured using 500 pi 
deionized water instead of sample, is the absorbance of the sample or positive 
controls (trolox/BHT). A lower absorbance of the reaction mixture indicated a higher 
DPPH radical-scavenging activity. The values are presented as the means of triplicate 
experiments.
3.2.2.4 Hydroxyl radical scavenging activity (HRSA) assay
In the HRSA, hydrogen peroxide was used to oxidize iron from the ferrous state (II) to 
the ferric state (III), and liberate the hydroxyl radical and a hydroxyl anion as follows
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+ H2O2  ► +0H  +0H
The HRSA assay was performed as described by Wu et al. (2003). The reaction mixture 
consisted of 0.1 ml o f 10 mM FeS0 4 , 0.1 ml of 10 mM EDTA, 0.5 ml of 10 mM a- 
deoxyribose, 0.9 ml sodium phosphate buffer pH 7.4, and 0.2 ml of peptides at different 
concentrations (0 .5 ,1 ,5 ,10  and 20 mg/ml). All reagents were then thoroughly mixed in 
a tube and 0.2 ml of 10 mM hydrogen peroxide was added. The reaction mixture was 
then incubated at 37 °C for 1 hour. Following incubation, 1 ml of 2.8% TCA and 1 ml 
of 1.0% TEA were added to the test tubes, and the contents boiled for 15 minutes. After 
cooling at room temperature, the absorbance of the mixture was measured at 532 nm 
using a UV-visible spectrophotometer (Kontron Instrument UNIKON 860, UK). Trolox 
and BHT (both used at concentration 0.2 mg/ml) were also tested as positive controls 
for comparison, following the same method as above. The HRSA was evaluated as a 
percentage of a-deoxyribose oxidation inhibition by the hydroxyl radical and calculated 
as follows:
HRSA(%) =  —-j  —■ X  100
Ac
Where Ac  is the absorbance for negative control samples measured using 500 pi 
deionized water instead of sample. As is the absorbance of the sample or positive 
controls (trolox/BHT). The values presented are the means of triplicate experiments.
3.2.2.5 Superoxide anion scavenging activity (pyrogallol)
In this assay, the alkaline condition enhances the autoxidation of pyrogallol to produce a 
superoxide anion which, in turn, accelerates the autoxidation process by auto catalysis.
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The autoxidation of a pyrogallol method described by Marklund and Marklund (1974) 
was applied to measure the superoxide anion scavenging power o f EYGF-23 and 
EYGF-33, The reaction mixture consisted of 1.0 ml o f peptides sample at different 
concentrations (0.5, 0.1, 5.0, 10 and 20 mg/ml) and 1.8 ml of 50 mM Tris-HCl buffer, 
previously adjusted to pH 8.2. The mixture was incubated at 25 °C for 20 minutes. 
Then, 40 pi of 45 mM pyrogallol (prepared previously in 10 mM HCl) was added. The 
absorbance of the reaction mixture was measured at 320 nm immediately after adding 
pyrogallol at 1 minute intervals up to 4 minutes using a UV-visible spectrophotometer 
(Kontron Instrument UNIKON 860, UK). Trolox and BHT (both used at a 
concentration of 0.2 mg/ml) were also tested as positive controls for comparison, 
following the same method as above.
The 02*~ scavenging activity was calculated as follows:
AAr — AA c
The O2 scavenging activity{%) = — — ------ x 100
Where (AAc) is the autoxidation rate of pyrogallol in negative control samples, 
measured using 1.0 ml deionized water, (AAs) is the oxidation rate of pyrogallol for 
samples or positive controls (trolox/BHT). The values presented are the means of 
triphcate experiments.
3.2.2.6 Ferrous chelating activity assay
The activity of the peptide to chelate ferrous Fe^ "^  ions was measured according to the
method of Boyer and McCleary (1987). In this method, ferrozine was used to determine
the chelating activity of EYGF-23 and EYGF-33. Ferrozine normally forms a water-
soluble magenta-coloured complex with ferrous ions, which can be measured
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spectrophotometrically. In the presence of chelating agents (e.g. peptides), the complex 
formation is interrupted and subsequently the intensity of the magenta colour is reduced, 
as shown by reduced absorbance at 563 nm. Thus, lower absorbance indicates higher 
chelating activity.
The reaction mixture contained 0.5 ml of isolated peptides at different concentrations 
(0.5, 1,5, 10 and 20 mg/ml), 1.6 ml deionized water and 0.05 ml of 2 mMFeCb. After 
30 seconds, 0.1 ml of 5 mM ferrozine was added. After 10 minutes at room temperature, 
the absorbance o f the Fe^^-ferrozine complex was measured at 563 nm using a UV- 
visible spectrophotometer (Kontron Instrument UNIKON 860, UK). EDTA (0.2 mg/ml) 
was also tested as a positive control for comparison, following the same method as 
above.
The activity of the peptide to chelate Fe^ "^  was calculated as:
A —A
Chelating ability (%) = — — - x 100
Ac
Where Ac  is the absorbance of the control, using 0.5ml deionized water instead of 
sample. As is the absorbance of the sample or positive control EDTA (0.2 mg/ml). The 
values presented are the means of triplicate experiments.
3.2.3 Statistical analysis
All experimental procedures were performed with at least three independent repeats. 
Results were analysed using Graph?ad Prism version 6.0. Statistical analysis 
comparisons were made by one-way analysis of variance (ANOVA) followed by
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Duimett’s multiple comparisons test, p  < 0.05 was considered statistically significant. 
Data are presented as means ± SD.
3.3 Results
3.3.1 Reducing power assay
The ability of EYGF-23 and EYGF-33 to reduce the ferricyanide complex to the ferrous 
form was measured in this study using a wide concentration range of peptide (0.5-20 
mg/ml). Ferrous ion can, therefore, be monitored by measuring the Perl’s Prussian blue 
that formed at 700 nm. Table 3.1 shows that the reducing power of EYGF-23 and 
EYGF-33 increased with increased concentration in a dose-dependent manner. The 
absorbance reaches a maximum of 0.26 and 0.29 at a concentration of 20 mg/ml from 
EYGF-23 and EYGF-33, respectively.
Sample concentration (mg/ml)
0.5 ' 1 i 5 : 10 20
EYGF-23 0.06 ±0.01 0.07 ±0.01 0.13 ±0.01 0.18 ±0.01 0.26 ±0.01
EYGF-33 0.04 ±0.01 0.10 ±0.02 0.15 ±0.01 0.23 ±0.01 0.29 ± 0.01
Table 3.1. Reducing power of EYGF-23 and EYGF-33. Reducing power was measured at a 
concentration range of 0.5 to 20 mg/ml. The activity was measured at 700 nm. Data correspond 
to the means ± SD of three independent experiments. Analysis was performed in Graphpad 
Prism version 6.0.
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3.3.2 DPPH radical-scavenging activity
DPPH radical scavenging activity of a range of concentrations of EYGF-23 and EYGF- 
33 was measured and the results were compared with trolox and BHT (positive 
controls) (table 3.2). The scavenging activity of EYGF-23 and EYGF-33 increased with 
the concentration in a dose-dependent manner. The radical scavenging activity exhibited 
by 0.5, 1, 5, 10, 20 mg/ml of EYGF-23 were 8.10, 11.32, 15.61, 19.40, and 28.46 % 
respectively. On the other hand, the activity shown by EYGF-33 for the same 
concentrations was 6.15, 10.99,13.58, 16.47 and 30.65% respectively. When comparing 
the scavenging activity of EYGF-23 and EYGF-33 with trolox, all the concentrations 
used from both fractions were significantly lower than trolox (38.46%, p  <0.05). In 
contrast, only the highest concentration of both fractions (20 mg/ml) exhibited 
significantly higher scavenging activity when compared with BHT (23.60%,/? <0.05).
Sample concentration (mg/ml) Trolox" BHT"
0.5 1 5 10 20 0.2 mg/ml 0.2 mg/ml
EYGF-23 8.10%
±1.43"**
11.32%
±1.05^^
15.61%
±2.30""
19.40%
±1.10"
28.46%
±2.13"" 38.46%
±1.43
23.60%
±1.66EYGF-33 6H594
±lT5*b
10.99%
±1.90"''
13.58%
±1.16""
16.47%
±1.49""
30.65%
±2.86""
Table 3.2. Comparative DPPH radical scavenging activity of EYGF-23 and EYGF-33. The
scavenging activity was measured over a concentration range o f 0.5 to 20 mg/ml from each 
isolated fraction using DPPH radical scavenging. The activity of both fractions was measured at 
517 nm and were compared to BHT as a synthetic antioxidant standard and trolox as a natural 
antioxidant standard (both 0.2 mg/ml). Data correspond to the mean ± SD of three independent 
experiments. ANOVA was performed in Graphpad Prism version 6.0. followed by Dunnetf s 
multiple comparisons test. Values with subscript a to present significant differences with trolox, 
and subscript b to present significant differences with BHTp  <0.05.
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3.3.3 The hydroxyl radical-scavenging activity
A comparison of hydroxyl radical scavenging activity of EYGF-23, EYGF-33, trolox 
and BHT is presented in table 3.3. The scavenging activity of EYGF-23 and EYGF-33 
increased with the concentration in a dose-dependent manner. From the table 3.3, it can 
be seen that all peptide concentrations from EYGF-23 were significantly less effective 
at scavenging hydroxyl radicals in comparison with trolox (70.03%, p  < 0.05). The 
same pattern was observed with EYGF-33 with the exception of the highest 
concentrations (20 mg/ml) which exhibited a non-significant effect compared to trolox. 
Comparative activity was also done between all concentrations and BHT. The results 
show that all concentrations less than 20 mg/ml had a significantly lower effect than 
BHT (58.97%, p  <0.05). While there was no significant difference between EYGF-23 
and BHT at 20 mg/ml, the same concentration of EYGF-33 was significantly more 
effective as a scavenger compared with BHT.
Sample concentration (mg/ml) Trolox" BHT"
0.5 1 5 10 20 0.2mg/ml 0.2 mg/ml
EYGF-23 5.62%
±2.33""
10.575
±1.36""
26.05%
±2.86""
37H5%4
±2.15""
62.37%
±2.21" 70.03%
±3.48
58.97%
±1.02
EYGF-33 5.08%
±1.44""
12.66%
±1.74""
26.78%
±1.57""
42.50%
±2.45""
69.28%
±3.62"
Table 3.3. Comparative hydroxyl radical scavenging activity assay (HRSA) of EYGF-23 
and EYGF-33. The scavenging activity was measured over a concentration range of 
0.5 to 20 mg/ml from each isolated fraction using HRSA assay. The activity o f both fractions 
was measured at 532 nm and compared to BHT as a synthetic antioxidant standard and trolox as 
a natural antioxidant standard (both 0.2 mg/ml). Data correspond to the mean ± SD o f three 
independent experiments. ANOVA was performed in Graphpad Prism version 6.0. followed by 
Dunnett’s multiple comparisons test. Values with subscript a to present significant differences 
with trolox, and subscript b to present significant differences with BHTp  < 0.05.
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3.3.4 Superoxide anion scavenging activity
Table 3.4 presents percentage of radical scavenging activity exhibited by EYGF-23, 
EYGF-33, trolox and BHT. The scavenging activity of EYGF-23 and EYGF-33 
increased with the concentration in a dose-dependent manner. From the table 3.4, it can 
be seen that all peptide concentrations less than 20 mg/ml from both fractions EYGF-23 
and EYGF-33 were significantly less effective as superoxide scavengers in comparison 
with trolox (63.48%,/? < 0.05) as well as BHT (67.45%,/? <0.05). At 20 mg/ml EYGF- 
23, there was no significant difference between the activities shown by this fraction 
(67.66%) compared to trolox or BHT. In contrast, when the same concentration used for 
EYGF-33, the scavenging effect was significantly higher than trolox as well as BHT.
Sample concentration (mg/ml) Trolox" BHT"
0.5 1 5 10 20 0.2 mg/ml 0.2mg/ml
EYGF-23
11.63%
±2.32""
18.12%
±0.51""
30.62%
±1.86""
41.01%
±1.70""
67.66%
±2.14 63.48%
±1.63
67.45%
±1.67
EYGF-33
11.59%
±1.70""
28H394
±2.77""
35.43%
±3.90""
48.85%
±3.14""
82.88%
±2.49""
Table 3.4. Comparative superoxide anion scavenging activity assay of EYGF-23 and 
EYGF-33. The scavenging activity was measured over a concentration range of  
0.5 to 20 mg/ml from each isolated fraction using superoxide anion scavenging activity assay. 
The activity of both fractions was measured at 320 nm and were compared to BHT as a 
synthetic antioxidant standard and trolox as a natural antioxidant standard (both 0.2 mg/ml). 
Data correspond to the mean ± SD of three independent experiments. ANOVA was perfonned 
in Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test. Values with 
subscript a present significant differences with trolox, and subscript b present significant 
differences with BHT/? <0.05.
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3.3.5 chelating activity assay
Table 3.5 shows that the chelating activity of EYGF-23 and EYGF-33 increased with 
the concentration in a dose-dependent manner. From the table, it can be seen that all 
peptide concentrations from both fractions EYGF-23 and EYGF-33 were significantly 
less effective as chelating agent in comparison with EDTA (97.54%,/? < 0.05).
Sample concentration (mg/ml) EDTA"
0.5 1 5 10 20 (0.2 mg/ml)
EYGF-23 12.69%
±1.15"
20.32%
±1.79"
32.45%
±1.84"
64.05%
±1.49"
94.01%
±1.40" 97.54
±1.79
EYGF-33 10.24%
±0.99"
24.39%
±0.94"
41.37%
±0.98"
61.88%
±1.41"
92.22%
±1.66"
Table 3.5. Comparative chelating activity assay of EYGF-23 and EYGF-33. Chelation 
activity was measured over a concentration range o f 0.5 to 20 mg/ml from each fraction using 
Fe^ "^  chelating activity assay. The activity was measured at 563 nm and results were compared 
to EDTA (0.2 mg/ml). Data correspond to the mean ± SD of three independent experiments. 
ANOVA was performed in Graphpad Prism version 6.0. followed by Dunnett’s multiple 
comparisons test. Values with subscript a present significant differences with EDTA/? <0.05.
3.4 Discussion
In order to understand the action of EYGF-23 and EYGF-33 as antioxidants, many 
assays were applied to illustrate the antioxidant mechanism.The results obtained in this 
study from reducing power assay (table 3.1) suggested that EYGF-23 and EYGF-33 
possibly contained amino acids that functioned as electron donors and could react with 
free radicals to fonn more stable products. This result is in agreement with other
86
Chapter 3: Antioxidant mechanisms o f  peptides derived from egg yolk protein
researchers who concluded that the antioxidant activity of isolated peptides related to 
their abilities to donate electrons (Wu et al., 2003; Zhu et al., 2006; He et al., 2013),
According to the amino acid profile of EYGF-23, the presence of pro line (8.01%), 
tyrosine (12.40%), tryptophan (16.40%) and lysine (11.03%) residues could explain its 
activity as a scavenger. The monophenolic structure of tyrosine and the presence of 
an indole ring in tryptophan can both increase stability of the residues and increase their 
reducing power, hereby enabling the isolated fraction to act as a radical scavenger. 
Moreover the presence of proline with its unique cyclic structure can also enhance the 
scavenging properties of the peptide. EYGF-33 also contains leucine (13.82%) and 
tryptophan (9.44%) that might contribute to the scavenging activity. The results 
presented herein concur with previous studies where the researchers report that the 
effect of peptides as antioxidant scavengers is related to the nature and composition of 
amino acids present in this peptide (Je et al., 2005; Kong and Xiong, 2006; Elias et al., 
2008). Many studies have also shown that the hydroxyl radical scavenging activity 
demonstrated by isolated peptides is related to presence of specific amino acids such as 
tyrosine and tryptophan (Mendis et ah, 2005; Pihlanto, 2006; Hemandez-Ledesma et 
a l, 2007; Kim et a l, 2007; Zhuang and Sun, 2011).
Scientists have also reported that the radical scavenging activity of the isolated peptide
is not only related to the composition of amino acids and their nature but also to their
sequence in the peptide. Suetsuna et al. (2000) found that the presence of a glutamate-
leucine sequence in an isolated peptide from casein is responsible for its antioxidant
activity. In other research. Park et al. (2001) suggested that the presence of leucine at
the N-terminus of a peptide isolated from lecithin-free egg yolk protein was mainly
responsible for the scavenging power. Similarly, Ma et al. (2010) demonstrated that the
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presence of a tryptophan at the C-terminus of isolated buckwheat peptides may be 
responsible for its radical scavenging activity. Luo et al. (2013) isolated a peptide with 
the sequence leucine-aspartate-lysine from Sphyma lewini muscle protein, which 
exhibited powerful scavenging activity.
In the current study, the chelating of ferrous ions was used to evaluate the activity of 
EYGF-23 and EYGF-33 as a ferrous chelator. The result obtained revealed that both 
fractions have the ability to act as chelating agents although the activity was 
significantly lower in comparison with EDTA at the concentrations used (table 3.5). 
Ferrous ions can act as catalysts which enhance the generation of free radicals and 
subsequently initiate the oxidative chain reactions. Therefore, chelating agents may 
result in reduced availability of these ions and inhibit the oxidative chain reactions 
(Pokomy et al., 2001). Chen et al. (1995) demonstrated that the sequence of amino 
acids also plays an important role in the metal chelating activity of isolated peptides 
from soybean. The degree of peptide hydrolysis, the type of amino acid and their 
sequence in the isolated peptides have all been shown to alter chelation activity 
(Thiansilakul et al., 2007; Samaranayaka and Li-Chan, 2008; Jamdar et al., 2010; 
Torres-Fuentes et al., 2012). It was noted that, in all methods conducted in this study, 
the efficiency of the peptide as a reductant, scavenger and chelator was dose-dependent.
3.5 Conclusion
In conclusion, the results of the current study show that EYGF-23 and EYGF-33 
possessed notable antioxidant activity. The isolated fraction can act as a reductant and 
quench three different radicals; DPPH, the superoxide anion and the hydroxyl radical. It 
can also exhibit chelating behaviour. In all assays, a good correlation existed between
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the activity shown and the amount of peptide used. According to the amino acid 
analysis presented in the previous chapter (chapter 2), the activities shown in this study 
could be related to the high content of specific amino acids such as tryptophan, and the 
hydrophobic moieties present in the peptide. The variety of mechanisms by which 
EYGF-23 and EYGF-33 exerts their antioxidant activity is indicative of their potential 
to function in diverse oxidising environments.
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4 Antioxidant effect of egg yolk peptide against t-BHP- 
induced oxidative stress in Caco-2 cells
4.1 Introduction
Reactive oxygen species (ROS) are produced in living cells as a result of normal cell 
metabolism and xenobiotic detoxification. Oxidative stress is a consequence o f an 
excess o f ROS, which participate in cellular damage by reacting with lipid membranes, 
proteins, and DNA. The effects of oxidative stress in mammalian cells range from rapid 
cell mortality to disturbance of many cell signalling processes (Klotz et a l, 2003). As a 
result, ROS are implicated in the pathogenesis of many diseases that include 
cardiovascular diseases (Cai and Harrison, 2000), certain cancers (Valko et ah, 2004) 
and Alzheimer’s disease (Christen, 2000).
In response to these threats, aerobic cells utilize a wide array of enzymatic and non- 
enzymatic mechanisms that tightly control unwanted ROS accumulation. Cellular 
antioxidative enzymes such as superoxide dismutase (SOD), glutathione peroxidase 
(GPx) and catalase (CAT) can protect cell membranes and cellular content by 
scavenging ROS. Under certain conditions, excess ROS formation overwhelms the 
prooxidant/antioxidant balance despite the presence o f the antioxidant defence system 
(Kehrer, 1993; Cimen, 2008).
Therefore, there is growing interest to find food-derived antioxidants that can protect 
tissues from free radical-mediated oxidative stress. Natural compounds that have 
antioxidative properties have been identified from plant include polyphenols and some 
dietary protein compounds. Curtin et al. (2002) found that the antioxidant activity of
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these natural products could be mediated by upregulating intracellular defence systems 
or intercepting ROS formation.
The human colon carcinoma (Caco-2) cell line was applied in this research because it 
displays morphological and physiological characteristics that are similar to intestinal 
epithelial cells under standard culture conditions (Meunier et ah, 1995). The purpose of 
using the organic hydroperoxide, tert-butylhydroperoxide (f-BHP), was to generate 
oxidative stress that results in cell injury which initiates intestinal degenerative 
processes (Parks et ah, 1983). The resulting impact of ROS generated by /-BHP leads to 
a depletion of GSH and protein thiols, peroxidation of membrane lipids, DNA damage 
and a loss of mitochondrial membrane potential (Ochi and Cerutti, 1989; Lapshina et 
ah, 2005).
Previous studies indicated that a phosvitin oligophosphopeptide, isolated from egg yolk 
protein, protected intestinal cells from oxidative stress induced by hydrogen peroxide by 
suppressing lipid oxidation, enhancing the synthesis of GSH and increasing its level 
(Katayama et ah, 2006). Prevention of the deleterious effects of excess ROS is 
beneficial to protect cellular membranes and their components. Therefore, the aim of 
this study was to use cultured Caco-2 cells as an epithelial model to investigate the 
antioxidant behaviour of egg yolk peptide in cells exposed to pro-oxidant f-BHP. To 
meet this aim, the change in protective cellular antioxidant defence systems in response 
to oxidative stress was evaluated.
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4.2 Materials and methods
4.2.1 M aterials
Materials Suppliers
Human colon epithelial carcinoma cell line 
(Caco-2).
European Collection of Cell Cultures 
(ECACC).
Pencillin/ streptomycin (antibiotics solution at 
50U/ml)
3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl- 
tetrazolium bromide (MTT) dye Sigma-Aldrich, Dorset, UK
Dimethyl sulphoxide (DMSO)
Tert-\mty\ hydroperoxide (f-BHP)
Lysis buffer
Dulbecco’s modified Eagle’s medium 
(DMEM, high glucose without pyruvate)
Foetal bovine serum (FBS)
5 -(and-6)chloromethyl-2 7 - 
dichlorodihydrofluorescein diacetate acetyl 
ester (CM-HzDCFDA)
Invitrogen, Paisley, UK.
Hanks buffer saline solution (HBSS)
Typsin-EDTA solution (0.03%)
L-glutamine (200 mM)
Non-essential amino acids (NEAA)
Phosphate buffered saline tablet (PBS) Oxoid, Hampshire, UK.
Caspase-Glo® 3/7 Assay. Promega, Southampton, UK.
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Superoxide Dismutase Activity Assay Kit 
(Colorimetric) catalog number ab65354
Abeam®, Cambridge, UK.
OxiSelect™ Catalase Activity Assay Kit 
(Colorimetric) catalog number STA-341 Cell Biolabs, INC., Cambridge, UK.
OxiSelect™ Total Glutathione (GSSG/GSH) 
Assay Kit, catalog number STA-312
4.2.2 Experimental methods
4.2.2.1 Isolation and purification of peptide
The peptides (EYGF-23) and (EYGF-33) were isolated as described in chapter 2, 
section 2.2.
4.2.2.2 Cell culture and treatment
Caco-2 cells were grown in DMEM cell culture medium supplemented with 20% FBS, 
1% glutamine, 1% NEAA, and 1% penicillin/streptomycin. Cells were seeded in 25cm^ 
tissue culture flasks at a concentration of Ix lO" cells/ml and were incubated at 37 “C in 
a 5% CO2 humidified incubator. Cells were sub-cultured when they reached 80% 
confluence and were exposed to treatment when at 50% confluence. Confluent cells 
were harvested using 1 ml trypsin/EDTA after washing with 3 ml PBS.
4.2.2.3 Cell viability (MTT assay)
4.2.2.3.1 Effect of antioxidant egg yolk peptide on cell viability
To determine the effect of EYGF-23 and EYGF-33 on cell proliferation and viability, 
the MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl-tetrazolium bromide) assay was 
conducted. The MTT assay is an in vilxo assay for the measurement of cell proliferation
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and reduction of cell viability. The principle of the assay is based on the reduction of 
tétrazolium MTT salt (yellow colour) to intracellular insoluble formazan crystals 
(purple colour). The reduction is carried out by dehydrogenase enzymes produced by 
metabolically active cells. Formazan crystals are solubilized with dimethyl sulphoxide 
(DMSO) and quantified by spectrophotometry at a wavelength of 492 nm (Roehm et 
a l, 1991).
In order to conduct the assay, cells were cultured in 96-well tissue culture plates by 
adding 200 pl/well of a cell suspension at a concentration o f IxlO''cells/200 pi. After 
24 hours, culture medium was replaced with 200 pi fresh medium containing different 
concentrations of EYGF-23 or EYGF-33 ranging from 0.2 to 4 mg/ml for 24 or 
48 hours. Dose ranges and exposure times were selected to determine the effect of 
peptides on viability in a concentration- and time-dependent manner. Following the 
designated treatment exposure period, 20 pi of 5 mg/ml MTT dye (prepared in PBS) 
were added to each well and incubated at 37°C in a humidified atmosphere with 5% 
CO2. After the 4 hour incubation period, the culture medium was aspirated and 200 pi 
of DMSO were added to solubilize the purple formazan crystals formed. Cell culture 
plates were shaken for 5 minutes at room temperature and the colour intensity was 
measured at 492 nm using a plate reader (Behring Co, Marburg, Germany). A column 
of wells containing untreated cells was used as a negative control at each time point. 
Each experimental condition was tested in triplicate and the experiment repeated three 
times to ensure reproducibility.
95
Chapter 4: Antioxidant effect o f  egg yolk peptide against t-BHP-induced oxidative stress in Caco-2
cells
4.2.2.3.2 Induction of oxidative stress by t-BHP
To determine the minimum concentration o f f-BHP to induce oxidative stress, different 
concentrations were tested using the MTT assay to assess cell viability. Cells were 
cultured in 96-well tissue culture plates by adding 200 pi/ well of cells at a 
concentration of IxlO''cells/200 pi. After 24 hours, culture medium was replaced with 
200 pi fi-esh medium containing different concentrations of f-BHP (1, 3, 5, 10 mM). 
After 2 hours incubation period, MTT assay was carried out as described before (section 
4.2.2.3.1).
4.2.2.3.3 Treatment of Caco-2 cells with EYGF-23 or EYGF-33 peptides and 
t-BHP
The effect of antioxidant peptides on cells stressed with f-BHP was assessed by MTT 
assay. After 24 hours, the culture medium was replaced with 200 pi fresh medium 
containing different concentrations of peptides ranging from 0.2 to 4 mg/ml. Following 
24 hours of incubation, the pre-determined concentration of ^-BHP was added for an 
additional 2 hours. At the end of the incubation time, the MTT assay was carried out as 
described before (section 4.2.2.3.1).
4.2.2.4 Cell morphology
Caco-2 cells were seeded at a density of Ixio" cells/ml in 25cm^ cell culture flasks. 
After reaching 50% confluence, cells were treated with 1.0 mg/ml egg yolk peptide. 
After 24 hours of incubation, 10 pi of 3 mM f-BHP was added and incubated for 
another 2 hours. Changes in cell morphology between untreated control, cells treated 
with f-BHP alone, cells treated with peptide alone and cells treated with f-BHP and
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peptide were investigated using a phase contrast microscope fitted with a camera 
(Nikon Eclipse TSIOO). A 10 x magnification was used to image all cells.
4.2.2.S Measurement of intracellular ROS
The intracellular ROS level in Caco-2 cells was evaluated by flow cytometry with the 
use of a non-fluorescent cell permeable probe (CM-H2DCFDA). This probe was used as 
an intracellular precursor of the fluorescent compound 2 '-dichlorofluorescein (DCF) 
for assessment of oxidative stress levels. Once the non-fluorescent probe penetrates the 
cell membrane, the ester group is removed by intracellular esterases and the product is 
oxidised by cellular ROS to produce highly fluorescent DCF. Fluorescence intensity is 
then measured and analysed at excitation and emission wavelengths of 490 nm and 520 
nm, respectively, using a flow cytometer. Fluorescence is assumed to be directly 
proportional to the concentration of ROS in the cells (Bass et ah, 1983).
Briefly, Caco-2 cells were seeded in 25cm^ flasks at a concentration Ix io" cells/ml. 
When cells reached 50% confluence, the medium was replaced with fresh medium 
containing samples of egg yolk peptides. After a 24 hour incubation period at 37°C in a 
humidified atmosphere with 5% CO2, medium from each flask was collected in 15 ml 
centrifuge tubes and attached cells were washed with 1 ml PBS. After washing, cells 
were harvested using 3 ml trypsin. Trypsinised cells were re-suspended in their 
corresponding collected medium and centrifuged for 3 minutes at 150 x g. After media 
aspiration, cells were resuspended in 500 pi PBS and loaded with 5 pM DCFDA 
(prepared freshly in DMSO). Loaded cells were incubated for 30 minutes at 37°C in a 
humidified atmosphere with 5% CO2. After incubation, cells were kept on ice and in the 
dark until the time of analysis to minimise the photo-oxidation of DCFDA by light.
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Cellular ROS levels were measured using a BD FACSCanto flow cytometer (BD 
Biosciences, California, USA). Forward and side scatters were gated to exclude cell 
debris. At least 10,000 events were acquired in list mode.
4.2.2.6 TEARS formation in Caco-2 cells
MDA formed as a secondary product of lipid oxidation was measured using TBARS 
assay according to the method of Ohkawa et ah (1979). Briefly, Caco-2 cells were 
seeded in 25 cm^ flasks at a concentration Ixio" cells/ml. Cells were treated with
1.0 mg/ml peptide at 50% confluence. After a 24 hour incubation period at 37°C in a 
humidified atmosphere with 5% CO2, cells were washed with 1 ml PBS. After washing, 
cells were treated with 10 pi of 3 mM f-BHP and incubated for 2 hours. Cells were then 
washed with PBS and were removed fi*om the flask by scraping and lysing with 20% 
tricholoroacetic acid (TCA). After lysing, 2 ml of 0.7% TBA was added and the cell 
solution was heated at 100 °C for one hour. After cooling, the solution was centrifuged 
for 10 minutes at 150 x g. The absorbance was measured at 532 nm using a 
spectrophotometer (UVIKON 860, Kontron instrument, UK). A standard curve of
1,1,3,3 -tetramethoxypropane (TEP) was prepared from a 200 pg/ml stock solution 
(curve concentration range: 10, 50, 100, 150 and 200 pg/ml) to estimate the 
concentration of MDA in the sample (Appendix 2).
4.2.2.7 The Caspase-Glo 3/7 assay
The Caspase-Glo 3/7 is a homogeneous, luminescent, assay used in this study to 
measure the activities of caspase-3 and caspase-7. Caspase-3 and -7 are members of the 
caspase family (cysteine aspartic acid-specific protease) that play a key role in apoptosis 
(programmed cell death) in mammalian cells.
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The assay contains a luminogenic caspase-3/7 substrate that contains a tetrapeptide 
sequence (DEVD) in its structure. By adding Caspase-GloR 3/7 Reagent to cultured 
cells, cell lysis will occur followed by caspase cleavage of the substrate. Following 
caspase cleavage, aminoluciferin (a substrate for luciferase) is released resulting in the 
luciferase reaction and generation o f a glow type luminescent signal as depicted in 
figure 4.1. Generated luminescence is proportional to the amount of caspase activity 
present in the sample.
Apoptotic
cell
Caspase substrate
Caspase-3/7
released
Aminoluciferin + DVED-Z + ATP + 0-,
Luciferase
hmnncsocnt
c
=9» r
  ^
Figure 4.1. Schematic diagram to illustrate the principle of Caspase-Glo 3/7 assay.
Caspase-3/7 cleavage of the luminogenic caspase substrate followed by luciferase reaction and 
generation of a glow-type luminescent signal.
The assay was conducted by culturing cells in white-bottomed 96-well tissue culture 
plates by adding 100 pF well of a cell suspension of 1x10"^  cells/100 pi. After 24 hours, 
culture medium was replaced with 100 pi fresh medium / well containing 1.0 mg/ml of 
tested peptide and incubated for another 24 hours. This was followed by 2 hours of 
3 mM r-BHP exposure. In a new white-bottomed 96-well tissue culture plate, 100 pi of
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oxidatively stressed cells and 100 pi Caspase-Glo 3/7 reagent were added and incubated 
for 30 minutes. Luminescence was measured using a luminometer (GloMax® 96 
Luminometer, Promega, USA). The amount of luminescence generated is proportional 
to the amount of caspase activity present.
4.2.2.S Effect of egg yolk peptide on endogenous antioxidant defence 
systems in Caco-2 cells under oxidative stress
4.2.2.8.1 Preparation of cell lysate
Caco-2 cells were seeded in 25cm^ flasks at a concentration o f 1x10^ cells/ml and 
incubated at 37°C in a humidified atmosphere with 5% CO2. When cells reached 50 % 
confluence, the medium was replaced with fresh medium containing samples of
1.0 mg/ml egg yolk peptide and incubated for a further 24 hours. Cells were then treated 
with 3 mM r-BHP to induce stress, and were incubated for 2 hours. Following the 
incubation, culture medium from each tested flask was collected in 15 ml centrifuge 
tubes and attached cells were washed with 1 ml PBS. After washing, cells were 
harvested using 3 ml trypsin. Trypsinised cells were re-suspended in their 
corresponding collected medium and centrifuged for 3 minutes at 150 x g. The 
supernatant was decanted and cell pellets were lysed using 300 pi lysis buffer (50 mM 
Tris HCL, 150 mM NaCl, 1% Nonidet P40 (NP-40), 0.2% SDS solution, 20 pM PMSF, 
1 pg/ml Aprotinin, 1 pg/ml Leupeptin, and ImM Na3V0 4 ). After lysing, cells were kept 
in ice for 20 minutes and stored at -  80°C until used further.
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4.2.2.5.2 Determination of total glutathione concentration
The total reduced and oxidized (GSH and GSSG respectively) glutathione concentration 
was measured quantitatively using the OxiSelect™ Total Glutathione Assay Kit 
according to the manufacturer’s instructions. The principle of this assay is based on the 
ability o f the glutathione reductase enzyme to reduce GSSG to GSH in the presence of 
NADPH (reduced form of nicotinamide adenine dinucleotide phosphate). 
Consequently, the chromogen included in the kit reacts with the thiol group of GSH to 
produce a chromophore compound. The absorbance of the coloured compound was then 
read at a wavelength of 405 nm using a microplate reader (Behring Co, Marburg, 
Germany). Glutathione concentration in cell lysate is proportional to the amount of 
chromophore produced. The unknown concentration o f GSH in the samples was 
calculated by generating a GSH standard curve supplied with the kit. Each experimental 
condition was tested in triplicate and the experiment repeated three times to ensure 
reproducibility.
4.2.2.8.3 Superoxide dismutase assay
Superoxide dismutase (SOD) activity was determined in Caco-2 cell lysate. SOD 
activity was measured using the SOD Activity Assay Colorimetric Kit according to the 
manufacturer’s instructions. The principle of the assay is based on the ability o f SOD to 
catalyze the dismutation of the superoxide anion to H2O2 and molecular oxygen. In the 
kit, WST-1 was used to produce a water soluble formazan dye upon reduction with any 
superoxide anion present in the reaction mixture. The absorbance of formazan dye 
formed was measured at 450 nm using micro plate reader (Behring Co, Marburg, 
Germany). Reduced colour intensity indicated increase the activity of SOD enzyme.
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Each experimental condition was tested in triplicate and the experiment repeated three 
times to ensure reproducibility,
4.2.2.S.4 Catalase assay
In order to measure the level o f catalase in Caco-2 cell lysate. The OxiSelect™ Catalase 
Assay Colorimetric Kit was used according to the manufacturer’s instructions. The 
principle of the assay involves a two-step reaction. In the first step, hydrogen peroxide 
(H2O2) in the cell lysate is decomposed into water and oxygen by the action of catalase. 
The second step occurs when the remaining H2O2 facilitates the coupling of 
chromogenic reagent A and chromogenic reagent B in the presence of horseradish 
peroxide (HR?) as a catalyst. The quinoneimine dye formed is then measured at 520 nm 
using microplate reader (Behring Co, Marburg, Germany); the absorbance measured is 
correlated with the amount o f remaining H2O2 in the reaction mixture. The unknown 
concentration of catalase in the samples was calculated by generating a catalase 
standard curve supphed with the kit. Each experimental condition was tested in 
triphcate and the experiment repeated three times to ensure reproducibility.
4.2.3 Statistical analysis
Each experimental condition was tested in triplicate and the experiment repeated three 
times on separate occasions to ensure reproducibility. Results were analysed using 
GraphPad Prism software version 6.0. Statistical analysis comparisons were made by 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons 
test or by two-way analysis of variance followed by Tukey’s multiple comparisons test 
when appropriate. Details of the statistical test used are provided in the figure legends of
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presented results. P < 0.05 was considered statistically significant. Data were presented 
as means ± standard deviation (SD).
4.3 Results
4.3.1 Cell viability (MTT assay)
4.3.1.1 Cell viability of Caco-2 cells treated with peptides alone
The effect of EYGF-23 and EYGF-33 on the cell viability of Caco-2 cells was assessed 
by MTT assay. Caco-2 cells were cultured and treated with EYGF-23 and EYGF-33 
then incubated for 24 and 48 hours. There was no significant difference in cell viability 
between any of the concentrations used (0.2, 0.4, 0.6, 0.8, 1.0, 2.0, 3.0 and 4.0 mg/ml) 
and the untreated cells after 24 hours in cells treated with either peptide fractions (figure 
4.2).
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Figure 4.2. Cell viability of Caco-2 cells treated with EYGF-23 and EYGF-33 for 24 hours.
Caco-2 cells were cultured and incubated with EYGF-23 and EYGF-33 individually over a 
concentration range o f 0.2 to 4.0 mg/ml. The MTT assay was used to evaluate cell viability after 
24 hours and the absorbance o f solubilised formazan crystals was measured at 492 nm. Data 
correspond to the means ± SD of three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Tukey’s multiple comparisons test.
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At 48 hours, a marked reduction in cell viability was observed in those cells treated with 
EYGF-33 at a concentration of 0.8 mg/ml (71 .51% ,<0.01) (figure 4.3). Cell viability 
significantly decreased with increased EYGF-33 concentration starting from 
1.0-4.0 mg/ml (p <0.001) compared with untreated cells. At 48 hours, EYGF-23 did not 
lower cell viability at any concentration and actually looked to increase cell viability 
compared with the untreated cells. Based on the results obtained, only the EYGF-23 
fraction was studied further in relation to antioxidant activity. Conversely, EYGF-33 
was chosen for study as a potential anticancer agent.
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Figure 4.3. Cell viability of Caco-2 cells treated with EYGF-23 and EYGF-33 for 48 hours.
Caco-2 cells were cultured and incubated with EYGF-23 and EYGF-33 individually over a 
concentration range o f 0.2 to 4.0 mg/ml. The MTT assay was used to evaluate cell viability after 
48 hours and the absorbance o f solubilised formazan crystals was measured at 492 nm. Data 
correspond to the means ± SD o f three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Tukey’s multiple comparisons test. * < 0.05, ** =
p < 0.01, *** =p< 0.001 versus untreated cells.
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4.3.1.2 Cell viability of Caco-2 cells treated with t-BHP as oxidative inducer
In the current study, /-BHP was used to induce oxidative stress in Caco-2 cells. Figure
4.4 demonstrates the cytotoxic effect induced by different concentrations of aBHP 
ranging from 1.0-10.0 inM when cells were treated for 2 hours. The toxicity of /-BHP 
occurred in a dose-dependent manner. All concentrations, including the lowest 
concentrations used, significantly inhibited cell viability {p <0.001) compared with the 
untreated cells. The cytotoxic effect of 1.0, 3.0, 5.0 and 10.0 mM was 85.53, 66.18, 47.7 
and 44.31 % respectively. Based on these results, 3 mM r-BHP was chosen to induce 
stress in Caco-2 cells in the following experiments because it reduces cell viability by 
almost 30 %. The following experiments were performed with the aim of elucidating 
the antioxidant activity of the isolated EYGF-23 peptide.
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Figure 4.4. Effect of t-BHP on Caco-2 cell viabilty. Cultured cells were incubated with a 
range of t-BHP concentrations (1.0 to 10.0 mM) for 2 hours. The MTT assay was used to 
evaluate cell viability, and the absorbance of solubilised formazan crystals was measured at 492 
nm. Data correspond to the means ± SD of tliree independent experiments. ANOVA was 
performed in Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test. * = 
p  < 0.05, ** = p <  0.01, *** = p  < 0.001 versus untreated cells.
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4.3.1.3 Effect of EYGF-23 on Caco-2 cell viability under oxidative stress
To study the effect of EYGF-23 on Caco-2 cells stressed by /-BHP, Caco-2 cells were 
cultured and incubated with different concentrations of EYGF-23 (0.2, 0.4, 0.6, 0.8, 1.0, 
2.0, 3.0 and 4.0 mg/inl) for 24 hours followed by a 2 hour incubation with 3mM /-BHP. 
As depicted in figure 4.5, cells treated with 0.2 - 0.8 ing/ml of EYGF-23 demonstrated 
cell viability levels comparable to cells treated with /-BHP alone. At concentrations of 
EYGF-23 >1.0 mg/ml, cell viability significantly increased compared with the /-BHP 
control ip <0.01 at least). A cell viability of 87.31 % was achieved at 1.0 mg/ml 
ip <0.01), which continued to increase significantly when treated with 2.0, 3.0, and
4.0 mg/ml (93.70, 94.45, and 96.35 % respectively; all p  <0.001). As concentrations of
1.0 mg/ml EYGF-23 and above significantly increased cell viability, the minimum dose 
of 1.0 mg/ml was used to conduct further experiments.
EYGF-23 (mg/ml) + 3mM f-BHP
Figure 4.5. Effect of EYGF-23 on Caco-2 cells stressed with /-BHP. Caco-2 cells were 
incubated with EYGF-23 using a concentration range o f 0.2 to 4.0 mg/ml for 24 hours, followed 
by a 2 hour incubation with 3 mM /-BHP to induce stress. The MTT assay was used to assess 
cell viability, and the absorbance of solubilised fonnazan crystals was measured at 492 nm. 
Data correspond to the means ± SD of tliree independent experiments. ANOVA was perfonned 
in Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test versus treated 
cells with /-BHP alone * ^ p  < 0.05, ** = p  < 0.01, *** - /?  < 0.001.
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4.3.2 Effect of EYGF-23 on the m orphology o f Caco-2 cells under 
oxidative stress
The effect of the EYGF-23 peptide in protecting Caco-2 cells from the oxidative stress 
induced by /-BHP was observed by microscopy. Figure 4.6 illustrates the morphology 
of untreated Caco-2 cells (A), cells stressed with /-BHP alone (B), cells treated with 
EYGF-23 alone (C), and stressed cells treated with 1.0 mg/ml EYGF-23 (D). Stressed 
cells treated with egg yolk peptide appeared healthy compared with those treated with /- 
BHP alone.
aw
Figure 4.6. Morphological changes occurring in the Caco-2 cell line. Morphological changes 
occurring in the Caco-2 cell line in (A) untreated cells, (B) cells treated with /-BHP alone, (C) 
cells treated with 1.0 mg/ml EYGF-23 and (D) cells treated with 1.0 mg/ml EYGF-23 and 
stressed with /-BHP. Each image is magnified by lOx.
4.3.3 Effect of EYGF-23 on intracellular ROS levels in Caco-2 cells 
under oxidative stress
The amount of ROS generated by untreated cells was significantly lower (69.00 %;
p  <0.001) than that produced by cells stressed with /-BHP (75.27 %), as shown in figure
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4.7. ROS production levels in Caco-2 cells treated with 1.0 mg/ml EYGF-23 under 
oxidative conditions were markedly inhibited to 60.00 % {p < 0.001) when compared 
with cells treated by /-BHP alone (75.27%).
60.00%
Figure 4.7. Measurement of intracellular ROS levels in Caco-2 cells. ROS was measured 
using flow cytometry for untreated cells, cells treated with 1.0 mg/ml EYGF-23 alone for 
24 hours, cells exposed to 3 mM /-BHP only for 2 hours or treated with /-BHP for two hours 
after the 24 hour exposure to EYGF-23. Cellular ROS levels were monitored by loading treated 
cells with CM-H2DCFDA probe and measuring the intensity of DCF fluorescence at an 
excitation wavelength of 490 and an emission wavelength of 520 mn. Data correspond to the 
means ± SD of three independent experiments. ANOVA was performed in Graphpad Prism 
version 6.0. followed by Dunnett’s multiple comparisons test. * ^  p < 0.05, **=/>< 0. 01, *** 
= p<  0.001 versus treated cells with /-BHP alone.
4.3.4 Effect of EYGF-23 on lipid peroxidation product (TEARS) in 
Caco-2 cells under oxidative stress
When Caco-2 cells were treated with 3 mM /-BHP for 2 hours, almost 2-fold increase in
lipid peroxidation products was observed compared with untreated cells (32.19 pg/ml
versus 19.85 pg/ml, respectively) (p <0.001) as measured by TBARS (figure 4.8).
However, 1.0 mg/ml of EYGF-23 was able to significantly inhibit the fomiation of
MDA to a concentration of 24.15 pg/ml (p <0.05) in stressed cells when compared with
cells treated by /-BHP alone (32.19).
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Figure 4.8. Measurement of lipid peroxidation product malondialdehyde (MDA) formed 
in Caco-2 cells. MDA level was measured using TBARS method for untreated cells; cells 
treated with 1.0 mg/ml EYGF-23 alone for 24 hours; cells exposed to 3 mM /-BHP only for 2 
hours; or cells treated with /-BHP for two hours after the 24 hour exposure to EYGF-23. 
Harvested cells were treated with TCA and TBA followed by incubation at 100 °C for one hour. 
Absorbance was measured at 532 mn using a spectrophotometer. The amount of MDA in the 
sample was calculated using TEP as standard and was expressed as pg/ml of MDA. Data 
correspond to the means ± SD of three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test. * = p < 0.05, ** 
= /> < 0.01, ***=/)< 0.001 versus treated cells with /-BHP alone.
4.3.5 Caspase activity in Caco-2 cells under oxidative stress
Caspase 3/7 activity in Caco-2 cells under oxidative stress was assessed using a 
luminometer. As demonstrated in figure 4.9, Caco-2 cells exhibited high Caspase 3/7  
activity when treated with the oxidant /-BHP alone (78.00 %). Caspase 3/7 activity 
produced under oxidative stress was significantly inhibited to a third o f  this level 
(26.85 %), when cells were pre-treated with 1.0 m g/m l EYGF-23 (p < 0.001). These 
levels were comparable to when cells were treated with EYGF-23 alone, in the absence 
o f  stress induced by /-BHP.
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Figure 4.9. Measurement of caspase 3/7 activity in Caco-2 cells. Caco-2 cells were exposed 
to 3 mM /-BHP alone for 2 hours, or cells were treated with 1.0 mg/ml EYGF-23 in the 
presence and absence of /-BHP. Caspase 3/7activity was measured using a luminometer. Data 
correspond to the means ± SD of three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test. * = p < 0.05, ** 
= p<  0.01, *** =p < 0.001 versus treated cells with /-BHP alone.
4.3.6 Influence of EYGF-23 on antioxidant defence systems
4.3.6.1 Effect of EYGF-23 on the amount of total glutathione (GSH)
There was a significant depletion of total glutathione in cells treated with /-BHP 
(glutathione 0.10 pM) compared with untreated cells (0.18 pM; p  <0.01). Total 
glutathione level was significantly elevated in stressed cells pretreated with 1.0 mg/ml 
EYGF-23 (0.29 pM) in comparison to cells treated with /-BHP alone {p <0.001). These 
findings are represented in figure 4.10.
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Figure 4.10. Effect of EYGF-23 on the amount of total glutathione (GSH) in Caco-2 cells.
The amount of total glutathione was measured for untreated cells, cells treated with 1.0 mg/ml 
EYGF-23 alone for 24 hours, cells exposed to 3 mM /-BHP only for 2 hours or treated with /- 
BHP for two hours after the 24 hour exposure to EYGF-23. Data correspond to the means ± SD 
of three independent experiments. ANOVA was performed in Graphpad Prism version 6.0. 
followed by Dunnett’s multiple comparisons test. * = p  < 0.05, ** = p  < 0.01, *** = p  < 0.001 
versus cells treated with /-BHP.
4.3.6.2 Effect of EYGF-23 on superoxide dismutase (SOD) activity
Figure 4.11 illustrates that SOD activity was significantly inhibited in cells stressed 
with /-BHP (44.22 %) compared with untreated cells (50.75% ; p  <  0 .05). Cells treated 
with 1.0 m g/ml EYGF-23 prior to oxidative induction exhibited significantly higher 
SOD activity (55.10 %) when compared with cells treated with /-BHP {p <  0.01).
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Figure 4.11. Effect of EYGF-23 on the percentage of superoxide dismutase (SOD) activity 
in Caco-2 cells. The percentage of SOD was measured for untreated cells, cells treated with
1.0 mg/ml EYGF-23 alone for 24 hours, cells exposed to 3 mM /-BHP only for 2 hours or 
treated with /-BHP for two hours after the 24 hour exposure to EYGF-23. Data correspond to 
the means ± SD of three independent experiments. ANOVA was performed in Graphpad Prism 
version 6.0. followed by Dunnett’s multiple comparisons test. * - p <  0.05, ** - p  < 0.01, *** = 
p  < 0.001 versus cells treated with /-BHP.
4.3.6.3 Effect of EYGF-23 on the amount of catalase
There was no significant difference in the concentration o f  catalase between untreated 
cells (18.80 U /m l), cells treated with /-BEEP alone (20.88 U/m l) and cells pretreated with
1.0 m g/m l EYGF-23 prior to their exposure to /-BHP (19.46 U/m l) (figure 4.12).
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Figure 4.12. Effect of EYGF-23 on the level of catalase in Caco-2 cells. The amount of  
catalase in Caco-2 cells was measured for untreated cells, cells treated with 1.0 mg/ml 
EYGF-23 alone for 24 hours and cells exposed to 3mM /-BHP only for 2 hours or treated with 
/-BHP for two hours after the 24 hour exposure to EYGF-23. Data correspond to the means ± 
SD o f tliree independent experiments. ANOVA was perfonned in Graphpad Prism version 6.0. 
followed by Dunnett’s multiple comparisons test. * = p  < 0.05, ** = p  < 0.01, *** = p  < 0.001 
versus cells treated with /-BHP alone.
4.4 Discussion
The results obtained from cell viability assay w hen cells were treated with isolated 
peptide fractions indicated that EYGF-23 in the concentration range used (0.2 - 4 .0  
mg/m l) and under the study conditions, was not toxic to Caco-2 cells. However, at 48 
hours, and at concentrations > 0.8 mg/ml, a second peptide fraction EYGF-33 exhibited  
cytotoxicity (figure 4.3). It is w ell known that the nature and sequence o f  amino acids 
that comprise isolated peptides are important factors that dictate peptide activity (Elias 
et al., 2008; Samaranayaka and Li-Chan, 2011). The cytotoxic behaviour exhibited by  
EYGF-33 could be associated with these factors which are discussed further in chapter 
5.
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In this chapter only fraction EYGF-23 has been considered in relation to its effect on 
reducing oxidative stress in Caco-2 cells. Many studies have demonstrated that /-BHP 
exhibits oxidative stress in different mammalian cells (Heo and Lee, 2005; 
Shivananjappa et a l, 2012; Kim et ah, 2012). Once /-BHP penetrates the cell 
membrane, it can easily degrade to alkoxyl and peroxyl radicals to generate ROS. 
Generating an excess amount of ROS causes changes in membrane integrity and 
permeability, lipid oxidation, DNA damage, and glutathione depletion by alterations in 
intracellular calcium homeostasis (Domanski et al., 2005; Lapshina et al., 2005). Rao et 
al. (1997) demonstrated that oxidative stress induced in Caco-2 cells by peroxides was 
due to tyrosine phosphorylation of membrane proteins causing disruption o f paracellular 
junctional complexes.
In this study, stressed Caco-2 cells were treated with different concentrations of 
EYGF-23. The results obtained in figure 4.5 indicated that the EYGF-23 egg yolk 
peptide had the ability to enhance cell viability and to protect Caco-2 cells from the 
oxidative toxicity induced by /-BHP. The protective effect of EYGF-23 could be related 
to its scavenging activity which was reported in chapter 3. Results obtained from the 
measurement of cellular ROS (figure 4.7) and MDA levels (figure 4.8) in Caco-2 cells 
treated with EYGF-23 under oxidative conditions confirmed the scavenging activity of 
this fraction. These results concur with those observed with peptides isolated from 
Alaska pollack (Je et al., 2005), hoki fish (Kim et a l, 2007), giant squid (Mendis et a l, 
2005a) and silver carp (Zhong et a l, 2011). The observations obtained from 
morphological images confirm the protective effect exhibited by EYGF-23 when 
Caco-2 cells were oxidatively stressed (figure 4.6).
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Peptides with low molecular weight have the ability to easily permeate cell membranes. 
Moreover, the presence of specific amino acids with hydrogen donating ability 
increases the activity of peptides as scavengers. In the current study, EYGF-23 is not 
only characterised by low molecular weight (200-750 Da) as depicted in chapter 2 but 
also by the presence of tyrosine and tryptophan which have a high capacity as hydrogen 
donors.
Cells o f the intestinal epithelium have a very rapid cell turnover rate because tissue 
homeostasis is balanced by cell proliferation and cell death. Any inducing shifts in the 
redox balance by oxidants such as /-BHP could lead to an enhancement in mutagenic 
and apoptotic responses. Subtoxic levels of hydroperoxide result in DNA damage and 
apoptosis, via the activation of the caspase family (Dandrea et al., 2004). Caspases 3 
and 7 are members of this family and represent the downstream caspases. They are 
activated by the upstream proteases and act by themselves to cleave cellular targets 
(Danial and Korsmeyer, 2004). In the current study, the caspase 3/7 activity observed in 
stressed cells was related to the ability of /-BHP to permeate the cell membrane, and 
generate an array of ROS that were involved in a fi*ee radical chain reaction. These 
radicals attack vital components in the cell, causing membrane lipid oxidation, DNA 
damage, and apoptosis. The presence of EYGF-23 as an antioxidant could help intercept 
the free-radical chain reaction, preventing caspase activation and hence inhibiting cell 
apoptosis (figure 4.9).
In this research, the antioxidative activity of EYGF-23 as a radical scavenger and lipid 
peroxidation inhibitor in vitro was confirmed. Therefore, we investigated further 
whether the presence of this peptide in a cell model has potential impact on cellular
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antioxidative enzyme levels. In this regard, Caco-2 cells were treated with EYGF-23, 
prior to inducing stress with /-BHP, in order to measure the activity of superoxide 
dismutase and also to measure the level of total glutathione and level o f catalase.
Glutathione plays a major role in the elimination of hydroperoxide. In a healthy system, 
the high level of total glutathione plays a substantial role in protecting cells from 
unexpected attack by hydroxyl radicals. Under oxidative stress, the increase in 
concentration of peroxides leads to a shift in thiol redox status represented by a severe 
decrease in the reduced form of glutathione (GSH) and an increase in the level of the 
oxidised form (GSSG). In the current study, 3 mM of /-BHP caused significant 
depletion of total glutathione, but this was elevated back to basal levels when cells were 
treated with the isolated fraction prior to stress induction (figure 4.10). The findings 
related to the imbalance of reduced and oxidised forms of glutathione due to /-BHP, led 
to the further examination of other antioxidant enzymes namely SOD and catalase in 
Caco-2 cells when treated with EYGF-23 under oxidative stress.
SOD is responsible for the dismutation of the superoxide anion to hydrogen peroxide 
and a molecule of oxygen (Scandalios, 1993; Inoue et al., 2003). In this study (figure 
4.11), cells treated with 1.0 mg/ml EYGF-23 prior to oxidative induction exhibited 
significantly higher SOD activity (55.10 %) as compared with cells treated with /-BHP 
{p <0.01). These findings illustrate the effect of EYGF-23 on enhancing the activity of 
SOD under oxidative stress.
In contrast, there was no significant difference in catalase level between cells stressed 
with /-BHP and unstressed cells (figure 4.12); this may be explained as follows. The
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role of catalase enzyme in the defence system is to catalyse the decomposition of H2O2 
to water and oxygen; this action is similar to the role o f glutathione peroxidase. Baud et 
a l (2004) measured the Km value (which represents the affinity between the enzyme 
and the substrate) of catalase and glutathione peroxidase. The above author found that 
the high Km of catalase in removing H2O2 (up to 25mM), was 4000-fold higher than the 
Km of glutathione peroxidase (6 pM); this indicated a lower level of activity for catalase 
as compared to that o f glutathione peroxidase. The concentration level of /-BHP used in 
this study may, therefore, not be enough to activate catalase and may explain why there 
was no significant difference in the amount of catalase between cells stressed with 
/-BHP and unstressed cells (figure 4.12).
Although the molecular mechanism of EYGF-23 in the induction of antioxidative 
enzymes is not fully understood, similar up-regulation of antioxidative enzymes has 
been observed following the administration of antioxidants. For example, gelatin 
hydrolysate, obtained from hold skin, significantly increased levels of superoxide 
dismutase, catalase and glutathione peroxidase in a hepatoma cell line (Mendis et a l, 
2005). Young et al. (2010) also prepared egg yolk peptides that have the ability to 
increase the glutathione levels in red blood cells by increasing its synthesis.
4.5 Conclusion
Although both isolated egg yolk protein fractions EYGF-23 and EYGF-33 exhibited 
antioxidant activity by FTC and TBARS methods in oxidising linoleic model systems 
(chapter 2), they exhibited different behaviour on cell viability. EYGF-23 possessed 
antioxidant activity in oxidatively stressed Caco-2 cells and protected them against
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programmed cell death. In contrast, EYGF-33 did not show any protection to Caco-2 
cells at concentrations > 0.8 mg/ml. The protective effect of EYGF-23 was 
demonstrated by the significant increase in Caco-2 cell viability under stressed 
conditions (3 mM /-BHP). Intracellular ROS and malondialdehyde levels were also 
reduced in stress-induced cells treated with EYGF-23. Moreover, EYGF-23 was able to 
inhibit the activity of caspase 3/7 in stressed cells and thus protected cells from induced 
caspase-dependent apoptosis. EYGF-23 was able to increase the level of total 
glutathione and SOD activity but had no significant effect on the level of catalase. All 
of these findings indicate that EYGF-23 causes favourable changes within the cell to act 
as an antioxidant, protecting cells from oxidative stress conditions.
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5 Antiproliferative activity of egg yolk protein 
hydrolysates in a human colon cancer cell line
5.1 Introduction
Cancer is the unrestrained growth of cells forming malignant tumours. Cells undergoing 
unregulated growth can easily invade surrounding tissue and can metastasise to nearby 
sites in the body (Surh, 2003). Due to its uncontrolled and rapid spread, cancer is 
considered a major cause of mortality all over the world. According to the latest cancer 
research UK statistics (2011), colorectal cancers are one of the top ten causes of cancer- 
related deaths and incidence in the UK. Colorectal cancers are the second most 
common cause of cancer mortality (10%) and the third most common cancer incidence 
in men and women (14%) (CRUK, 2011).
Although causes of cancer are diverse and their mechanisms are still not fully defined, a 
wealth of evidence points to lifestyle and diet as risk factors contributing to the cause 
and progression of some types of cancer (Anand et ah, 2008). Lifestyle interventions 
and the development of preventive approaches to control the development of this 
disease have gained interest in recent years. One approach is to use natural bioactive 
compounds occurring in dietary substances as chemopreventative agents (Milner, 2004; 
Stan et a l, 2008).
Bioactive compounds have a wide range of functional groups that allow them to exhibit
many biological functions. In order to exhibit their biological activity, it is important
that they are released or extracted from the parent food source and are resistant to
degradation by gut enzymes (Kris-Etherton et al., 2002). Many studies have revealed
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that bioactive compounds exhibit anti-carcinogenic activity via different mechanisms. 
They may quench ROS and thereby protect cellular components from oxidative stress, 
inhibit cell growth, induce apoptosis, alter cell cycle kinetics and interfere with 
intracellular signal transduction events in cancer cells (Yun, 2003; Hou, 2003; Heber, 
2004).
Bioactive peptides released from plant and animal protein have been the focus of 
increasing interest as anticancer agents due to their properties of multi-functionality and 
high stability (Lee et ah, 2005; Leng et al., 2005). Several protein-rich sources 
including soy bean, milk, and cereal grains that can bear potential anticancer peptides 
have been reported (Kim et al., 2000; Xiao et al., 2004; Ward et al., 2005; Kannan et 
a l, 2008).
Anticancer properties have also been documented in several egg proteins (Kovacs- 
Nolan et a l, 2005). Mine and Kovacs-Nolan (2006) reported that ovomucin, an egg 
white protein, has the potential to inhibit tumour growth by limiting angiogenesis in 
cells. The role of the egg white protein avidin as an anticancer agent may involve 
changes in the host-tumour relationship or the host-mediated antitumor response 
(Gasparri et a l, 1999). Egg white cystatin was also reported as a potential novel 
anticancer agent through its suppression of cysteine proteases. These proteases, when 
tested in cancer cells, are implicated in multiple steps of cancer progression, for 
example in the early stages of immortalization and transformation, in the intermediate 
steps of tumour invasion and angiogenesis, and in the late steps of metastasis and drug 
resistance (Keppler, 2006).
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Colon cancer is second to lung cancer as a leading cause of cancer-related deaths in men 
and women in the UK (CRUK, 2011). Thus, there is an urgent need to intensify efforts 
to identify novel agents that could delay or prevent the development of colon cancer. 
The potential of egg yolk peptides to contribute to anticancer effects has not been 
previously investigated. Therefore, the aim of this study was to examine the effects of 
the isolated egg yolk peptide EYGF-33 on apoptosis, and the generation of ROS in a 
Caco-2 colon carcinoma cell culture model. To achieve this aim, the effect of EYGF-33 
on cell viability and morphology of Caco-2 cells and normal colon cells (HCEC) was 
studied, along with cellular and mitochondrial ROS levels and cell death mechanisms 
induced by EYGF-33.
5.2 Materials and methods
5.2.1 M aterials
Materials Suppliers
Human colon epithelial normal cells 
(HCEC)
Gratefully gifted from Dr. Karen Brown, 
University of Leicester, UK.
Bovine serum albumin (BSA)
Sigma-Aldrich Ltd, Dorset, UK.Propidium iodide (PI)
RNase
Collagen
Invitrogen, Paisley, UK.
Fibronectin
MitoSOX(C43H43N3lP)
WesternBreeze® Chemiluminescent Kit- 
Anti-Rabbit
WesternBreeze® Chemiluminescent Kit- 
Anti-Mouse
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NuPAGE® Novex 4-12% Bis- Tris Gel 1.0 
mm
Invitrolon™ PVDF/Filter Paper 
Sandwiches
NuPAGE® Transfer Buffer (20X) (1 L)
NuPAGE® MOPS SDS running Buffer Kit 
(for Bis-Tris Gels)
NuPAGE® Sample Reducing Agent (lOX) 
(250 pi)
Invitrogen, Paisley, UK.
NuPAGE® EDS Sample Buffer (4X) (10 
ml).
Annexin V-FITC apoptosis detection kit. Merck Chemicals Ltd, Nottingham, UK.
Poly ADP-ribose polymerase (PARP - 
antirabbit # 9532) Cell signaling technology, Elertfordshire, 
UK
p-actin (antimouse #3700).
Champion Amfix developing and fixing 
solution.
First call photography. West Monkton, 
UK
5.2.2 Experim ental m ethods
5.2.2.1 Isolation and purification of EYGF-33
EYGF-33 was isolated and purified as explained previously in chapter 2, sections
2.2.2.1,2.2.2.2,2.2.2.3 and 2.2.2.4.
5.2.2.2 Cell culture
Caco-2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 20% heat-inactivated foetal bovine serum (FBS), 1% pencillin/
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streptomycin, 1% glutamine, and 1% non-essential amino acids. Cells were seeded at 
concentrations of (1 x 10  ^ cells/ml) in 25 cm^ tissue culture flasks (Coming Co., 
Cambridge, MA). Cells were then incubated at 37 °C in a humidified atmosphere with 
5% CO2. When cells reached 80 % confluence, 5 ml phosphate buffered saline solution 
(PBS) was used for cell washing following by 3 ml trypsin/EDTA for cell detaching. 
Fresh medium was added and cells were counted as required in each cell experiment.
HCEC (human colon epithelial normal cells) were cultured in the same way but a 
coating solution was used before the seeding step. Flasks and plates used for culturing 
HCEC cells were coated for at least 10 minutes. Coating solution consisting of 50 
ml culture medium without FBS, 65 pi of 5% BSA, 125 pi fibronectin, and 500 pi of
2.7 % collagen was freshly prepared for each coat.
5.2.2.3 Cell viability (MTT assay)
In order to determine the effect of EYGF-33 on cell proliferation and viability, the MTT 
assay was performed on Caco-2 and HCEC cells according to the method described by 
Roehm et al. (1991). The principle o f the assay is the reduction o f the yellow 
tétrazolium MTT salt to a purple intracellular insoluble formazan crystal, the formation 
of which is quantified by spectrophotometry. The reduction is carried out by 
dehydrogenase enzymes produced by metabolically active cells. The formazan crystals 
formed were solubilized in DMSO and quantified by spectrophotometry at 492 nm.
Briefly, cells were cultured in 96-well tissue culture plates by adding 200 pEwell of a
cell suspension at a concentration of 1x10^ cells/well. After 24 hours, culture medium
was replaced with fresh medium containing different concentrations of EYGF-33
ranging from 0.2 to 4 mg/ml, to determine the time- and concentration-dependent
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effects of EYGF-33 on growth. After incubation for the indicated time point (24 or 48 
hours), 20 pi of 12 mM MTT dye was added to each well and incubated at 37 °C in a 
humidified atmosphere with 5% CO2. Following 4 hours incubation, culture medium 
was aspirated and 200 pi of DMSO was added to solubilize the purple formazan crystals 
formed. Colour intensity was measured at 492 nm using a plate reader (Behring Co, 
Marburg, Germany). Untreated cells at each time point were used as a control.
5.2.2.4 Cell morphology
Caco-2 and HCEC cells were seeded at 1%10  ^ cells/ml in 25 cm^ cell culture flasks. 
After reaching 50 % confluence, cells were treated with EYGF-33 (0, 0.4, and
1.0 mg/ml) and incubated for 24 or 48 hours. Changes in cell morphology were 
investigated using phase contrast microscope fitted with a camera (Nikon Eclipse 
TSIOO). A lOx magnification was used to image all cells.
5.2.2.5 Measurement of intracellular reactive oxygen species (cellular ROS)
The intracellular ROS level in Caco-2 cells was evaluated by flow cytometry with the 
use of a non-ftuorescent cell permeable probe (CM-H2DCFDA). Once the non- 
fluorescent probe penetrates the cell membrane, the ester group is removed by 
intracellular esterases and the product is oxidised by cellular ROS to produce highly 
fluorescent 1 \ 7 -dichlorofluorescein (DCF). Fluorescence intensity is then measured 
and analysed at excitation and emission wavelengths of 490 nm and 520 nm, 
respectively, using a flow cytometer. Fluorescence is assumed to be directly 
proportional to the concentration of ROS in the cells (Bass et al., 1983).
Briefly, Caco-2 cells were seeded in 25 cm^ flasks at a concentration 1%10  ^ cells/ml.
When cells reached 50% confluence, the medium was replaced with fresh medium
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containing samples of EYGF-33 (0, 0.4 and 1.0 mg/ml). After a 48-hour incubation 
period at 37 °C in a humidified atmosphere with 5% CO2, the medium from each flask 
was collected in 15 ml centrifuge tubes and attached cells were washed with 1 ml PBS. 
After washing, cells were harvested using 3 ml trypsin (0.03 % in EDTA). Trypsinised 
cells were re-suspended in their corresponding collected medium and centrifuged for 3 
minutes at 150 xg . After media aspiration, cells were re-suspended in 500 pi PBS and 
loaded with 5 pM DCFDA (prepared freshly in DMSO). Loaded cells were incubated 
for 30 minutes at 37 °C in a humidified atmosphere with 5% CO2. After incubation, 
cells were kept on ice and in the dark until the time of analysis to minimise the photo­
oxidation of DCFDA by light. Cellular ROS levels were measured using a BD 
FACSCanto flow cytometer (BD Biosciences, California, USA). Forward and side 
scatters were gated to exclude cell debris. At least 10,000 events were acquired in list 
mode.
5.1.2.6 Measurement of mitochondrial superoxide production (Mitosox 
ROS)
Mitochondrial ROS were evaluated by flow cytometry using MitoSOX dye. MitoSOX 
is selectively oxidised by superoxide occurring in the mitochondria in living cells to 
produce red fluorescence upon binding to nucleic acids (Robinson et al., 2008). This 
fluorescence can be detected by flow cytometry at an excitation wavelength of 400 nm 
and an emission wavelength o f 590 nm.
For this assay, Caco-2 cells were seeded in 25 cm^ flasks at a concentration
1%10  ^ cells/ml. Cells were treated with samples of EYGF-33 (0, 0.4 and 1.0 mg/ml)
when at 50 % confluence. After 48 hours incubation at 37 °C in a humidified
atmosphere with 5% CO2, medium from each tested flask was collected in 15 ml
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centrifuge tubes and attached cells were washed with 1 ml PBS. After washing, cells 
were harvested using 3 ml trypsin (0.03 % in EDTA). Trypsinised cells were re­
suspended in their corresponding collected media and centrifuged for 3 minutes at 150 x 
g. After media inspiration, cells were re-suspended in 1000 pi HBSS containing calcium 
and magnesium and then loaded with 5 pM of fresh stock solution of MitoSOX 
prepared in DMSO. MitoSOX dye consists of (3,8-phenanthridinediamine, 5-6'- 
triphenylphosphoniumhexyl and 5,6-dihydro-6-phenyl). Loaded cells were incubated 
for 10 minutes at 37 °C in a humidified atmosphere with 5% CO2. After incubation, 
cells were kept on ice and in the dark until analysis to minimise the photo-oxidation of 
MitoSOX by light. Mitochondrial ROS levels were measured with a BD FACSCanto 
flow cytometer. Forward and side scatters were gated to exclude cell debris with 10,000 
events acquired in list mode.
S.2.2.7 Western blotting 
5.2.2.7.1 Preparation of cell lysate
Caco-2 cells were seeded in 25 cm^ flasks at a concentration 1x10^ cells/ml and 
incubated at 37 °C in a humidified atmosphere with 5% CO2. When cells reached 50 % 
confluenee, the medium was replaced with fresh medium containing samples of 
EYGF-33 (0, 0.4, 1.0 mg/ml) and incubated at 37 °C in a humidified atmosphere with 
5% CO2. After 48 hours, culture medium from each tested flask was collected in a 15 
ml centrifuge tube and attached cells were washed with 1 ml PBS. After washing, cells 
were harvested using 3 ml trypsin (0.03 % in EDTA). Trypsinised cells were re­
suspended in their corresponding collected media and centrifuged for 3 minutes at 150 x 
g. The supernatant was decanted and cell pellets were lysed using 300 pi lysis buffer
(50 mM Tris HCL, 150 mM NaCl, 1 % Nonidet P40 [NP-40], 0.2 % SDS solution, 20
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pM PMSF, Ipg/ml Aprotinin, Ipg/ml Leupeptin, and ImM Na3V0 4 ). After lysis, cells 
were incubated on ice for 20 minutes and stored at -  80 °C until required.
5.22.1.2 Quantification of cellular protein concentration
Protein quantification was carried out according to Bradford (1976), using a BioRad 
assay kit. In this assay, bovine serum albumin (BSA; stock concentration 1.5 mg/ml) 
was used to generate a protein standard curve ranging from 0.2-1.5 mg/ml BSA.
Samples were prepared in 96-well plates. A 50 pi aliquot of each standard solution or 
cell lysate (diluted 1:10 in milli-Q water) was added per well. To each well, 25 pi 
working solution (20 pi reagent S / 1000 pi reagent A) was added, followed by 200 pi 
of reagent B. The absorbance of the resulting solution was measured at 690 nm using a 
plate reader (Behring Co, Marburg, Germany). The protein concentration of each 
sample was calculated from the BSA standard curve.
5.2.2.7.3 Gel electrophoresis
Gel electrophoresis was used for the separation of proteins by molecular weight. 
Briefly, 4 pi of sample buffer was added to a micro centrifuge tube containing 20 pg 
protein sample. Then 2 pi of reducing agent was added per tube and made up to a final 
volume of 20 pi with distilled water. Samples were heated at 70 °C for 10 minutes and 
placed immediately in ice for a few minutes. Invitrogen NuPAGE 4-12 % Bis-Tris gel 
was used for electrophoretic separation. An Invitrogen Xcell SureLock Mini-cell 
chamber was filled with NuPAGE® SDS Running Buffer (50 ml MOPS and 950 ml 
distilled water). Each sample (20 pi) was loaded per well into the gel. One well was
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used for loading 20 pi of a pre-stained ladder (Novex Sharp, Invitrogen, Paisley, UK). 
The loaded gel was then run at room temperature for 2.5 hours at 120 V.
S.2.2.7.4 Blotting and developing
After electrophoresis, the gel cassette was removed, washed with distilled water and 
opened with a gel knife. The removed gel and transfer PVDF membrane were soaked in 
methanol and placed into an Invitrogen transfer chamber. The chambers were filled with 
buffer consisting of 50 ml of transfer buffer + 100 ml methanol to a final volume of 1 L 
with distilled water. The transfer step was carried out at room temperature for 2 hours at 
30 V. At the end of transfer period, the transfer membrane was washed three times with 
20 ml distilled water for 5 minutes per wash.
After washing with water, the membrane was soaked in 10 ml blocking solution (0.5 g 
BSA, 2 ml blocker/diluent (Part A), 3 ml blocker/diluent (Part B) and 5 ml distilled 
water) and placed on a rotary mixer at 4 °C to saturate the membrane and reduce non­
specific binding. After one hour, the membrane was exposed to 10 ml primary antibody 
solution (0.5 g BSA, 7 ml distilled water, 2 ml blocker/ diluent (Part A) and 1 ml 
blocker/ diluent (Part B) and 10 pi primary antibody) and incubated overnight at 4 °C 
on a rotary mixer. The membrane was then washed three times with 20 ml antibody 
washing solution (10 ml antibody wash solution and 150 ml distilled water). After the 
washing step, the membrane was exposed to 10 ml of secondary antibody solution (anti­
mouse or anti-rabbit) for 1 hour on a rotary mixer to allow binding of the secondary 
antibody to the primary antibody.
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For developing the protein band on the membrane, the Chemiluminescent Western Blot 
Immunodetection kit was used (Invitrogen, Paisley, UK). In the dark, 2.5 ml 
chemiluminescent substrate was applied to the membrane surface for 5 minutes. Excess 
chemiluminescent reagent was removed using filter paper, the membrane was covered 
with a sheet o f cling film and inserted into a cassette. A piece o f Amersham 
development film was placed on top of the membrane and the cassette was closed 
securely. The exposure time varied from 30 seconds to 10 minutes depending on the 
type of antibody used (table 5.1). After the indicated time, the films were developed and 
fixed using 1 litre of champion amfix developing and fixing solution, respectively (First 
call photography. West Monkton, UK).
Type of antibody Host Concentration(Antibody:soIution)
Exposure
time
PARP Rabbit 1:1000 (v/v) 10 minutes
P-actin Mouse 1:1000 (v/v) 1 minute
Table 5.1. Type, concentration and exposure time of antibodies used in Western blotting. 
5.2.2.8 Apoptosis assay (Annexin V-FITC)
In this study, the occurrence of apoptosis was evaluated using the Annexin V-FITC 
staining technique. In healthy viable cells, phosphatidylserine (PS) is located in the 
inner layer of the plasma membrane bilayer. When apoptosis is induced, the cell 
membrane loses its integrity, which permits PS to move and relocate to the outer 
membrane layer. Externalised PS can be detected using Annexin V-FITC. To
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discriminate living cells from apoptotic, necrotic, and dead cells, the combination of 
Annexin V-FITC and propidium iodide (PI) staining was used. In healthy cells with an 
uncompromised cell membrane, cells cannot be stained with either Annexin V-FITC or 
PI. In early apoptosis, cells are stained only with Annexin V-FITC but not PI. As these 
cells began to die (late apoptosis or necrosis), they are stained with Annexin V-FITC 
and PI (double positive). Cells stained only with PI are dead (figure 5.1).
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Q4
Q4: Dead cells 
AV(-ve), PI(+ve)
Q1
Ql: Live cells 
AV(-ve), PI (-ve)
Q3: Late apoptotic 
AV(+ve), PI (+ve)
Q2; Early apoptotic 
AV(+ve), PI ( ve)
Figure 5.1. A typical histogram obtained by flow cytometry for cells treated with Annexin.
(Ql) represents healthy non-stained cells (AV-ve/PI-ve); (Q2) represents cells in early apoptotic 
stage conjugated with AV (AV+ve/PI-ve); (Q3) represents cells in late apoptotic stage 
conjugated with AV and stained with PI (AV+vcyPI+ve); and (Q4) represents dead cells stained 
with PI (AV-ve/PI+ve).
The procedure was carried out according to methods described in the Annexin V-FITC 
apoptosis detection kit (Merck Millipore, Nottingham, UK). Briefly, Caco-2 cells were 
seeded in 25 cm^ flasks at a density of 1x10* cells/ml and incubated at 37 °C in a 
humidified atmosphere with 5% CO2. When cells reached 50% confluence, they were 
treated with EYGF-33 (0, 0.4, and 1.0 mg/ml) and maintained for 48 hours. Growth 
medium was collected from each flask before trypsinisation to collect cells detached 
during cell death process. After washing with PBS, cells were trypsinised and re­
suspended in this media. The suspended cells were centriftiged for 5 minutes at 150 xg .
The cell pellet was then re-suspended in 500 pi ice-cold binding buffer followed by the 
addition of 25 pi conjugated Annexin V-FITC. After 15 minutes incubation in the dark 
at room temperature, the suspension was centrifuged, the supernatant was discarded, 
and the cell pellet was suspended in 500 pi binding buffer. The addition and gentle 
mixing of 10 pi (1 mg/ml) PI to the final volume was performed to identify cells with 
diminished membrane integrity. The cells were kept on ice until analysed by BD
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FACSCanto flow cytometer (BD Biosciences, San Jose, USA) to quantitatively measure 
cells undergoing cell death. Forward and side scatters were used for gating to exclude 
cell debris. Fluorescence emission was detected in the FL-1 channel (519 nm) for cells 
labelled with Annexin V-FITC and in the FL-2 channel (617 nm) for cells labelled with 
PL For each experimental sample, a total of 10,000 events were acquired for Annexin 
V-FITC and PI stain.
5.2.2.9 Cell cycle assessment
Caco-2 cells were seeded in 25 cm^ flasks at a density of 1x10* cells/ml and incubated 
at 37 °C in a humidified atmosphere with 5% CO2. EYGF-33 (0, 0.4, and 1.0 mg/ml) 
was added when cells reached 50 % confluence. Treated cells were then maintained for 
48 hours. The media was collected from each flask before trypsinisation and retained so 
that cells could be re-suspended in this media after washing with PBS. The suspended 
cells were then centrifuged for 5 minutes at 150 x g. The pellet was then re-suspended 
with 200 pi cold PBS followed by 1 ml cold fixing buffer (70% ethanol in PBS). Fixing 
buffer was added drop-wise while vortexing to achieve full fixation and full clump 
separation. Fixed cells were spun in order to remove ethanol fixing buffer after 
overnight incubation at 4 °C. PBS was used for cell washing followed by the addition of 
10 pM of RNAse. After 30 minutes incubation at 37°C, 10 pi (1 mg/ml) PI staining dye 
was added and cells were kept on ice until analysed using a BD FACSCanto flow 
cytometer. A minimum of 10,000 events was acquired in list mode and analysed at 
excitation and emission wavelengths of 535 nm and 617 nm, respectively.
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5.2.3 Statistical analysis
Each experimental condition was tested in triplicate and the experiment repeated three 
times on separate occasions to ensure reproducibility. Results were analysed using 
GraphPad Prism software version 6.0. Statistical analysis comparisons were made by 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons 
test or by two-way analysis of variance followed by Tukey’s multiple comparisons test 
when appropriate. Details o f the statistical test used are provided in the figure legends of 
presented results, p  <0.05 was considered statistically significant. Data are presented as 
means ± standard deviation (SD).
5.3 Results
5.3.1 Effect of EYGF-33 on cell viability and morphology
The MTT assay evaluated the number of living cells that remained after exposure of 
EYGF-33 to Caco-2 and HCEC cells. After 24 hours incubation (figure 5.2), cell 
viability of Caco-2 cells was similar to untreated cells with no significant difference 
among all concentrations used. After the same incubation period, there was a significant 
increased in HCEC cell viability {p < 0.001) when a higher concentration range of 
EYGF-33 (from 0.6 to 4.0 mg/ml) was used.
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Figure 5.2. Cell viability of Caco-2 cells and HCEC treated with EYGF-33 for 24 hours 
using the MTT assay. Cells were treated with different concentrations (0.2, 0.4, 0.6, 0.8, 1.0, 
2.0, 3.0 and 4.0 mg/ml) o f EYGF-33. Cell viability was measured after 24 hours incubation 
with the peptide fi-action. The absorbance of formazan crystals was monitored at 492 nm using 
a spectrophotometer. Data correspond to the means ± SD o f three independent experiments. 
ANOVA was performed in Graphpad Prism version 6.0. followed by Tukey’s multiple 
comparisons test. The result was considered statistically significant versus the control, untreated 
cells, {* = p<  0.05, ** ^  p < 0.01, *** =p < 0.001).
After 48 hours, cell viability of Caco-2 cells was significantly reduced (p < 0.01) when 
treated with 0.8 mg/ml EYGF-33 compared with untreated cells (71.51 % and 100 % 
viability respectively; figure 5.3). Cell viability reduced to 54.26%, 45.15% and 43.10% 
when cells were treated with 1.0, 2.0 and 3.0 mg/ml EYGF-33, respectively. The largest 
reduction in Caco-2 cell viability (34.36 % ,p < 0.001) was observed in the presence of
4.0 mg/ml EYGF-33. In contrast, HCEC cell viability was not significantly affected by 
any concentration of EYGF-33 (figure 5.3). This result indicates that EYGF-33 peptide 
significantly reduced the viability of cancer cells after 48 hours, whilst causing no 
toxicity to nonnal colon cells. According to the results obtained in figure 5.3, the I C 5 0  
was estimated to be 1.0 mg/ml when using a 48-hours incubation time with EYGF-33 .
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Figure 5.3. Cell viability of Caco-2 cells and HCEC treated with EYGF-33 for 48 hours 
using the MTT assay. Cells were treated with different concentrations (0.2, 0.4, 0.6, 0.8, 1.0, 
2.0, 3.0 and 4.0 mg/ml) o f EYGF-33. Cell viability was measured after 48 hours incubation with 
the peptide fraction. The absorbance o f fonnazan crystals was monitored at 492 nm using a 
spectrophotometer. Data correspond to the means ± SD of three independent experiments. 
ANOVA was performed in Graphpad Prism version 6.0. followed by Tukey’s multiple 
comparisons test. The result was considered statistically significant versus the control, untreated 
cells, ( *= / ? <  0.05, ** - p <  0.01, *** = p  < 0.001).
The effect of EYGF-33 on the morphology of both cell types was monitored for 24 and 
48 hours. Cells were treated with 1.0 mg/ml and 0.4 mg/ml EYGF-33 and the 
morphology was compared with untreated cells. After 24 hours incubation, the 
morphology of Caco-2 cells as well as HCEC cells did not show noticeable difference 
between untreated and treated cells. The same observation was noticed in cell growth 
when both types of cells were treated with 0.4 mg/ml EYGF-33 and incubated for 
48 hours. At 1.0 mg/ml EYGF-33, Caco-2 cell growth was considerably inhibited after 
48 hours (figure 5.4) while HCEC cells treated with same concentration, exhibited no 
noticeable change in cell morphology (figure 5.5). These observations confmned the 
results obtained from cell viability assays, which indicated that EYGF-33 reduces cell 
viability of colon cancer cells without cytotoxic effects in normal colon cells, at the
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concentrations used, after 48 hours incubation. Therefore, based on both MTT results 
and morphological observations, subsequent experiments used EYGF-33 concentrations 
of 1.0 and 0.4 mg/ml with an incubation period of 48 hours.
EYGF-33
Control 0.4 m g/m l 1.0 m g/m l
24 hour
48 hour
mm
Figure 5.4. Morphological characteristics of the Caco-2 cell line after 24 and 48 hours.
Caco-2 cells were treated with 0.4 and 1.0 mg/ml EYGF-33. Images were taken after 24 and 
48 hours incubation using light microscopy at lOx magnification.
EYGF-33
Control
24 hour
48 hour
0.4 m g/m l 1.0 m g/m l
^mmwm
mmm
Figure 5.5. Morphological characteristics of the HCEC cell line after 24 and 48 hours.
HCEC cells were treated with 0.4 and 1.0 mg/ml EYGF-33. Images were taken after 24 and 
48 hours incubation using light microscopy at lOx magnification.
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5.3.2 Effect o f EYGF-33 on cellular and m itochondrial ROS
Changes in the eellular and mitochondrial redox status of Caco-2 cells, when treated 
with EYGF-33, were monitored by flow cytometry using a fluorescent probe. In figure 
5.6-A, cellular ROS levels in untreated cells (55.2%) were similar to levels in cells 
treated with 0.4 mg/ml (58.8%) and 1.0 mg/ml EYGF-33 (47. 4%; figure 5.6-A).
Although there was no significant difference in intracellular ROS levels between 
untreated and treated cells, mitochondrial ROS levels in cells treated with 1.0 mg/ml 
EYGF-33 were significantly higher than untreated cells (p <0.05). In figure 5.6-B, 
mitochondrial ROS levels in untreated cells and in cells treated with 0.4 mg/ml 
EYGF-33 were 53.8% and 62.9% respectively. In cells treated with 1.0 mg/ml 
EYGF-33, mitochondrial ROS levels were 67.0% which is significantly higher than the 
mitochondrial ROS level in untreated cells (53.8%; p  <0.05).
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Figure 5.6. Effect of EYGF-33 on cellular and mitochondrial ROS levels using flow 
cytometry. Caco-2 cells were treated with 0.4 and 1.0 mg/ml EYGF-33 for 48 hours. (A) 
Cellular ROS were monitored by loading treated cells with CM-H2DCFDA probe and 
measuring the intensity o f DCF fluorescence at 490 nm excitation and 520 nm emission. (B) 
Mitochondrial superoxide was monitored by loading treated cells with MitoSOX dye and 
measuring the intensity o f fluorescence at 400 nm excitation and 590 nm emission. Data 
correspond to the means ± SD of three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Dunnett’s multiple comparisons test. The result was 
considered statistically significant versus the control, untreated cells, {* = p  < 0.05, 
* * - p < O . O I ,  * * * = p <  0.001).
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5.3.3 Effect of EYGF-33 on Poly ADP-ribose polym erase (PARP) 
expression
Western blotting was performed to determine if PARP protein expression was affected 
by EYGF-33 treatment, with the intention of elucidating the mechanism of cell death. 
PARP cleavage was detected when cells were treated with 1.0 mg/ml EYGF-33 only, as 
shown in (figure 5.7). PARP is an important downstream biomarker of apoptosis; 
therefore, its cleavage indicated programmed cell death (apoptosis).
EYGF-33
concentration
U ntreated 0 .4  m g /m l 1.0  m g /m l
PARP (116 kDa)
Cleaved PARP 
(89kDa)
^  p-actin  
(45 kDa)
Figure 5.7. Western blot of PARP expression in Caco-2 cells treated with EYGF-33.
Cellular protein was extracted from Caco-2 cells after treatment with 0.4 mg/ml or 1.0 mg/ml 
EYGF-33 for 48 hours. Gel electrophoresis was used for protein separation and Western blot 
analysis, accompanied with chemiluminescence detection when a PARP-specific antibody was 
applied to develop protein bands. Equal protein loading (20 pg/well) was confirmed using 
P-actin expression.
5.3.4 Effect of EYGF-33 on phosphatidylserine (PS) externalization
The initiation of cell death by apoptosis was also investigated by examining the effect 
of EYGF-33 on PS externalization in Caco-2 cells using flow cytometry. The images 
(figure 5.8 A) represent the flow cytometry results obtained for untreated cells (control),
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cells treated with 0.4 mg/ml EYGF-33 and cells treated with 1.0 mg/ml EYGF-33 
respectively. Apoptosis was significantly induced in Caco-2 cells when treated with
1.0 mg/ml EYGF-33 ip <0.001; figure 5.8), while there was no significant difference 
between untreated cells and cells treated with 0.4 mg/ml EYGF-33 in early apoptotic 
(Q2), late apoptotic (Q3) and dead cells (Q4).
Figure 5.8-B, represents the percentage of cells in each quadrant (Q). In early apoptotic 
(Q2), the percentage of cells was 3.3%, 5.7% and 14.9% for untreated cells, cells treated 
with 0.4 mg/ml EYGF-33 and cells treated with 1.0 mg/ml EYGF-33, respectively. In 
addition, cell percentage in late apoptotic (Q3) was 1.4%, 2.7% and 30.6% for untreated 
cells, cells treated with 0.4 mg/ml EYGF-33 and cells treated with 1.0 mg/ml EYGF-33, 
respectively. The percentage of dead cells (Q4) was elevated significantly when cells 
were treated with 1.0 mg/ml EYGF-33 (4.8%, p <0.001) in comparison to untreated 
cells (0.8%).
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(A)
Untreated cells 0.4 mg/ml EYGF-33
Q3Q4 Q4 Q3
Ql
Q.
1.0 mg/ml EYGF-33
‘ Q4
' 0.1 Q2
Annexin V-FITC
(B)
Untreated EYGF-33 EYGF-33
cells (0.4 mg/ml) (1.0 mg/ml)
Q l : AV(-ve),PI(-ve) 93.4 ± 0.8 90.3 ± 1.3 46.4±2.1(***)
Q2 : AV(+ve),PI(-ve) 3.3 ±0.5 5.7 ± 0.9 I4.9±I.3(***)
Q3 : AV(+ve),PI(+ve) 1.4 ±3.1 2.7 ± 0.7 30.6±0.7(***)
Q4:AV(-ve),PI(+ve) 0.8 ± 0.3 0.9 ± 0.4 4.8 ± 0.5(***)
Figure 5.8. Flow cytometry images of cell death associated with phosphatidylserine (PS) 
externalization. Caco-2 cells were untreated (control) or treated with 0.4 mg/ml or 1.0 mg/ml 
EYGF-33 followed by incubation for 48 hours. Cells were trypsinized and labelled with 
Annexin V-FITC (AV) and propidium iodide (PI). PS externalization was detected using a 
FACScanto flow cytometer. (A) flow cytometry images o f untreated cells, cells treated with 0.4 
mg/ml, and cells treated with I.O mg/ml EYGF-33. Data presented in (table B) correspond to 
the means ± SD of three independent experiments. (Ql) represents healthy non-stained cells (- 
ve/-ve); (Q2) represents cells in early apoptotic stage conjugated with AV (+ve/-ve); (Q3) 
represents cells in late apoptotic stage conjugated with AV and stained with PI (+ve/+ve); and 
(Q4) represents dead cells stained with PI (-ve/+ve). A total o f 10,000 cells were counted for 
each experiment. ANOVA was perfonned in Graphpad Prism version 6.0. followed by 
Dunnett’s multiple comparisons test. The result was considered statistically significant versus 
the control, untreated cells, ( * = / > <  0.05, ** < 0.01, *** = p  < 0.001).
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5.3.5 Cell cycle assessment
In this assay PI stain was used due to its ability to permeate the cell membrane and 
chelate cellular DNA. The intensity of the PI signal is assumed to be directly 
proportional to DNA content. Figure 5.9 demonstrates the effect of 0.4 and 1.0 mg/ml 
EYGF-33 on Caco-2 cell cycle phases.
The cell population of untreated cells was distributed as follows: 74.1% in G1 phase 
(growth phase), 18.5% in S phase (DNA synthesis phase), and 7.4% in G2 phase 
(growth 2 phase). After treatment with 0.4 mg/ml EYGF-33, there was no significant 
change in the distribution of cells in the G l, S, and G2 phases of the cell cycle (72.1%, 
21.4% and 6.6%, respectively) compared with untreated cells. When Caco-2 cells were 
treated with 1.0 mg/ml EYGF-33, there was a significant reduction in the cell 
population in the Gl phase (34.6%, p  < 0.01) whereas a significant elevation was 
noticed in the cell population in the S phase (55.3 %, p  < 0.05) when compared with 
untreated cells (18.5%). However, treatment with 1.0 mg/ml EYGF-33 caused no 
significant change in the proportion of cells in the G2 phase (9.9%) compared with 
control cells (7.4%).
142
Chapter 5: Antiproliferative activity o f egg yolk protein hydrolysates in a human colon cancer cell
line
U n tr e a ted  ce lls
0 .4  m g /m l  
EYGF-33
1 .0  m g /m l  
EYGF-33
GO Gl G0/G1=74.1% ■ G(^G1 G0/G1=72.1 % - GOlGl G0/G1=34.6 %
1 S=18.5 % r r i  5=21.4%
co G2/M=7.4 % - 1 G2/M=6.6% 1 G2/M=9.9 %
ro 1 1
3
Q.
O
Q.
-
G2/Mhi - 1  G2/Mk ï
â .. . M .
DNA content (PI)
100-1
8 0 -
co
60-
40-
C _>
,6
B3
m
c
EYGF-33
co n cen tra tio n
(mg/ml)
Figure 5.9. Effect of EYGF-33 on Caco-2 cell cycle distribution using flow cytometry.
Caco-2 cells were treated with 0.4 and 1.0 mg/ml of EYGF-33 and compared with untreated 
cells. Cells were fixed in 70% ethanol after 48 hours, followed by staining with 10 pi of 
propidium iodide (PI, 1 mg/ml stock). Flow cytometer images represent cell cycle distribution, 
with 10,000 cells counted for each experiment. 01 phase represents growth phase, S phase 
represents DNA synthesis phase, and 0 2  phase represents growth 2 phase. The bar graph 
represents mean ± SD of three independent flow cytometry experiments. ANOVA was 
performed in Graphpad Prism version 6.0. followed by Tukey’s multiple comparisons test. The 
result was considered statistically significant versus the control, untreated cells, ( * = / ? <  0.05, 
* * = / ? < 0 . 0 1 ,  * * *  = p <  0 . 0 0 1 ) .
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5.4 Discussion
In the last 10 years, the chemotherapeutic effects of bioactive peptides on different 
cancer cells have gained considerable attention (Picot et al., 2006; Kannan et al., 2008; 
Hsu et a l, 2011; You et al., 2011). However, the relationship between the molecular 
mechanisms and the chemotherapeutic effects of bioactive peptides needs more 
investigation. The present study was designed to investigate the possible molecular 
mechanisms responsible for the cytotoxic effect exerted by EYGF-33 on Caco-2 cells, 
as presented in chapter 4,
The cell viability results (figure 5.2) and morphological observations (figure 5.4) 
indicated that EYGF-33 exerts its toxic effects specifically on colon cancer cells after 
48 hours. At the same time and dose, no harmful effects on normal HCEC cells were 
observed (figure 5.3 and figure 5.5). The mechanism of cell death appears to be due to 
the ability of EYGF-33 to significantly enhance the production of the superoxide anion 
in the mitochondria of cancer colon cells, leading to cell death by apoptosis.
Mitochondria are critical for cellular regulatory processes and hence cell survival, 
therefore mitochondrial dysfunction can be a key determinant of cell death (Schulze- 
Osthoff et a l, 1992; Kamp et al., 2011). The respiratory chain reaction that occurs in 
mitochondria is considered to be one of the major sources of free radicals, namely the 
superoxide anion. Although this radical is not a strong oxidant, it is considered to be a 
precursor of other ROS and thus becomes involved in the propagation of the oxidative 
chain reaction (Turrens, 2003). There is now mounting evidence that excess ROS are 
not only the source of direct damage to proteins, lipids, and DNA but are also
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considered to be major mediators in cell death pathways (Fleury et al., 2002; Lovric et 
a l, 2005; Circu and Aw, 2010).
Some researchers have suggested that damage to mitochondrial function occurs due to 
the accumulation of mitochondrial ROS leading to cell death (Kowaltowski and 
Vercesi, 1999; Fleury et a l, 2002; Kroemer et a l, 2007). Therefore, in our current 
study, the significant increase in superoxide anion in cells treated with 1.0 mg/ml 
EYGF-33 (figure 5.6-B) may lead to the activation of cellular death pathways.
EYGF-33 could disrupt the functions of mitochondria by the elevation of ROS levels, in 
particular the superoxide anion. This could subsequently cause PARP cleavage as 
observed in Western blot result (figure 5.7). PARP has the ability to induce 
programmed cell death (apoptosis) as a result of stimulating mitochondria to release the 
apoptosis inducing factor (AIF) (Green and Reed, 1998; Yu et al., 2006). AIF is 
involved in initiating a caspase-independent pathway of apoptosis by causing DNA 
fragmentation and chromatin condensation in the absence of caspase cascade activation 
(Candé et al., 2002). Therefore, the results observed in this study suggest that EYGF-33 
causes activation of a mitochondrial apoptotic pathway, by increases mitochondrial 
ROS leading to typical PARP degradation.
The induction of apoptotic cell death by EYGF-33 was supported by the externalisation 
of PS (figure 5.8). Kaufrnann and Eamshaw (2000) suggested that chemotherapeutic 
agents trigger cell apoptosis by two pathways; an extrinsic pathway that involves the 
ligation of cell-surface death receptors as TNF-a, and an intrinsic pathway that involves 
mitochondrial release of cytochrome C and caspase activation.
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Induction of apoptosis is considered to be an important mechanism of cancer prevention 
treatment by chemo-preventive agents. Many researchers have reported that excess ROS 
generation causes cell cycle arrest (Shackelford et ah, 2000; Burhans and Heintz, 2009). 
In agreement with this, our current research also suggested that oxidative stress induced 
in mitochondria caused cell death via arrest of the Caco-2 cell-cycle in S-phase. 
Accumulation of cells in S-phase as a result o f EYGF-33 treatment suggests a block in 
the transition from S phase to G2 phase. Alternatively, the cyclin A/CDK2 protein 
complex, which controls the progression of cell cycle in S phase, may have been 
altered. Disruption of the A/CDK2 complex would interfere with the DNA replication 
process and subsequently arrest cell cycle progression. This is suggested by the findings 
of the cell viability assay and morphological observations. Further elucidation of the 
mechanism of EYGF-33-mediated apoptosis, as suggested above, would provide further 
support for its use as a potential therapeutic and chemo-preventive agent.
5.5 Conclusion
The present results suggest that EYGF-33 is a promising peptide candidate for reducing 
cancer due to its anti-proliferative potential. Cytotoxic effects of EYGF-33 were 
observed in vitro in colon cancer cells without any toxicity in normal colon cells. 
Apoptosis was mediated by mitochondrial ROS generation and PARP cleavage, which 
was confirmed by Western blotting and Annexin-V conjugation. Reduced cell viability 
can be explained by cell cycle arrest in S-phase in which DNA replication normally 
takes place. However, preclinical efficacy and safety studies using animal models, as 
well as carefully designed pharmacokinetics studies are needed before clinical trials of 
peptides as cancer preventive or therapeutic agents can be initiated.
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6 Isolation and identification of ACE inhibitory 
peptides
6.1 Introduction
High blood pressure is a chronic medical symptom leading to worldwide health 
problems because o f its ability to trigger cardiovascular complications. About one 
billion people suffer from hypertension, resulting in over 7.1 million deaths per year 
globally (WHO, 2012). Approximately 20% of adults in the world are estimated to 
have hypertension, especially patients over 60 years of age. In the UK, the number of 
people diagnosed with hypertension rose by 2.7 % from 2004 to 2008 (WHO, 2012).
Regulation of arterial blood pressure in the human body is mainly achieved through 
diverse physiological systems including the kinin-nitric oxide system (KNOS), the 
neutral endopeptidase system (NEPS), the renin-chymase system (RCS) and the 
renin-angiotensin system (RAS). Any disturbance in the blood pressure by increase 
(hypertension) or decrease (hypotension) will trigger a number of chronic diseases, 
such as cardiovascular diseases, peripheral vascular disease and renal dysfunction .
It has been recognized that the renin-angiotensin system exists in various human body 
organs, such as the brain, kidneys and lungs, as well as in the circulatory blood 
system (Cholewa et al., 2005). One of the key elements constituting the renin- 
angiotensin system is the angiotensin converting enzyme (ACE; EC3.4.15.1, 
dicarboxy peptidase). ACE hydrolyses inactive decapeptide (angiotensin-I), through 
the removal of the dipeptide His-Leu from the C-terminus, to produce the potent 
vasoconstrictor octapeptide (Angiotensin-II) (Johnston, 1990; Crowley et al., 2006).
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Angiotensin-I results from the cleavage of angiotensinogen (Asp-Arg-Val-Tyr-Ile- 
His-Pro-Phe-His-Leu-Val-Ile-His-Glu-Ser) from the liver by the action of renal renin.
It is noteworthy that ACE enhances the reabsorption of renal tubular sodium by 
increasing the release of adrenal aldosterone. ACE also plays an important role in the 
depressor hormonal (kinin-kallikrein) system. In this system, ACE hydrolyses 
vasodilatory bradykinin to inactive metabolites (Tschope et ah, 2002; Zhao and Xu, 
2008). Therefore, the utilisation o f ACE inhibitors blocks the generation of the 
vasoconstrictor angiotensin II and potentiates the action of the vasodilator bradykinin.
Although potent synthetic ACE inhibitors namely captopril, lisinopril, fosinopril, and 
enalapril are used extensively in the clinical treatment of hypertension, they have 
significant adverse effects on health such as a diy cough, skin rashes, and headache 
(Morimoto et a i, 2004; Coleman and Cox, 2011). On the other hand, the most recent 
studies on food-derived ACE inhibitors such as peptides from food proteins, such as 
whey and soy protein, have so far indicated that these inhibitors do not have known 
side effects on the human body (Hong et al., 2008; Kim and Wijesekara, 2010; Norris 
and FitzGerald, 2013). Accordingly, more studies are now directed towards 
understanding how to produce food-derived peptides that can act as ACE inhibitors 
for the clinical treatment of hypertension.
ACE is a dipeptide carboxy peptidase which characterised by its three dimensional 
(3D) stmcture that consists of a-helices, chloride and zinc ions. The active site is 
composed of two subdomains (N-domain and C-domain), which are separated by a 
deep, narrow channel. Although there is some sequence similarity between these 
subdomains, they differ in their affinity for the substrate and inhibitors, as well as
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their extent of activation by chlorine ions. There is also an amino terminal (lid) on the 
top of the active site that permits the small peptide substrate to access the active site 
cleft (Natesh et ah, 2003; Natesh et ah, 2004).
Researchers have purified bioactive peptides with ACE inhibitory activity from 
enzymatic hydrolysates of various food proteins (Brian et ah, 2005). These food 
proteins are contained in whey (FitzGerald and Meisel, 1999), egg (Miguel and 
Aleixandre, 2006b), soybean (Lo and Li-Chan, 2005) and chicken breast muscle 
(Saiga et ah, 2006). Some peptides were also tested for their activity as 
antihypertensives in a spontaneous hypertensive rat (SHR) model (Yamamoto et ah, 
1994; Miguel et ah, 2005; Nakano et ah, 2006; Miguel et ah, 2009; Thewissen et ah, 
2011).
The aims of this study were to isolate and characterize peptides from hydrolyzed egg 
yolk protein, with respect to ACE inhibitory activity and to examine whether 
additional purification improves the activity of the inhibitor. Furthermore, this study 
aimed to identify the amino acid composition of the isolated peptide and to investigate 
the mechanism of ACE inhibition.
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6.2 Materials and methods
6.2.1 M aterials
Materials Suppliers
Acetonitrile HPLC grade
Fisher Scientific, Loughborough, 
UK.
ACE (Angiotensin-I-converting enzyme, 
1 unit/mg) fi*om rabbit lung
Sigma -Aldrich Ltd, Dorset, UK
Trifluoroacetic acid (TEA)
Captopril
Hippuryl-histidyl-leucine (HHL)
Hippuric acid (HA)
Histidyl-leucine (HL)
6.2.2 Experim ental m ethods
6.2.2.1 Protein extraction and hydrolysate preparation
As described previously in chapter 2, sections 2.2.2.1 and 2.2.2.2.
6.2.2.2 Fractionation of egg yolk hydrolysate by ultrafiltration
As described previously in chapter 2, section 2.2.2.S.
6.2.2.3 Determination of angiotensin converting enzyme inhibitory 
activity
The measurement of ACE inhibitory activity was conducted using HPLC in 
accordance with the method of Wu et al. (2002), modified to improve the method of 
Cushman and Cheung (1971).
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All samples were prepared with 100 mM borate buffer, containing 300 mM NaCl at 
pH=8.3. The total reaction volume was 70 pi, consisting of 50 pi of 2.17 mM 
hippuryl-histidyl-leucine (HHL), 10 pi of peptide fi-actions and 10 pi of 2 mU 
angiotensin converting enzyme (ACE). The peptide fractions and HHL were mixed 
and maintained at 37 °C for 10 minutes in 2 ml polyethylene microcentrifuge tubes. 
ACE was maintained at 37 “C for 10 minutes before the two solutions were combined. 
The combined mixture was incubated at 37 °C for 30 minutes with continuous 
agitation. In order to terminate the reaction, 85 pi of 1 M HCl was added. Samples 
were analyzed on a C l8 column (3.0x150 mm, 5 pm, phenomenex) and hippuric acid 
(HA) and HHL were detected at 228 nm using HPLC system (Ultimate 3000 HPLC, 
Thermo Fisher Scientific Inc., Loughborough, UK). Data were analysed using 
integration software (Chromeleon).
The column was eluted at a rate of 1 ml/ min with a two solvent system: (A) 0.05% 
trifluoroacetic acid (TFA) in water and (B) 0.05% TFA in acetonitrile, with a 5-60% 
acetonitrile gradient for the first 10 minutes, maintained for 2 min at 60% acetonitrile, 
then returned to 5% acetonitrile for 1 minute. This was followed by isocratic elution 
for 4 min at the constant flow rate of 1 mPmin. The ACE inhibitory activity was 
calculated as follows:
C — S
ACE inhibitory a c tiv ity  (%) =  - — - x  100
C — B
Where C is the peak area of control (buffer added instead of test sample), B the peak 
area of the reaction blank (without ACE and sample), and S is the peak area in the 
presence of a sample or captopril.
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6.2.2.4 Gelfiltration chromatography
As described previously in chapter 2, section 2.2.2.4.
62.1.5  Reversed-phase high performance liquid chromatography 
(RP-HPLC)
The egg yolk fi-action with the highest ACE inhibitory activity was injected on to a 
reversed-phase high performance liquid chromatography (RP-HPLC) column for 
further purification. The sample was loaded into a Partisil 10 ODS-1 column (9.5 mm 
X 500 mm) (Whatman pic, UK). The elution was a linear gradient of acetonitrile 
(0-70 % containing 0.1 % TFA) with flow rate of 1 ml/min for 50 minutes. Peaks 
detected at 215 nm or 250 nm were collected and lyophilised at -80 °C for further 
study.
6.2.2.6 Determination of IC50
In order to determine IC50, a wide range of isolated peptide concentrations (2, 4, 6, 8 
and 10 mg/ml) was prepared as mentioned previously in section 6 2 2 3  and analysed 
using HPLC.
6.2.2.7 Amino acid analysis
As described previously in chapter 2, section 2.2.2.6.
6.2.2.5 ACE inhibition mechanism
In order to determine the mechanism of the ACE inhibition, different concentrations 
of ACE inhibitory peptide (0, 4, and 10 mg/ml) and HHL substrate (1, 2.17, 5.5, and 
11 mM) were used. Resultant mixtures were analysed by measuring ACE inhibition
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activity using HPLC as described in the previous section 6.2.2.3. Enzyme kinetics in 
the presence of the peptide was determined using Lineweaver-Burk plots.
6.2.3 Statistical analysis
All experimental procedures were conducted with at least three independent replicates 
on three separate occasions. Results were analysed using GraphPad Prism software 
version 6.0. Statistical analysis comparisons were made by one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparisons test. P  <0.05 was 
considered statistically significant. Data are presented as means ± standard deviation 
(SD).
6.3 Results
6.3.1 Purification o f ACE peptide
ACE inhibition was measured by quantification of HA which appears at 228 nm as a 
reaction product. The ACE inhibitory activity exhibited by 10 mg/ml o f ultrafiltration 
fractions obtained after hydrolysis (EYUF-10, EYUF-5 and EYUF-2) was compared 
with that of 10 mg/ml captopril (figure 6.1). Among the fractions, the highest 
inhibitory activity was observed in the EYUF-2 sample, followed by EYUF-5, then 
EYUF-10 (49.7 %, 42.2 %, and 33.1 % inhibition, respectively). Inhibitory activity 
increased with decreasing fraction molecular weight, although none was as potent as 
captopril (98.8 %; p  <0.001).
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Figure 6.1. ACE inhibitory activity of fractionated egg yolk protein hydrolysates. The
activity o f 10 mg/ml EYUF-10, EYUF-5 and EYUF-2 to inhibit ACE was measured by 
HPLC. Captopril (10 mg/ml) was used as a positive control. Data correspond to the means ± 
SD of three independent experiments. ANOVA was perfomied in Graphpad Prism version 
6.0, followed by Dunnett’s multiple comparisons test. The result was considered statistically 
significant versus captopril ( * = p <  0.05, * * = p <  0.01, *** = p <  0.001).
The EYUF-2 fraction with the highest ACE inhibitory activity was collected from the 
ultrafiltration process and separated by gel filtration chromatography using a 
Sephadex G-25 column to further purify the peptides.
Fractions obtained from different runs of gel filtration chromatography were pooled 
and lyophilized before their ACE inhibition activity was assayed. The method was 
conducted for all fractions to test their ability to inhibit the activity of the enzyme 
when used at a concentration of 10 mg/ml. Figure 6.2 shows that ACE inhibition 
activity was widely observed for all fractions, but the most effective fraction (depicted 
by a shaded bar) was EYGF-56 (69.2% inhibition) compared with 10 mg/ml 
captopril. EYGF-56 fraction was, therefore, collected for further study.
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Figure 6.2. ACE inhibitory activity (%) of egg yolk protein fractions separated on a 
Sephadex G-25 column. The activity of 10 mg/ml for each gel filtration fraction to inhibit 
ACE was measured by HPLC. Captopril (10 mg/ml) was used as a positive control. Data 
correspond to the means ± SD of three independent experiments. ANOVA was performed in 
Graphpad Prism version 6.0. followed by Dumiett’s multiple comparisons test. The result was 
considered statistically significant versus captopril (* = p  < 0.05, ** = p  < 0.01, *** = p  < 
0.001).
The EYGF-56 fi*action with the highest ACE inhibitory activity (as identified in 
figure 6.2 above) was pooled and collected fi-om the gel filtration process and 
separated by RP-HPLC using a Partisil 10 ODS-1 column to obtain peptides of 
greater purity. The elution profile generated with a flow rate of 1 mPmin is shown in 
figure 6.3. One prominent peak appeared in the chromatogram labelled by EYLCF- 
16, which corresponded to the presence of the peptide.
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Figure 6.3. Elution profile of EYGF-56 separated by reverse-phase high performance 
liquid chromatography. Separation was achieved using a Partisil 10 ODS-1 column and 
peaks were detected at 215 nm with flow rate of Iml/min.
As before, the fi-actions obtained from different RP-HPLC runs were pooled and 
lyophilized prior to assaying ACE inhibition activity. The purified EYLCF-16 
fi*action (10 mg/ml) achieved 91.8% ACE inhibition compared with the same 
concentration used by captopril (figure 6.4). The activity exhibited by EYLCF-16 was 
significantly lower than that of captopril (98.8%; p  <0.05), which was used as a 
positive control in the experiment. The ACE inhibition activity shown by EYLCF-16 
was more effective than the ultrafiltered EYUF-2 and gel filtration fraction EYGF-56, 
which inhibited the activity of ACE by only 49.7% and 69.2%, respectively.
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Figure 6.4. ACE inhibitory activity of EYUF-2 obtained after ultrafiltration, EYGF-56 
obtained by gel filtration and EYLCF-16 obtained by RP-HPLC. The activity of  
10 mg/ml o f each fraction to inhibit ACE was measured by HPLC. Captopril (10 mg/ml) was 
used as a positive control. Data correspond to the means ± SD of three independent 
experiments. ANOVA was perfomied in Graphpad Prism version 6.0. followed by Dunnett’s 
multiple comparisons test. The result was considered statistically significant versus captopril 
(* < 0.05, ** < 0.01, *** ^  p<  0.001).
The 50% enzyme inhibitory concentration (IC50) of the fractions with the highest 
ACE inhibition activity obtained from each purification step was calculated. As 
observed in table 6.1., ACE inhibition activity was enhanced with further purification; 
EYUF-2 exhibited the lowest activity (49.7%) with an IC50 of 5.44 mg/ml, followed 
by EYGF-56 with 69.2 % activity and IC50 of 3.35 mg/ml. In contrast, EYLCF-16, 
obtained from the final purification step exhibited the highest activity (91.8%) with 
the lowest IC50 concentration (1.53 mg/ml). The IC50 values among the three fractions 
were significantly different (p <0.001).
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Fractions
ACE inhibitory 
activity (%)
I C 5 0  ( m g / m l )
EYUF-2 49.7 5.44 ± 0.02***
I EYGF-56 692 3.35 ±0.05***
EYLCF-16 91.8 1.53 ±0.13***
Table 6.1. IC50 values for of EYUF-2 obtained from ultrafiltration, EYGF-56 obtained 
from gel filtration and EYLCF-16 obtained from RP-HPLC. The activity of different 
concentrations of each fraction to inhibit ACE, was measured by HPLC. Data correspond to 
the means ± SD of three independent experiments. ANOVA was performed in Graphpad 
Prism version 6.0, followed by Tukey’s multiple comparisons test. The result was considered 
statistically significant between all fractions (* =p< 0.05, **=p< O.OI, *** =p< 0.001).
6.3.2 Amino acid analysis
Given the substantial inhibitory effect of EYLCF-16 on ACE activity, the fraction 
was subjected to amino acid analysis in order to elucidate the possible effect of amino 
acid composition on ACE inhibitory activity. The chromatogram of amino acids and 
calculated composition of the selected fractions after RP-HPLC is presented in figure
6.5 and table 6.2, respectively. EYLCF-16 contained a high proportion of leucine 
(20.26%), electrically charged arginine (14.69%) and lysine (10.90%), aromatic 
tryptophan (12.49%) and hydrophilic glutamic acid (8.42%).
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(A)
(B)
Figure 6.5. Amino acid chromatograms of (A) amino acid standards, (B) EYLCF-16 
after hydrolysis with 6 N HCI. Amino acids were separated on a CIS reverse-phase column 
and detected at 254 nm. Gradient mobile phase was used consisting o f two eluents; A and B. 
Eluent A was composed o f 0.22 M sodium acetate buffer containing 0.05 % (v/v) TEA, pH 
6.2 (adjusted using glacial acetic acid). Eluent B was composed of 60:40 acetonitrile: water.
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Am ino acids Amino acid residues (%) in 
EYLCF-16
Aspartic acid 4.06 ±0.27
Glutamic acid 8.42 ±0.26
Serine 4.80 ±0.13
Glycine 2.02 ± 0 .11
Histidine 1.96 ±0.26
Arginine 14.69 ±0.12
Threonine 0.77 ± 0.04
Alanine 3.55 ±0.14
Proline 2.99 ± 0.07
Tyrosine 2.10±0.16
Valine 3.90 ± 0.23
Methionine 2.82 ±0.17
Cysteine 1.03 ±0.17
Isoleucine 0.09 ± 0.05
Leucine 20.26 ± 0.39
Phenylalanine 3.10±0.10
Tryptophane 12.49 ±0.07
Lysine 10.90 ±0.02
Table 6.2. Amino acid composition of egg yolk fraction EYLCF-16. Data correspond to 
the means ± SD of three independent experiments.
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6.3.3 Inhibition kinetics
In order to elucidate how the isolated peptides bind to ACE and inhibit its activity, 
ACE inhibition kinetics were studied using Lineweaver-Burk plots. Enzyme kinetics 
were investigated for uninhibited ACE (control) and ACE in the presence of two 
different concentrations of EYLCF-16 (4 mg/ml and 10 mg/ml) (figure 6.6). The 
Michaelis-Menten constant (Km) in the absence of EYLCF-16 (control) was 0.53 mM, 
whereas the Km in the presence of two different concentrations (4 and 10 mg/ml) of 
EYLCF-16 was 0.99 and 1.75 mM, respectively. Furthermore, the maximum velocity 
(Vmax) values for the control, 4 mg/ml, and 10 mg/ml of EYLCF-16 were 1.05, 1.15 
and 1.19 mM/min, respectively (table 6.3). As shown in figure 6.6, there is no 
significant difference between the y-axis intercept of the control and the two 
concentrations of tested peptide, but there is a significant difference in the x-axis 
intercepts. According to these results, EYLCF-16 is a competitive inhibitor of ACE 
because the Km changed while Vmax remained the same.
Control EYLCF-16 EYLCF-16
(no inhibitor) (4 mg/ml) (10 mg/ml)
[ Vmax (mM/min) 1.05 1.15 1.19
Krn(mM) 0.53 0.99 1.75
Table 6.3. Vmax and Km values of ACE control (no inbibitor) and ACE witb two different 
concentrations of EYLCF-16 (4 and 10 mg/ml).
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Control 
4 mg/mi 
10 mg/ml
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Figure 6.6. Lineweaver-Burk plots for determination the inhibition pattern of 
EYLCF-16 on ACE. ACE inhibition activity was determined in the absence of the pq)tide 
(control) and in the presence of the peptide (4 mg/ml and 10 mg/ml).
6.4 Discussion
ACE inhibitory peptides isolated fi*om different sources of protein have potential as 
antihypertensive compounds in nutraceutical applications and functional foods 
(Meisel, 1997; Holdt and Kraan, 2011). Historically, these peptides have been isolated 
fi*om both plant and animal proteins. In this study, ACE inhibitory peptides were 
isolated fi*om egg yolk protein and purified using a sequence of chromatographic 
techniques. In the current study, the aim o f using an ultrafiltration process was to 
separate the hydrolysed protein into different molecular weight fi-actions. As observed 
fi*om the result depicted in figure 6.1, ACE inhibition activity was inversely 
proportional to peptide molecular weight. EYUF-2, which is the lowest molecular 
weight fi-action separated by ultrafiltration, exhibited the highest activity (49.7% 
inhibition) compared with EYUF-5 (42.2%) and EYUF-10 (33.1%). The observation 
that ACE inhibitory activity increases with lower molecular weight concurs with 
many studies in this field (Howell and Kasase, 2010; Balti et al., 2010; Dai et a l, 
2013).
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In order to separate the most effective fraction, further purification steps were 
conducted by gel filtration chromatography followed by RP-HPLC. ACE inhibitory 
activity increased after each purification step with a concomitant decrease in IC50 
values (table 6.1). Thus, the highest ACE inhibitory activity (91.8%) and lowest IC50 
value (1.53 mg/ml) was exhibited by the EYLCF-16 fi-action obtained fi-om the final 
purification step of this study. This observation is in agreement with previous studies 
reporting that purification decreased IC50 values (Pihlanto-Leppala, 2000; Jung et a l, 
2006; Dai et al., 2013). IC50 values obtained in the present study were in the same 
range (1.18-1.86 mg/ml) as those reported in earlier studies on egg proteins (Yoshii et 
a l, 2001; Miguel and Aleixandre, 2006b).
The structure-activity relationships of ACE inhibitory peptides is highly influenced by 
the sequence of the tripeptide positioned in the C-terminal (Li et al., 2004). In this 
research, the presence of positively charged arginine (14.69%) and lysine (10.90%) in 
EYCLF-16, as well as the presence of hydrophobic tryptophan (12.49%) and leucine 
(20.26%) may be responsible for the high activity shown by the fi-action. Li et al. 
(2004) revealed that the presence of hydrophobic amino acids increased ACE 
inhibitory activity. The hydrophobic and hydrophilic properties of the isolated 
peptides enhanced the stabilisation of complex formed between the peptide and the 
active site of the enzyme (Fernandez et ah, 2003; Andujar-Sanchez et al., 2004; 
Masuyer et al., 2012; Pihlanto and Makinen, 2013). This stabilization is achieved by 
hydrogen bonding and electrostatic interaction and, hence, enhances the inhibition 
activity (Pan et ah, 2012).
Zhao and Xu (2008) explained that the interaction between ACE inhibitors and the
Zn^^ in the active site of the enzyme plays a crucial role in enzyme inhibition. Pan et
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al. (2012) suggested that leucine and the Zn^ "^  ion are linked via the carbonyl group of 
leucine and this coordination is responsible for the enzyme inhibition activity. The 
presence of leucine in the composition of EYCLF-16 may explain the inhibition 
activity shown in the current study. Many studies have suggested that the ACE 
inhibitory activity of peptides may be due to the presence of a positive charge on e- 
amino of lysine, or the guanidino group of arginine at the C-terminal of the isolated 
peptide (Cheung et a l, 1980; Murray and FitzGerald, 2007).
The mechanism of ACE inhibition by EYLCF-16 was identified by the use of 
Lineweaver-Burk plots. The results of the kinetics study showed that EYLCF-16 is a 
competitive inhibitor of ACE (figure 6.6), that is, it competes with the substrate 
(HHL) at the active site of the enzyme. The inhibitory mechanism of the isolated 
peptide is similar to that of Captopril, which is widely used as an antihypertensive 
drug (Natesh et al., 2004; Dalkas et al., 2010). Due to the various amino acid 
compositions of different isolated peptides, some exhibit competitive inhibition 
(Yokoyama et al., 1992; Fujita and Yoshikawa, 1999; Choi et al., 2001; Hyoung Lee 
et ah, 2004) while others demonstrate non-competitive action (Jung et al., 2006; Ono 
et al., 2006; Jang et al., 2011; Asoodeh et al., 2012).
6.5 Conclusion
A peptide fi-action with high ACE inhibitory activity was isolated successfully from 
egg yolk protein. The isolated peptide EYLCF-16, obtained after a combination of 
chromatographic techniques, exhibited the highest ACE inhibition activity (91.8%) at 
10 mg/ml and IC50 value =1.53. The presence of predominantly leucine, which can 
bind to Zn^^ at the enzyme active site, as well as positively charged lysine and
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arginine and hydrophobic tryptophan in this fi-action maybe responsible for its 
activity. The isolated fraction EYLCF-16 exhibited competitive inhibition towards the 
enzyme. Although these findings indicate a huge potential for producing peptides 
with ACE inhibitory activity fi-om egg yolk, clinical studies are needed before they 
can be used for pharmaceutical applications and functional foods.
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7 General discussion and conclusions
7.1 General discussion
7.1.1 Egg yolk protein fractionation and peptide purification
Nowadays, people are becoming increasingly aware about the benefits of healthy 
foods and, therefore, scientists have been working on the identification of food- 
derived bioactive compounds that maintain health and reduce the risk of chronic 
disease. There is wide consensus among scientists that there are other uses of 
bio active peptides yet to be unraveled and more studies are needed in order to 
examine the efficacy of bio active peptides on human health prior to their application 
as ingredients of functional foods. From this point of view, the current research is 
built on the investigation of bioactive properties exhibited by peptides isolated from 
egg yolk protein.
Although several studies have focused on egg albumen proteins, few have examined 
the nutritional value of egg yolk proteins, mainly due to their lipid content that 
negatively affects human health. The main components of egg yolk are phospholipids, 
triacylglycerol and proteins. The first two components are used as lecithin in food or 
cosmetics. The third component of egg yolk is protein that represents approximately 
30% of dried egg yolk. Therefore, this research aimed to investigate the possibility of 
producing bioactive peptides from egg yolk protein using physiological proteases, and 
to identify the bioactive properties of isolated peptides.
Enzyme specificity and degree of hydrolysis are some of the important factors that 
affect peptide activity when prepared in vitro. In the current study, gasterointestinal
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proteases were used to achieve a high degree of hydrolysis. Therefore, a combination 
of pepsin and pancreatin was used in the hydrolysis step. The resultant hydro lysates 
were subjected to fractionation, as the first purification step, using 10, 5 and 2 kDa 
molecular weight cut off (MWCO) ultrafiltration membranes and tested for their 
activities as antioxidants, anti-cancer agents and ACE inhibitors. The high yield 
(70%) of the lower molecular weight (EYUF-2) fractions obtained from the 
ultrafiltration process indicated that EYP had been hydrolysed extensively. Because 
the highest activity as an antioxidant or ACE inhibitor was exhibited by EYUF-2, this 
fraction was collected and purified further using gel filtration and high performance 
liquid chromatography. After purification, the amino acid composition of the most 
effective antioxidant and ACE inhibitory fraction was analysed by HPLC. The 
following diagram demonstrates the experimental design applied in this study.
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Figure 7.1. Flow chart of thesis expermintal design.
7.1.2 Antioxidant activity and mechanism of isolated peptides from 
egg yolk protein
Lipid peroxidation is a free radical chain reaction; radicals formed in the first stage 
(initiation) of lipid oxidation are primary oxidation products such as peroxides and 
hydroperoxides. In the second stage (propagation) of oxidation, further degradation of 
primary oxidation products occurs and produces secondary oxidation products such as 
carbonyl compounds. In this study the antioxidant activity of peptides obtained from
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egg yolk protein was measured in an oxidizing linoleic acid model system and the 
oxidation process was monitored for 7 days. Two methods were used to monitor the 
oxidation inhibition activity: the ferric thiocyanate method (FTC) was used to monitor 
the primary oxidation products and the thiobarbituric reactive substances (TEARS) 
test was used to monitor the secondary oxidation products which include 
malondialdehyde (MDA). Hydroperoxides and malodialdehyde are considered as 
biomarkers of lipid oxidation.
The results obtained from both tests indicated that egg yolk hydrolysate (EYH) 
contained peptides with antioxidant activity. Among the fractions, the highest activity 
was highlighted by two fractions that were obtained after gel filtration purification 
namely EYGF-23 and EYGF-33. Purified peptides were effective antioxidants; at 
80 mg/ml, both fractions EYGF-23 and EYGF-33 were comparable to the positive 
controls trolox and BHT.
The amino acid content and sequence in the isolated peptide and peptide size, together
play an important role in determining the activity of a peptide (Elias et ah, 2008;
Bougatef et al., 2009). The amino acids profile of EYGF-23 indicated that this
fraction contained tryptophan (16.40%), tyrosine (12.40%), lysine (11.03%) and
proline (8.01%) while EYGF-33 contained leucine (13.82%), arginine (11.80%),
tryptophan (9.44%), lysine (8.27%), valine (6.71%) and alanine (7.80%). The result
obtained from amino acid residue analysis of both EYGF-23 and EYGF-33
demonstrated that both of the isolated fractions contained considerable amounts of
hydrophobic amino acid residues such as valine, tryptophan, leucine and tyrosine. It is
well known that the presence of hydrophobic amino acid residues in protein
hydrolysates or peptides elevates their antioxidant activity by increasing peptide
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solubility in a lipid system (Rajapakse et a l, 2005; Wang et al., 2007). Chen et al. 
(1995) isolated antioxidative peptides that contained hydrophobic amino acid 
residues, valine and leucine at the N-terminus and demonstrated that the presence of 
hydrophobic moieties in an antioxidant peptide was important to obtain access to 
hydrophobic groups in membranes and lipids. Tryptophan is also an important amino 
acid and removal of the labile hydrogen attached to the nitrogen of its indole ring 
produces a free radical that is easily stabilised due to electron delocalization, thereby 
allowing tryptophan to break free radical chain reactions and stop the oxidation 
process (Tsopmo c/ a/., 2011).
Tyrosine-containing peptides can also scavenge radicals as shown by peptides derived 
from pepsin-digested cow casein (Suetsuna et al., 2000), and hydrolysed 
beta-lactoglobulin produced both tyrosine and tryptophan that could quench radicals 
(Hemandez-Ledesma et al., 2008). Saeed et al. (2006) suggested that, due to the 
ability of tyrosine to donate hydrogen, protein containing tyrosine was preferentially 
oxidised by radicals to protect lipid systems from oxidation. Tsopmo et al. (2011) also 
found that the presence of tryptophan in human milk hydrolysates was essential to 
maintain scavenging activity; activity was markedly decreased upon tryptophan 
deletion. As a result, antioxidant activities of EYGF-23 and EYGF-33 are thought to 
be related to their amino acid compositions.
In order to understand the action of EYGF-23 and EYGF-33 as an antioxidant, many
assays were applied to illustrate the antioxidant mechanism. The results obtained from
measuring the ability of EYGF-23 and EYGF-33 to react as a reductant illustrates
how this peptide reacts with free radicals to convert them to a more stable form.
Moreover, the ability o f EYGF-23 and EYGF-33 to quench DPPH, superoxide anions
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and hydroxyl radicals indicated that the isolated fractions act as good scavengers. 
EYGF-23 and EYGF-33 were also able to chelate transition metals ions (Fe^^ which 
act as catalysts that initiate and accelerate free radical chain reaction processes. The 
results revealed that, although both fractions have the ability to act as chelating 
agents, the activity was significantly lower in comparison with EDTA at the 
concentrations used. However, similar results to EDTA could be obtained by using 
concentrations greater than 20 mg/ml. Therefore, using chelating agents may reduce 
the availability of these ions and inhibit the oxidative chain reactions in food systems 
and, consequently, improve food stability (Pokomy et a l, 2001). It was noted that, in 
all methods conducted in this study, the efficacy of the peptide as a reductant, 
scavenger and chelator was dose-dependent. Because of the good antioxidant 
properties demonstrated by the peptides in an oxidising linoleic model system, further 
antioxidant studies were conducted in human cells.
7.1.3 Antioxidant activity o f isolated peptides from egg yolk protein  
on epithelial colon cells under oxidative stress
Reactive oxygen species (ROS) are produced in living cells as a result of normal cell
metabolism and xenobiotic detoxification. Oxidative stress is a consequence of an
excess of ROS, which participate in cellular damage by reacting with lipid
membranes, proteins, and DNA. Therefore, the aim of this study was to use cultured
Caco-2 cells as an epithelial model to investigate the antioxidant behaviour of egg
yolk peptide in cells exposed to the pro-oxidant t-BHP.
The results obtained from cell viability assays, in which cells were treated with
isolated peptide fractions, indicated that EYGF-23 in the concentration range used
(0.2 - 4.0 mg/ml) was not toxic to Caco-2 cells. However, at 48 hours, and at
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concentrations > 0.8 mg/ml, a second peptide fraction EYGF-33 exhibited 
cytotoxicity (figure 4.3). The cytotoxic behaviour exhibited by EYGF-33 could be 
associated with the nature and sequence of amino acids that comprise isolated 
peptides. Based on the results obtained, only the EYGF-23 fraction was studied 
further in relation to antioxidant activity. Conversely, EYGF-33 was chosen for study 
as a potential anticancer agent.
To investigate the ability of EYGF-23 to protect oxidativly stressed cells, stressed 
Caco-2 cells were treated with different concentrations of EYGF-23. The results 
(figure 4.5) indicated that the EYGF-23 egg yolk peptide enhanced cell viability and 
protected Caco-2 cells from oxidative toxicity induced by /-BHP. The protective 
effect of EYGF-23 could be related to its scavenging activity as, once /-BHP 
penetrates the cell membrane, it can easily degrade to alkoxyl and peroxyl radicals to 
generate ROS. The scavenging activity of EYGF-23 was confirmed by the significant 
reduction in cellular ROS (figure 4.7) and MDA levels (figure 4.8) in Caco-2 cells 
treated with the fraction under oxidative conditions. Subtoxic levels of hydroperoxide 
result in DNA damage and apoptosis, via the activation of the caspase family of 
enzymes (Dandrea et al., 2004). In this study, caspase 3/7 activity observed in 
stressed cells was related to the ability of t-BHP to permeate the cell membrane and 
generate an array of ROS that were involved in a free radical chain reaction. These 
radicals attack vital components in the cell, causing membrane lipid oxidation, DNA 
damage and apoptosis. In the current study, EYGF-23 protected stressed cells from 
programmed cell death (apoptosis); this protection was evident by the significant 
reduction in caspase 3/7 activity in cells treated with EYGF-23 prior to stress 
induction. The low molecular weight (200-750 Da) of the EYGF-23 fraction and
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presence of hydrophobic amino acid residues in its composition probably helped the 
fraction to permeate cell membranes and intercept the free-radical chain reaction by 
scavenging free radicals.
In a healthy system, the high level of total glutathione plays a substantial role in 
protecting cells from unexpected attack by hydroxyl radicals. Under oxidative stress, 
the increase in concentration o f peroxides leads to a shift in thiol redox status, as 
represented by a severe decrease in the reduced form of glutathione (GSH) and an 
increase in the level of the oxidised form (GSSG). In the current study, 3 mM of 
r-BHP caused significant depletion of total glutathione, but this was elevated back to 
basal levels when cells were treated with the isolated fraction prior to stress induction 
(figure 4.10). The findings, related to the imbalance of reduced and oxidised forms of 
glutathione due to /-BHP, led to further examination of other antioxidant enzymes 
namely SOD and catalase in Caco-2 cells when treated with EYGF-23 under 
conditions of oxidative stress.
SOD is responsible for the dismutation of the superoxide anion to hydrogen peroxide 
and molecule of oxygen (Scandalios, 1993; Inoue et a l, 2003). In the current study 
(figure 4.11), cells treated with 1.0 mg/ml EYGF-23 prior to oxidative induction 
exhibited significantly higher SOD activity (55.10 %) as compared with cells treated 
with r-BHP (p <0.01 ). These findings illustrate the effect of EYGF-23 on enhancing 
the activity of SOD under oxidative stress.
In contrast, there was no significant difference in catalase activity between cells 
stressed with /-BHP and unstressed cells (figure 4.12); this may be explained as 
follows. The role of catalase enzyme in the defence system is to catalyse the
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decomposition of H2O2 to water and oxygen; this action is similar to the role of 
glutathione peroxidase. Baud et al. (2004) measured the Km value (which represents 
the affinity between the enzyme and the substrate) of catalase and glutathione 
peroxidase. The high Km of catalase in removing H2O2 (up to 25 mM), was 4000- 
fold higher than the Km of glutathione peroxidase (6 pM); this indicated a lower level 
of activity for catalase as compared to that of glutathione peroxidase. The 
concentration of /-BHP used in this study may, therefore, not be enough to activate 
catalase and may explain why there was no significant difference in the amount of 
catalase between cells stressed with /-BHP and unstressed cells (figure 4.12).
7.1.4 Antiproliferative effect o f  isolated peptide on human colon  
cancer cells
The highlight of this study was that the peptide EYGF-33 inhibits the proliferation of 
Caco-2 colon cancer cells but not normal HCEC cells. The cell viability results 
(figure 6.1) and morphological observations (figure 6.3) indicated that EYGF-33 
(IC5o=1.0 mg/ml) exerts its toxic effects specifically on colon cancer cells after 
48 hours. At the same time and dose, no harmful effects on normal HCEC cells were 
observed. The mechanism of cell death appears to be due to the ability of EYGF-33 to 
significantly enhance the production of the superoxide anion in the mitochondria of 
cancer colon cells, leading to cell death by apoptosis.
Mitochondria are critical for cellular regulatory processes and hence cell survival;
therefore, mitochondrial dysfunction can be a key determinant of cell death (Schulze-
Osthoff et ah, 1992). The respiratory chain reaction that occurs in mitochondria is
considered to be one of the major sources of fi*ee radicals, namely the superoxide
anion. Although this radical is not a strong oxidant, it is considered to be a precursor
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of other ROS and, thus, becomes involved in the propagation of the oxidative chain 
reaction (Turrens, 2003). Therefore, the significant increase in superoxide anion in 
cells treated with 1.0 mg/ml EYGF-33 (figure 5.5-B) may lead to the activation of 
cellular death pathways.
EYGF-33 could disrupt the functions of mitochondria by the elevation of ROS levels, 
in particular the superoxide anion. This could subsequently cause PARP cleavage as 
observed in the Western blot result (figure 5.6). PARP has the ability to induce 
programmed cell death (apoptosis) as aresult of stimulating mitochondria to release 
the apoptosis inducing factor (AIF) (Green and Reed, 1998; Yu et a l, 2006). AIF is 
involved in initiating a caspase-independent pathway of apoptosis by causing DNA 
fragmentation and chromatin condensation in the absence of caspase cascade 
activation (Candé et al., 2002). Therefore, the results observed in this study suggest 
that EYGF-33 causes activation of a mitochondrial apoptotic pathway, by increases 
mitochondrial ROS leading to typical PARP degradation. The induction o f apoptotic 
cell death by EYGF-33 was supported by the externalisation of PS (figure 5.7). 
Induction of apoptosis is considered to be an important mechanism of cancer 
prevention treatment by chemo-preventive agents. Many researchers have reported 
that excess ROS generation causes cell cycle arrest (Shackelford et al., 2000; Burhans 
and Heintz, 2009). In agreement with this, our current research also suggested that 
oxidative stress, induced in mitochondria, caused cell death via arrest of the Caco-2 
cell-cycle in the S-phase. Accumulation of cells in the S-phase as a result of EYGF-33 
treatment suggests a block in the transition from S-phase to G2-phase. However, 
further elucidation of the mechanism of EYGF-33-mediated apoptosis would provide 
further support for its use as a potential therapeutic and chemo-preventive agent.
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7.1.5 Angiotensin converting enzym e inhibitory activity o f isolated  
peptide from egg yolk protein
ACE inhibitory peptides isolated from different sources of protein have potential as
antihypertensive compounds in nutraceutical applications and functional foods (Mine
and Shahidi, 2005). Historically, these peptides have been isolated from both plant
and animal proteins. In this study, ACE inhibitory peptides were isolated from egg
yolk protein and purified using a sequence of chromatographic techniques. The
isolated peptide fraction EYLCF-16 comprised leucine, arginine, lysine, tryptophan,
and glutamine residues. EYLCF-16 exhibited competitive ACE inhibition and
inhibited the enzyme activity by 91.8% at 10 mg/ml.
In order to separate the most effective fraction, further purification steps were 
conducted by gel filtration chromatography followed by RP-HPLC. ACE inhibitory 
activity increased after each purification step with a concomitant decrease in IC50 
values (table 6.1). Thus the highest ACE inhibitory activity (91.8%) and lowest IC50 
value (1.53 mg/ml) was exhibited by the EYLCF-16 fraction obtained from the final 
purification step of this study. This observation is in agreement with previous studies 
reporting that purification decreased IC50 values (Pihlanto-Leppala, 2000; Jung et a l,  
2006; Dai et a l, 2013).
The structure-activity relationships of ACE inhibitory peptides are highly influenced
by the sequence of the tripeptide positioned in the C-terminus (Li et a l, 2004). In this
research, the presence of positively charged arginine (14.69%) and lysine (10.90%)
residues in EYCLF-16, as well as the presence of hydrophobic tryptophan (12.49%)
and leucine residues (20.26%) may be responsible for the high activity shown by the
fraction. The hydrophobic and hydrophilic properties of the isolated peptides enhance
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the stabilisation of the complex formed between the peptide and the active site of the 
enzyme. This stabilization is achieved by hydrogen bonding and electrostatic 
interaction and hence, enhances the inhibition activity (Pan et al., 2012). Zhao and Xu 
(2008) explained that the interaction between ACE inhibitors and the Zn^ "^  in the 
active site of the enzyme plays a crucial role in enzyme inhibition. Pan et al. (2012) 
suggested that leucine and the Zn^^ ion are linked via the carboxyl group of leucine 
and this coordination is responsible for the enzyme inhibition activity. Therefore, the 
presence of leucine residues in the composition of EYCLF-16 may explain the 
inhibition activity shown in the current study. Many studies have suggested the ACE 
inhibitory activity of peptides may be due to the presence of the positive charge on e- 
amino group of lysine residues, or the guanidino group of arginine residues, in the C- 
terminus of the isolated peptide (Cheung et al., 1980; Murray and FitzGerald, 2007). 
The mechanism of ACE inhibition by EYLCF-16 was identified with the use of 
Lineweaver-Burk plots. The results of the kinetics study showed that EYLCF-16 is a 
competitive inhibitor of ACE (figure 6.6), that is, it competes with the substrate 
(HHL) at the active site of the enzyme.
7.2 G en era l con clu sion s
• The in vitro digestion of egg yolk protein using pepsin and pancreatin
produced several peptides that exhibited antioxidant properties; the most
effective fractions were EYGF-23 and EYGF-33.
• EYGF-23 and EYGF-33 inhibited the formation of peroxides and
malondialdehyde in a linoleic acid oxidising system in a dose-dependent
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maimer. Both fractions (80 and 100 mg/ml) exhibited antioxidant activity 
comparable to trolox and BHT.
• Amino acid residue composition and the low molecular weight of EYGF-23 
and EYGF-33 may help to explain the antioxidant activity possessed by these 
fractions. In particular the EYGF-23 fraction, with a molecular weight of 200- 
750 Da contained tryptophan, tyrosine, lysine and proline residues, while the 
EYGF-33, with a molecular weight o f 250-800 Da, contained leucine, 
tryptophan, alanine, valine, arginine, lysine residues .
• The variety of mechanisms: reducing power, radical scavenging and ferrous 
chelating, by which EYGF-23 and EYGF-33 exerted their antioxidant activity, 
is indicative of their potential to function in diverse oxidising environments.
• While EYGF-23 possessed antioxidant activity in oxidatively stressed Caco-2 
cells and protected them against programmed cell death, EYGF-33 exhibited a 
cytotoxic effect on the same cell line. Based on the results obtained, only the 
EYGF-23 fraction was studied further in relation to antioxidant activity. 
Conversely, EYGF-33 was chosen for study as a potential anticancer agent.
• Under stressed conditions, EYGF-23 enhanced Caco-2 cell viability, reduced 
ROS as well as malondialdehyde levels and inhibited caspase 3/7 activity.
• EYGF-23 increased the level of total glutathione and SOD activity without 
affecting catalase levels.
• EYGF-33 exhibited in vitro cytotoxic effects in colon cancer cells without any 
toxicity in normal colon cells. Apoptosis in cancer cells was mediated by 
mitochondrial ROS generation and PARP cleavage.
• EYGF-33 is a promising peptide candidate for reducing cancer due to its anti­
proliferative potential. However, preclinical efficacy and safety studies using
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animal models, as well as carefully designed pharmacokinetics studies are 
needed before clinical trials of peptides as cancer preventive or therapeutic 
agents can be initiated.
• The in vitro digestion of egg yolk protein using pepsin and pancreatin 
produced several peptides that exhibited ACE inhibitory activity; the most 
effective fraction, named EYLCF-16, showed 91.8% inhibition activity with 
an IC50 value of 1.53.
• EYLCF-16 comprising leucine, lysine, arginine and tryptophan residues is a 
competitive inhibitior for ACE.
7.3 F u tu re  w o rk
• To investigate the mechanism of ACE inhibition activity of egg yolk protein 
in in vitro using endothelial Eahy 962 cell line.
• To study the antihypertensive effect of egg yolk peptides in spontaneously 
hypertensive rats (SHR).
• To investigate the effect of egg yolk peptides as a colon cancer treatment 
agent in vivo in rats.
• To investigate the effect of egg yolk peptides on liver and breast cancer cell 
lines.
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Appendix 1: Dose response curve of ferrous chloride (FeCli)
0 .4 -1
7 = 1.40%+ 0.006 
i?^=9845Ec
oo
lO
0.3-
8 0 .2 -
0 .1 -
0.0
0.00 0.04 0.08 0.12 0.16 0.20 0.24
C o n cen tra tio n  (FeCl2) m g/m l
206
Appendix!: Dose response curve of Malondialdehyde (MDA)
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bioactive peptides from egg yolk. Postgraduate conference 2011, FHMS,
University of Surrey, Guildford, Surrey, UK.
• Marwa Yousr and Nazlin Howell. May, 2012. Angiotensin-1- Converting 
Enzyme (ACE) Inhibitory peptides from Egg yolk protein. Postgraduate 
conference 2012, FHMS, University of Surrey, Guildford, Surrey, UK.
• Marwa Yousr and Nazlin Howell. February, 2014. Antioxidant effect of egg 
yolk peptide against t-BHP-induced oxidative stress in Caco-2 cells. 
Postgraduate conference 2014, FHMS, University of Surrey, Guildford, 
Surrey, UK.
Oral Presentations
• Bioactive peptides from egg yolk. February, 2011. Nutrition seminar, division 
of nutrition and food science, FHMS, university of surrey, UK.
• Angiotensin-1- Converting Enzyme (ACE) Inhibitory peptides from Egg yolk 
protein. June, 2012. Nutrition seminar, division of nutrition and food science, 
FHMS, university of surrey, UK.
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